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Abstract  
A large number of bone substitute materials are available; for which some authors 
claim osteoconductivity and some osteoinductivity. In order to rank these materials 
an  in vivo analysis was carried out.  These materials were chosen based on their 
availability and claimed mode of action. Silicon substituted Hydroxyapatite (SiHA), 
Hydroxyapatite (HA), Resorbable Calcium Phosphate Silicon, Skelite [silicon-
stabilized tricalcium phosphate-based bone substitute], Pro Osteon 500R [coralline 
HA], BiIonic [Yttrium stabilized SiHA] and two non-calcium phosphate, 
Dimeneralised Bone Matrix (DBM) based biomaterials: Accell Connexus DBM putty 
and Grafton crunch DBM were implanted in sheep femoral condyle defects for 6 
weeks.  Implanted calcium phosphate (CaP) based biomaterials demonstrated 
superior bone formation in comparison with the DBM samples. Silicon within CaPs 
increased the rate of bone formation in vivo. Silicon substituted HA showed increased 
proliferation rate (P<0.05) of human marrow stromal cells compared to pure HA in 
vitro. Expression of osteoblastic marker genes RUNX2, Osterix and Osteopontin 
within the hMSCs indicated the differentiation of preosteoblasts into osteoblasts, and 
osteogenic development on both HA and SiHA. Expression of osteocalcin and bone 
sialoprotein genes  on HA and SiHA samples indicated the activation of 
mineralisation process. Differentiation of hMSCs into osteoblasts in vitro suggested a 
role in promotion of osteoinduction by both HA and SiHA. Implantation of porous 
SiHA and HA in paraspinous muscle of sheep,  exhibited  new bone formation 
through osteoinduction. SiHA indicated significantly higher new bone formation 
(P<0.01) compared to HA. SiHA and HA biomaterials with higher strut porosity 
(30%) indicated greater bone formation (P<0.05).  
   In conclusion, CaP based biomaterials demonstrate superior bone formation in 
comparison with DBM biomaterials. Silicon substitution within HA enhances the 
cellular activity of hMSCs. Osteoinduction was greatest on SiHA with higher strut 
porosity. This  result  is believed to be due to a combination of the  effect of 
interconnected porosity and chemical composition of the bone substitute.                                                                                                  
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1  Chapter I. Introduction  
Natural bone composition, structure and the interconnected trabecular structure of 
bone tissue have provided the structural model for design and construction of bone 
substitute materials.  The aim of  this t hesis was to investigate the mechanisms 
involved in the promotion of bone formation by calcium phosphate bone substitute 
materials including the effects of elemental substitution, specifically silicate ion 
substitution and material porosity.  
 
1.1     Bone 
Bone is a complex form of dense connective tissue that consists of collagen fibres, 
contributing to bone toughness, surrounded by a hard matrix of calcium salt deposits 
which provides the tissue with stiffness (Vander et al., 1994). Bones are rigid, porous 
and calcified structural organs of the body, responsible for the body’s shape and 
movement.  Seventy percent of the composition of the bone  is made of  calcium 
phosphates chemically arranged in a structure known as  hydroxyapatite 
([Ca3(P)4)2]3.Ca(OH)2). Calcium phosphate, calcium carbonate, calcium fluoride, 
calcium hydroxide and citrate make up the crystalline structure of hydroxyapatite 
(Hedges and van Klinken, 1992).  
   The bones of the skeleton are all made of an outer layer of dense, compact bone, 
known as the cortical bone, surrounding the cancellous bone; the spongy inner bone 
is composed of thin trabeculae (Cornuelle and Gronefeld, 1997). The skeleton is 
composed of different types of bone including flat bones, short bones, and long 
bones, irregular, sesamoid and wormian bones. The mechanical properties of bone 
provide the skeleton with the required support, shape, protection and locomotion. 
Cortical bone is stiffer and resists higher stress, but is less strain resistant than 
cancellous bone.  The porous structure of cancellous bone has a large capacity for 
energy storage and consequently is less stiff and withstands more strain (Table 2) 
(Nordin and Frankel, 2001). Bones provide protection to the internal organs, support 
for soft tissues and attachment sites for muscles and tendons. Bone also has a Chapter I. Introduction                                                                                                 
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function in calcium homeostasis, metabolism of minerals, and is a site for 
haematopoiesis. 
     Skeletal development involves close co-ordination of genetic processes 
controlling the specification, proliferation and differentiation of cells with apoptosis 
(programmed cell death) and remodelling of the extracellular matrix alongside 
vasculogenesis (Miclau et al., 2005). Skeletal development starts within 6 weeks of 
conception through the  process of ossification.  In the embryo the precursor 
cartilaginous tissue exhibits the characteristic shape of the forming bone tissues (Bell, 
1952). During fetus development, bones are formed  through endochondral 
ossification for the formation of long bones or intramembranous ossification for the 
formation and development of flat bones  (Cornuelle and  Gronefeld, 1997). The 
process of bone formation or osteogenesis continues throughout adult life as a bone 
remodelling process and is re-instigated during the  course of fracture repair 
(Ferguson et al., 1999). 
   Bone formation is a tightly controlled mechanism which involves the morphogen 
mediated patterning signals for identification of areas of initial mesenchyme 
condensation, followed by stimulation of cell  specific differentiation processes 
involving specific genes and protein expression for the production of chondrocytes 
and osteoblast cells (Franceschi, 1999). Intramembranous ossification starts with the 
condensation and differentiation of unspecialised MSCs into osteoprogenitor cells 
and  ultimately differentiation of osteoblasts, which then create the extracellular 
osteoid matrix (Komori and Koshimoto, 1998). Osteoblasts, which originate from 
multipotential undifferentiated progenitor cells known as marrow stromal cells 
(MSCs) (Beresfrod, 1989), do not divide and contain a large eccentric nucleus with 
one or two nucleioli and prominent rough endoplasmic reticulum (RER) (Franz-
Odendal et al., 2005). Marrow stromal cells are known as a heterogeneous population 
of stem/progenitor cells with a pluripotent capacity to self-renew and differentiate 
into many cell types, including the osteoblasts, osteocytes, adipocytes, chondrocytes, 
myocytes, cardiomyocytes, fibroblasts, myo-fibroblasts, epithelial cells, and neurons. 
Bone marrow is the primary source of MSCs, however adipose tissue, peripheral 
blood, cord blood, liver, and fetal tissues are also known to be sources of these cells 
(Peleld et al., 2002; Bobis et al., 2006; Liu et al., 2009). Osteoblastic cells exhibit a Chapter I. Introduction                                                                                                 
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variety  of  structural  morphologies and activities, ranging from polygonal 
preosteoblasts to cuboidal osteoblasts, matrix-synthesizing osteoblasts, matrix and 
mineral-embedded osteocytes and very flattened or thin bone lining cells (Malaval et 
al., 1999). Extracellular signals, including hormones, growth factors, or cytokines, 
regulate the osteoblasts’ function (Masato, 2001). The differentiated osteoblasts or 
the bone forming cells secrete the bone matrix proteins and synthesise the 
extracellular matrix or osteoid (Lecanda et al., 1997; Bronner and Farach-Carson, 
2003; Yoshiko, 2007). The secreted extracellular matrix undergoes modification by 
osteoblasts to meet the mechanical  requirements of the bone (Franceschi, 1999). 
Bone matrix deposited by osteoblasts is  composed of collagenous and non-
collagenous proteins with Type I collagen being the major component (90%) of the 
matrix, in addition to a small number of other collagen types (Fujisawa and Kuboki, 
1998). The collagen in the bone provides a scaffold for the formation of crystals of 
dahllite or carbonated apatite (Ca5 (PO4, CO3) (OH)) (Robinson, 1952). Collagen is a 
fibrous protein and the orientation of the collagen fibres within the bone matrix 
determines the  cortical or trabecular/cancellous  types of the  bone in the body 
(Robinson, 1952). Osteopontin, osteocalcin, osteonectin, Bone Gla protein (BGP) 
and bone sialoprotein (BSP),  in addition to a few other proteins,  are the non-
collagenous proteins of the bone matrix (Roach et al., 1994; Aerssens et al., 1994; 
Fujisawa and Kuboki, 1998) expressed at different stages of osteoblastic 
differentiation (Figure 1). Bone matrix proteins are important for processes such as 
cell differentiation, cell attachment, cell maturation, hydroxyapatite and calcium ion 
bonding, in addition to mineralization of the bone tissue (Castano-Izquierdo et al., 
2006; Young, 1991; Young 2003). As osteoid production by osteoblasts progresses 
some of the osteoblasts become embedded within the extracellular matrix, which 
subsequently becomes calcified. These cells develop into osteocytes (Figure 1) which 
exhibit reduced endoplasmic reticulum and golgi apparatus and consequently reduced 
protein synthesis and secretion (Franz-Odendaal et al., 2005). Osteocytes are mature, 
non-dividing, the longest living and the most abundant cell type of the bone whose 
precise functions are still obscure and are suspected to be involved in the regulation 
of calcium homeostasis, in addition to modulation of the function of other bone cells 
(Palumbo et al., 1990; Gu and Vanaanen, 2008). They contain numerous long cell Chapter I. Introduction                                                                                                 
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processes through which they connect with each other and the osteoblasts on the 
bone surface (Ikeda, 2008).  
 
Figure 1. Osteoblast differentiation (from: Current Opinion in Genetic and Development) 
 
 
Following deposition of the bone matrix, r andomly orientated deposited bone 
matrices form weak, woven o r coarse fibred bone, which is then replaced with 
mechanically stronger new linear or lamellar structured bone (Shapiro, 2008). The 
deposited  osteoid matrix undergoes mineralisation.  Osteoblasts secrete matrix 
vesicles in the osteoid which form the nucleation sites for the deposition of the first 
mineral crystals (Ray et al., 1997). Bone stiffness and rigidity is the result of the 
integration of minerals into the bone matrix.  During the process of bone 
mineralisation, osteoblasts mineralize the deposited matrix by inducting the diffusion 
of Calcium (Ca
2+) and Phosphorous (PO4
3-) ions through the interstitial space and 
pores of collagen present in the unmineralised matrix (Yokobori, 1998; Toshimitsu et 
al., 2002) and seeding of calcium phosphate crystals of carbonated hydroxyapatite 
(Ca, X)10(PO4, HPO4, CO3)6)(OH, Y)2 (LeGeros, 2002) in the sheltered interior of 
membrane-limited matrix vesicles. This is followed by spreading the hydroxyapatite 
mineral as needles orientated in the direction of collagen fibres onto the collagenous 
extracellular matrix (Posner, 1985; Hessle et al., 2002; Webster et al., 2003). The HA 
crystals in mineralized bone are in the form of irregular shaped thin plates which 
contribute to the exposure of a large surface area for rapid exchange of ions with the 
extracellular fluids (Barrere et al., 2006).  The mineralised bone contains narrow 
tunnels, known as the  osteocytic canaliculi,  filled with extracellular fluid through Chapter I. Introduction                                                                                                 
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which osteocytic cell processes travel and mediate the transport and exchange of ions 
and other bioactive substances (Bonewald et al., 2006; Lane et al., 2008).  
   Following mineralization of the bone matrix, resorption and remodelling of the 
newly formed bone tissue usually follows (Gerstenfeld et al., 2003). Bone is replaced 
through osteoclast-mediated bone resorption and bone replacement by osteoblast-
mediated bone formation as tightly coupled processes (Pederson et al., 2008). 
Osteoclast activation involves the receptor activator of nuclear factor- kB ligand, 
RANKL/RANK (a member of the  tumour necrosis family) signalling and the 
production of pro-inflammatory cytokines and chemokines for regulation of an 
inflammatory response (Xing et al., 2005). RANKL resides on the osteoblast surface 
and RANK on the preosteoclast surface therefore in order for osteoclast 
differentiation  these two different cell types must be in contact. Osteoclasts are 
specialized multinucleated macrophages of hematopoietic origin (Susa et al., 2004) 
which attach to the bone surface and develop a specialized cytoskeleton and other 
structures, such as the “ruffled border” associated with the degradation of the bone 
matrix. Bone resorption by these cells is carried out by secretion of hydrochloric acid 
and protease enzymes through extensive vesicle transport to the ruffled border and 
formation of an isolated acidic microenvironment on the bone-osteoclast interface 
called the resorption lacuna or Howships lacuna, within which hydroxyapatite 
crystals dissolve and the organic matrix of the bone degrades (Blair et al., 1986; 
Teitelbaum, 2000; Vaananen et al., 2000; Boyle et al., 2003; Takahashi et al., 2007).  
   Osteocytes mediate the mechanotransduction of the bone and translation of the 
mechanical strains into biochemical signals between osteocytes and to cells on the 
bone surface for the process of bone remodelling (Bonewald et al., 2006; Feng et al., 
2006). Bone resorption and formation processes are in balance and maintain a 
constant, homeostatically controlled amount of bone within the body (Rodan, 1998). 
  During the process of endochondral ossification, unspecialised mesenchymal stem 
cells condensate at a location where a future bone is formed. The cells within the 
centre of this structure then differentiation into chondrocytes and the cells on the 
outside edges differentiate into fibroblast-like perichondrial cells. T he formed 
chondrocytes proliferate and form cartilage templates. This is followed by  the 
formation of vascular networks around these templates and the expression of Chapter I. Introduction                                                                                                 
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angiogenic growth factor, VEGF, for differentiation and enlargement of 
chondrocytes to hypertrophic chondrocytes. Vascular invasion is an essential factor 
for bone formation for repair/replacement of bone tissue. Vascular endothelial 
growth factor (VEGF) is the most effective angiogenic factor involved in 
osteogenesis (Ferrera and Davis-Smyth, 1997). Neo-angiogenesis by VEGF signaling 
is known to be crucial for endochondral ossification as inhibition of bone formation 
and resorption in juvenile mice has been observed in the absence of VEGF activity 
(Gerber et al., 1999). Following the formation o f hypertrophic chondrocytes, 
secretion of collagen and other proteoglycans  ceases  and secretion of alkaline 
phosphatase  which is  essential for mineral deposition initiates. The hypertrophic 
chondrocytes further differentiate and mature and eventually, subsequent to 
calcification of the matrix, the chondrocytes die resulting in the formation of cavities 
which are then filled with blood vessels, nerves and lymph vessels. Concomitant with 
this process, the perichondrial cells on the periphery differentiate into osteoblasts 
and form the bone collar. The vascularisation ultimately recruits chondroclasts, the 
bone forming osteoblasts, and the bone resorbing osteoclasts for degradation of the 
mineralized cartilaginous matrix, osteoid secretion and remodelling of the 
extracellular matrix (ECM) respectively. The process of ECM remodelling eventually 
results in the synthesis of trabecular bone by osteoblasts’ precursor cells and the 
consequent formation of the bone marrow cavity (Chung et al., 2004; Ortega et al., 
2004).  
   Following completion of the skeletal growth, bone remodelling controls the bone 
turnover through which old bone tissue is replaced with new bone and consequently 
mineral homeostasis is regulated (Hill et al., 1998). Bone remodelling is a coordinated 
cycle of tissue resorption by osteoclast cells and bone formation by osteoblasts 
throughout life (Vaananen, 1993). Bone remodelling happens in small packets of cells 
known as basic multicellular units and new bone formation happens at approximately 
the same place as the resorbed bone and without any change in the density or shape 
of the bone.  Healing of non critical sized defects and fractures of the bone is 
achieved through this remodelling process; however, promotion of bone formation 
for repair of critical sized defects requires human intervention (Hill et al., 1998). 
Since the functionality of the bone is dependent on the balanced mechanism of bone Chapter I. Introduction                                                                                                 
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resorption and formation (Frost, 1964), alteration of this balance for the purpose of 
increasing bone formation has been the focus of many studies. The complex 
structure of bone tissue contributes to its function in resisting mechanical forces and 
fractures. The mass and the quality of bone tissue characterised by the geometry, 
bone shape, the microstructure of the trabecular bone, bone turnover, the mineral 
content, and the collagen levels are important factors contributing to bone strength 
(Viguet-Carrin et al., 2006).  
 
1.2  Bone Grafts 
Bone is known for its ability to self repair and remodel without the creation of scar 
tissue. However, large bony defects or poor bone healing, in addition to bone 
pathologies, require augmention to facilitate bone formation. The augmentation of 
bone tissue regeneration for repair of fracture defects, lesions, non unions or spinal 
fusions have been investigated for many years. Bone repair is described as restoration 
of the connection
 of the injured tissues, whereas bone regeneration involves the 
differentiation
 and proliferation of new cells and ultimately formation of new bone 
tissue with an increased volume (Al Aql et al., 2008). Regeneration of bone tissue was 
first achieved by a Dutch surgeon, Job van Meekeren, in 1668 through the repair of a 
soldier’s cranium using bone tissue from a dog (de Boer., 1988). Since the 1920s, 
various types of substances such as  Osmic acid, fibrin, blood, gelatine, calcium 
chloride, zinc chloride, thyroidin, glacial acetic acid, iodine tincture, adrenalin, 
hypophysis extract, bone marrow, copper sulphate, oil of turpentine, ammonia, lactic 
acid, silver nitrate solution, alcohol, carbolic acid, oak bark extract(tannic), vaccines, 
and sera have been used to promote bone regeneration; however, none of these are 
effective in promoting osteogenesis (Albee and Morrison, 1920).  
   Replacement of lost mineralised tissue and regeneration of bone has inspired the 
study of the inorganic chemistry associated with bone and its role in bone formation. 
The enhancement of bone formation using bone substitute materials is one of the 
mostly focused areas of orthopaedics and maxillofacial research. Bone grafts for the 
replacement or repair of bone defects have been used since the 17
th century 
(Yaszemski et al., 1968). Natural or synthetic scaffolds/implants, undifferentiated or Chapter I. Introduction                                                                                                 
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osteoblastic cells and many growth factors and proteins are known to promote bone 
growth within osseous or non-osseous tissue for the purposes of tissue 
repair/replacement (Meijer et al., 2007).  Autografts, allografts, xenografts (Brown 
and Cruess, 1982) and synthetic bone graft/substitute biomaterials have been used in 
orthopaedics and maxillofacial surgery over recent years.  Spinal fusion  in 
orthopaedics is one of the common techniques that employs the use of bone 
substitute materials. This technique involves the stabilisation of the spine by fusing 
two or more vertebrae together by placing bone graft material between the vertebrae. 
Bioactive bone grafts are available as dense or porous granules or blocks, wedges or 
cylinders, cements or as coatings on orthopaedic or dental implants (LeGeros et al., 
2008). The success of bone formation by bone graft depends on the intrinsic
 bone 
forming properties of the graft including surface composition, surface roughness, 
surface topography, porosity and crystallinity (Keiswetter et al, 1996), the bone 
forming potential
 of the host, the graft's mechanical stability, and the surface
 area of 
the host-graft contact (Taylor et al., 2007). Direct interactions between matrix 
proteins and their cell surface receptors contribute to the host response to the bone 
graft. In vivo and in vitro different bone graft materials induce specific biological and 
local responses (Figure 2) leading to initiation of specific mechanism of ossification 
(Boyan et al., 1996).  
   Different types of bone grafts stimulate different osteogenic, osteoinductive and 
conductive mechanisms (Bauer et al., 2000). Osteogenesis involves new bone 
formation through the effect of the host tissue or a bone graft material and the 
activity of osteoprogenitor cells and osteogenic precursor cells (Lieberman and 
Friedlaender, 2005). Osteoblasts and preosteoblasts transplanted from one part of 
the body to the repair site induce the mechanism of osteogenesis through which 
osteoid deposition by osteoblasts, release of growth factors, initiation of capillary 
formation and vascularisation ultimately leads to new bone formation (Kontio et al., 
2004). Osteoinduction is the induction of osteogenesis through the activation of 
cytokines, growth factors and also extracellular matrix proteins for proliferation and 
differentiation of pluripotent marrow stromal cells into osteoblasts (Helm, 1951; 
Albrektsson and Johansson, 2001). This mechanism involves the attraction of 
mesenchymal stem cells for induction of the repair or replacement of bone tissue Chapter I. Introduction                                                                                                 
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within osseous or non-osseous tissue (Luo et al., 2005). Bone grafts which transform 
connective tissue to bone in exoskeletal sites are osteoinductive. Urist et al. (1960s) 
demonstrated bone formation through osteoinduction by the intramuscular 
implantation of demineralised bone, which is bone tissue without the mineral 
constituents. Further identification of osteoinductive agents demonstrated the 
involvement of a soluble glycoprotein known as the bone morphogenic protein 
(BMP) in the mechanism of osteoinduction. BMPs are inductive agents naturally 
released in response to trauma for formation of bone or cartilage or during the 
process of bone remodelling. The mechanism of induction of bone formation by 
bone graft materials is suggested to be species dependant and dependant on the 
species’ specific concentrations of the BMPs (Ripamonti et al., 1996). An illustration 
of the species specific nature of the bone response was demonstrated by Ripamonti 
et al. (1996) using bone substitute materials. They reported that intramuscular 
implantation of porous coralline hydroxyapatite within rat and rabbit animal models 
does not promote any bone formation; however, substantial bone formation was 
observed in porous HA samples implanted in canine or primate animal models. 
Apart from the chemical inductive agents, including BMPs, physical stimuli such as 
stress, the bone graft’s physical structure and also electrical signals (Dealler, 1981) 
have also been shown to influence the mechanism of osteoinduction (Alberktsson 
and Johansson, 2001).  
  A bone graft is osteoconductive if it promotes bone formation within osseous 
tissue due to the effect of its composition, shape and surface texture (Bauer, 2007). 
Osteoconduction is the mechanism of stimulation of the attachment, migration and 
distribution of differentiated osteogenic and vascular cells for conduction of bone 
formation through the surrounding tissue into the repair/replacement site (Helm, 
1951). The sources of the differentiated osteoblasts that promote osteoconduction 
can be the primitive mesenchymal cells or the preosteoblasts activated by trauma. 
Therefore it can be suggested that osteoconduction is the continuation of an earlier 
mechanism of osteoinduction (Alberktsson and Johansson, 2001). Bone tissue, 
specifically cancellous bone, is osteoconductive. The porous and highly 
interconnected trabecular structure of the bone promotes the migration of cells and 
vessels from the surrounding tissue for new bone formation.  Adequate Chapter I. Introduction                                                                                                 
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vascularisation and development of a network of blood vessels for the provision of 
growth factors, proteins, hormones and nutrition is essential for bone formation 
(Trueta, 1963). In 1763, Albrecht von Haller stated that “the origin of the bone is the 
artery carrying the blood and in it the mineral elements”. It is known that 
endochondral and intramembranous ossification are both associated with blood 
vessels’ growth (Yeh and Lee, 1999). Differentiation of chondrocytes  in 
endochondral ossification and their appropriate alignment in the growth plate are 
dependant on the formation of an appropriate vascular network. Osteogenesis is 
suggested to be coupled with angiogenesis as endothelial cells in blood vessels are 
known to be adjacent to osteoprogenitor and osteoblast cells present at the site of 
new bone formation (Trueta, 1963; Yeh and Lee, 1999). Osteoblasts are sensitive to 
oxygen levels and oxygen tension and hypoxia trigger the processes of angiogenesis 
and osteogenesis by elevating the expression of the angiogenic gene, vascular 
endothelial growth factor (VEGF) in osteoblasts (Wang et al., 2007).   
   A wide range of mitogenic and angiogenic growth factors have been identified to 
be involved in the mechanism of osteoconduction (Alberktsson and Johansson, 
2001). Osteoconduction by bone grafts is achieved through the use of natural or 
synthetic scaffolds exhibiting porosity and chemical composition similar to that of 
natural bone, for the ingrowth of differentiated bone cells and blood vessels from the 
surrounding bone tissue concomitant with promotion of bone formation through 
osteoinduction (Cornell and Lane, 1963; Glowaschi and Mulliken, 1985).  
 
1.2.1  Autograft 
Autograft is transplanted fresh cancellous or cortical bone tissue or a combination of 
both, from one site (i.e. fibula, iliac crest, ribs or the removed  bony process 
associated with the spine during spinal surgery) in the body to another within the 
same patient. Autologous bone graft is the “gold standard” and the most effective 
method of bone regeneration as this source of bone tissue provides scaffolding for 
osteoconduction, growth factors for osteoinduction, and progenitor cells for 
osteogenesis and also osteoindution (Vaccaro, 2002; Weinand et al., 2005) without 
any associated immune response. The most common use of autograft is in spinal Chapter I. Introduction                                                                                                 
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fusions, which involve the stabilisation of the spine by fusing two or more vertebrae 
together by placing small pieces of bone graft material between the vertebrae to be 
fused for the elimination of problems of the vertebrae and back pain. Disadvantages 
such as limited supply, the harvest procedure and high donor site morbidity limit the 
use of this type of bone graft (Goulet et al., 1997).  
 
1.2.2  Allografts 
Allografts are transplanted cancellous, cortical or dimeneralised bone matrixes from a 
living/cadaver donor to a patient (Delloy et al., 2007). Allografts are an 
osteoconductive source of bone graft usually harvested from femoral heads taken 
from patients during total hip replacement surgery or sections of the pelvis from 
cadaveric donors. They also possess limited osteoinductive properties if used as fresh 
frozen or in a demineralised form (Moore et al., 2001; Nguyen et al., 2007). 
Complications such as risk of disease transmission, inconsistency in graft preparation 
techniques, immune rejection, bacterial infection, fracture and also non-union due to 
differential donor related bone quality have been related to the limitations of the use 
of this type of bone grafts (Ferrara et al., 2005). The risk of disease transmission is 
reducing the use of fresh frozen allograft.  Preparation for sterilisation and the 
sterilisation procedure itself reduce the bone forming potency of allograft.  
 
1.2.3  Bone Substitutes 
 
Due to the limitations of autograft and allograft, a variety of natural and synthetic 
bone substitutes have been identified and developed for the repair, reconstruction or 
replacement of bone tissue in procedures such as revision impaction grafting and 
spinal fusions.  Calcium phosphate composition of n atural bone  and the 
interconnected trabecular structure of bone tissue have provided the structural model 
for development of bone substitute materials. Plaster of Paris, a calcium sulphate 
based biomaterial was one of the very first synthetic bone substitutes developed in 
the 1890s.  Non-metallic bone substitutes include calcium p hosphate ceramics, 
bioactive glasses, glass ceramics,  aluminium oxide/alumina, tricalcium phosphates Chapter I. Introduction                                                                                                 
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(TCP), synthetic hydroxyapatite, dimeneralised bone matrix (DBM) and also coralline 
hydroxyapatite ( Table  1) (Moore et al., 2001; Bjerre et al., 2008).  Metallic bone 
substitutes include tantalum and titanium based alloys which are prominently used 
for load bearing purposes. Bioactive glasses are composed of SiO2, CaO, Na2O, and 
P2O5 with low mechanical strength and a greater osteoblastic activity compared to 
hydroxyapatite. The very first developed bioglass (45S5) is silica based (<60%) melt-
derived glass with a high CaO/PO ratio. The surface reactivity of the silica, calcium 
and phosphates within this biomaterial promote bone bonding and bone formation 
in osseous tissue (Thomas et al., 2005).  
 
Table 1. Bone grafts (Bauer et al., 2007) 
 
 
   Calcium phosphates are the most popular non-metallic bone substitute materials 
due to their similar chemical composition to the inorganic phase of bone, plentiful 
amounts and low cost (Bohner, 2000; Brandoff et al., 2008). Tricalcium phosphates 
(TCP), synthetic hydroxyapatite (HA) and combinations of TCP and HA were the Chapter I. Introduction                                                                                                 
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very first and most popular bone substitute materials due to their biocompatibility 
and osteoconductive potential (Knaack et al., 1998; Bjerre et al., 2008).  
   Metallic implants, such as titanium and its alloys are commonly used for the repair 
of skeletal tissue where mechanical strength is required (Table 2). However these 
biomaterials are perpetual non-biodegradable grafts and do not elicit a biologically 
functional bone/biomaterials interface for promotion of osteointegration and direct 
contact of bone tissue with the  implant surface.  Synthesis of bone substitute 
materials as coatings for metallic implants is required for enhanced osteointegration 
and consequent implant fixation (Thian et al., 2005; Bjerre et al., 2008).    
   Bone substitute materials are required to b e biocompatible, osteoconductive 
and/or osteoinductive, in addition to ultimately being totally replaced by natural 
bone.    Bone substitute materials represent differential resorbablity; some indicate 
complete replacement by new bone whereas only partial resorption has been 
identified in others. Bioglasses, silica-calcium phosphate nanocomposites, biphasic 
calcium phosphates such as ß -TCP/HA or a -TCP/HA and calcium deficit or 
amorphous calcium phosphates are amongst clinically used bone substitutes (Soballe 
et al., 1999; Hing et al., 2007). Porous bone substitute scaffolds have been shown to 
promote enhanced cellular and vascular ingrowth which is required for mechanical 
fixation to the surrounding tissue (Klawitter et al., 1976; Hing et al., 2004; 
Karageorgiou and Kaplan, 2005). The presence of the porous structure contributes 
to in-growth of vascular networks within the implant and enhanced angiogenesis, in 
addition to increased levels of fluids, nutrients and growth factors permeability into 
the implant area (Bonfield, 2006). Pore sizes of ~300-400µm have been identified as 
the optimal pore size for attachment,
 differentiation, growth of osteoblasts and also 
vascularisation (Tsurugo et al., 1997). Further, interconnected macro (>50µm) and 
micro (<20µm) structures provide greater surface area for exchange of ions (Daculsi 
et al., 1990), which is believed to be important. 
   The specific surface interactions of bone substitutes with the host cells and the 
extracellular fluids, in addition to their influence on ionic exchange and molecular 
and/or cellular activities within the tissue, contribute to their function in promotion 
of bone formation (Barrère et al., 2006). At the interface between bone substitutes 
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and precipitation from the solution onto the biomaterial (2) contribute to the process 
of ionic exchange and structural rearrangement (3) at the biomaterial-tissue interface. 
This is followed by interdiffusion of elements from the surface boundary layer into 
the biomaterial (4). Further, elements present in the solution influence the activity of 
cells (5), which attach following deposition of mineral (6a) or organic phases (6b). 
These phases may be integrated (7) into the biomaterial surface promoting 
chemotaxis on the biomaterial surface (8), stimulation of cell attachment and 
proliferation (9), followed by differentiation (10) and extracellular matrix 
production(11). 
 
Figure 2. Events at the interface between bioactive ceramics and the surrounding biological 
environment (Ducheyne and Qui, 1999) 
 
 
   Several physical features, including surface topography, surface energy, the level of 
porosity, pore size and graft three-dimensional structure of bone substitutes, 
influence the interaction of the cells with the biomaterials (Figure 3) (Helm, 1951). 
The signals from the surface topography/charge of the bone substitute are 
transferred to the cell through changes in the interaction of integrin proteins, the 
mediators of cell binding to its extracellular matrix, with both intra and extracellular 
proteins resulting in changes in bone cell phenotypic expression, protein synthesis 
processes and osteoblastic activity. Further, the morphology of bone substitutes in 
the form of grooved and porous surfaces influences the cell migration, attachment, 
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compression and tension on the mechanoreceptors of the cells and also vascular 
invasion (Boyan et al., 2006). The proliferation and differentiation of marrow stromal 
cells (MSCs) have been shown to be influenced by the pore size as Mygnid et al 
(2007) demonstrated that pores of 200µm size show faster osteogenic differentiation 
of MSCs and pores of 500µm size accommodate higher numbers of cells and an 
increased MSC proliferation rate.  
   Bone substitutes’ surface chemistry, in terms of charge density and net polarity of 
the charge, determines the hydrophobic or hydrophilic nature of the biomaterial in 
addition to surface tension or energy of adhesion. This in turn changes the local 
intermolecular interactions in terms of protein adsorption or the attraction of ions 
into the biomaterial surface for formation of the ideal host-biomaterial interface 
(Boyan et al., 2006). Further changes in the surface chemistry of bone substitutes 
influence the local pH levels, which in turn affects the cellular activities and the rate 
of bone formation (Hing et al., 2005). 
 
 
Figure 3 . Bone-bone substitute material communication pathways (Hing et al., 2005) 
 
 
   Dissolution of the bone substitute into its chemical constituents, concomitant with 
the process of osteogenesis and subsequent remodelling, promotes the ingrowth of Chapter I. Introduction                                                                                                 
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bone tissue and complete replacement of the substitute material with new bone. 
Random dissolution, phagocytosis or cell mediated resorption are the processes 
involved in bone substitutes’ replacement.  Cell mediated resorption of bone 
substitutes without random dissolution contributes to the elimination of 
uncontrolled physical degradation of the graft material and  optimal  material 
durability and ultimately, superior bone formation (Langstaff, 2001). The mechanism 
of bone substitute dissolution and resorption will be discussed in detail in the 
following sections. 
    Bone substitute materials are required to exhibit similar mechanical strength and 
load bearing to natural  bone.  Trabecular and cortical bone  are  known to  show 
resistance to elastic deformation (Elastic moduli, E, are 10.4 GPa and 18.6 GPa 
respectively as shown in Table 1). It should be noted that natural bone is anisotropic 
and exhibits different mechanical properties  in different directions  based on  the 
orientation of  collagen fibres and  hydroxyapatite crystals  (Brunet-Imbault et al., 
2005). Metallic bone substitutes exhibit greater mechanical properties compared to 
bone however such mechanical strength is not necessary in all instances of bone 
repair. Mechanical properties of non metallic bone substitutes are influenced by the 
biomaterial composition, the Ca/P ratio and the ions present, in addition to 
geometrical variations such as porosity, grain size and crystalline structure (Raynoud 
et al., 2001) ( Table  2). Changes in biomaterial porosity result in changes in the 
mechanical strength of the material as a result of the reduced resistance of micro and 
macro crack propagation (Ambard and Mueninghoff, 2006). Graft materials which 
exhibit lower mechanical strength in comparison with the host bone may cause 
failure of the constructs and bone repair. As a result, these constructs are only used 
at places where they are not subject to any significant mechanical loading (Lieberman 
and Friedlaender, 2005). Chapter I. Introduction                                                                                                 
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Table 2. The mechanical properties of bone and metallic and calcium phosphate implant materials 
(Kokubo et al., 2003;, Mahmoud et l., 2005, Levy et al., 2007)) 
 
 
Material 
 
Compressive 
Strength 
(MPa) 
 
Tensile 
Strength 
(MPa) 
 
Young’s 
Modulus 
(GPa) 
Bone 
Cortical Bone 
Cancellous Bone 
 
 
100-230 
0.15-27 
 
135-160 
0.2-4 
 
17-20 
13 
Metals 
316 I. Stainless 
Co-Cr alloy 
Titanium 6A14V 
 
 
400 
-- 
-- 
 
1000 
900 
950 
 
200 
220 
123 
Bioglass (45S5)  500  40-60  78 
Calcium Phosphates 
Porous 
Dense 
 
1-10 
30-130 
 
0.36 
10-28 
 
14 
-- 
 
 
  
1.2.3.1  Natural bone substitutes  
1.2.3.1.1  Coralline/Calcium Carbonate  
The carbonate structure of marine species, including mollusc shells, sponges and 
corals, has been the natural source of many bone and cartilage graft biomaterials. 
Marine species used as biocompatible biomaterials exhibit porous 3 -D structures 
similar to the structure of natural bone. Natural sea coral,  a calcium carbonate 
(CaCO3), has been the source of many orthopaedics and maxillofacial biomaterials 
for more than a decade (Ehlrich et al., 2006). Coralline is known to be a resorbable 
biocompatible material contributing to promotion of bone formation through 
formation of an aragonite or calcite structure (Richard et al., 1998). 
   Coral  calcium carbonate is known to undergo a  surface transformation of the 
aragonite  calcium carbonate  to a CaP-rich layer.  This  CaP-rich layer induces 
precipitation of a  biological apatite, promoting nucleation and consequent bone Chapter I. Introduction                                                                                                 
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formation due to dissolution of synthetic CaP crystals (Richard et al., 1998). The 
potential of coralline species in controlled adsorption and release of growth factors 
through modification of their particle sizes or the adsorption conditions, has 
contributed to their selection as valuable bone graft materials. Coralline bone grafts 
have proven to be osteoconductive due the mechanism of bone ingrowth into and 
throughout their porosity when in direct contact with viable bone (Shors, 1999).  
   Conversion of coralline apatite to hydroxyapatite was achieved hydrothermally (270 
°C; 103 MPa;) by Roy and Linnehan in 1974 where the aragonite on the surface of 
the coralline (calcium carbonate) was completely replaced by a layer rich in calcium 
and phosphate (Heness and Ben-Nissan, 2004), leaving an underlying scaffold of 
CaCO3.  In vivo studies on the mechanism of bone formation by coralline 
hydroxyapatites have shown the mechanism of rapid degradation of the calcium 
carbonate composition, concomitant with bone formation on the calcium phosphate 
component, as the bioactive behaviour of this bone substitute material (Ning et al., 
2008).  
 
1.2.3.1.2  Demineralised Bone Matrix 
Demineralised bone matrix (DBM) is a processed form of allograft bone with the 
mineral content removed. Dimeneralised Bone Matrix (DBM) was first used in 1889 
in the process of bone graft demineralisation for the purposes of obtaining aseptic 
tissue (Groeneveld et al., 1998). This was followed by the work of Urist (1965) who 
identified bone formation when rodent acid treated demineralised bone was 
implanted into muscle tissue (Kim, Vaccaro, Fessler, 2005). DBM is composed of the 
organic phase of bone (2%), collagen (93%), growth factors, BMPs and other non- 
collagenous proteins (5%) (Kenneth et al., 2005). The work of Urist (1965) led to the 
discovery of BMPs, the non-collagenous glycoproteins in the bone matrix. The 
presence of BMPs within DBM is known to contribute to the osteogenic property of 
this material (Laurence et al, 1984). BMPs involved in osteogenesis bond to specific 
receptors on the surface of mesenchymal stem cells, which transduce the signals for 
activation of genes that trigger the differentiation of mesenchymal cells to bone 
through endochondral and also intramembranous ossification (Dvorak et al., 2004). Chapter I. Introduction                                                                                                 
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Different BMP contents have been  identified in different DBM preparations: 
however, BMP-2, BMP-4 and BMP7 (or Osteogenic Protein-1) are amongst the most 
osteoinductive bone morphogenic proteins (Pietrzak et al., 2006) as they trigger 
differentiation of osteoprogenitor cells to mature osteoblasts (Einhorn and Lee, 
2001). The potential of BMP-2 and BMP-7 in bone generation has led to their 
therapeutic use in the form of recombinant proteins as replacements for autografts in 
spinal fusions and tibial non-unions (Lane et al., 2001). Recombinant BMPs have 
been successfully used in anterior fusions and when compared to autografts, are 
known to exhibit superior spinal fusion rates (Boden, 2006).  
   DBM is osteoinductive, osteoconductive and one of the least immunogenic 
allografts (Guizzardi et al., 1992) as the foreign antigens present in the allograft are 
removed during the processing period. The collagen component of DBM is known 
to provide the osteoconductive potential of DBM (Kenneth et al., 2005).  The 
osteoinductive mechanism of bone formation by DBM involves the differentiation 
of mesenchymal stem cells into osteoblasts, followed by bone matrix synthesis and 
subsequent tissue calcification (Wang and Glimcher, 1999). The in vivo study of DMB 
by Urist demonstrated the ectopic osteoinductive role of DMB when implanted 
subcutaneously in muscle of mice animal models (Kenneth et al., 2005). The process 
of osteoinduction by DBM is known to involve the process of chondrogenesis, 
where mesenchymal stem cells are differentiated into chondroblasts (Kenneth et al., 
2005). This osteoinductive process involves attraction of multinucleated giant cells to 
the material, followed by the migration of fibroblast-like mesenchymal stem cells to 
the site. Cartilage formation is known to commence within a week from 
implantation. The cartilaginous tissue then undergoes mineralization, is resorbed and 
finally replaced by new bone (Reddi and Huggins, 19972; Groeneveld et al., 1999).   
   DBM was first used in maxillofacial surgery in 1975 and has since been widely used 
in both orthopaedics and reconstructive maxillofacial surgery since.  Due to the 
special properties of DBMs, such as low cost, low immunogenicity and ease of 
availability, DBM bone substitute materials have been widely used in orthopaedics to 
augment fusion of the spine, repair of graft non-union, osteolytic lesions around total 
joint biomaterials and also replacement of benign bone cysts (Peterson et al., 2004). 
DBM is produced from different human and non-human sources. Studies on the use Chapter I. Introduction                                                                                                 
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of xenograft- tissues harvested from one species to use in a different species- DBM 
have not shown any inflammatory reaction and immunogenic response. This is due 
to the fact that during the production process of DBM most antigens and proteins 
triggering an immunogenic response are removed and the BMPs responsible for 
osteoinduction by this bone substitute are species independent (Urrotia et al., 2008). 
Studies on the use of xenograft DBM in humans have reported contradicting results, 
where some discourage the use of it and o thers count it as a useful alternative. 
However, DBM derived from autograft seems to show a better clinical outcome 
when compared to xenograft sources (Lofgren et al., 2000). Commercially available 
DBM is produced from human bone banks and is available in many forms, including 
powder, crushed granules, putty, and chips and also in gel-packed syringe. The DBM 
product of processed cortical bone is in a powder form which is hard to handle. In 
order to ease the handling and delivery of this material, DBM is mixed with other 
biocompatible substances known as carriers, such as glycerol (Grafton DBM), 
gelatine, poloxamer (Accell Connexus DBM) hyaluronic acid and calcium sulphate. 
The most popular form of DBM is DBM putty or paste (Kenneth et al., 2005). The 
bone forming potential of DBM is known to be dependent on the demineralisation 
process, sterilization, carrier choice and the amount and variety of BMPs available 
within the material (Peterson et al., 2004). Carrier osteoinductivity, resorbablity and 
biocompatibility are essential factors in the composition of the ideal DBM based 
bone substitute.  
    
1.2.3.2  Synthetic calcium phosphate bone substitutes 
The potential of calcium phosphate based biomaterials in promotion of bone 
formation have been extensively studied by various scientists. Due to the prominent 
amounts of calcium phosphates within bone tissue and pathological solid tissues 
(Dorozhkin, 2007), the use of calcium phosphates in medicine was proposed in the 
1890s. Studies of Albee in 1920s on tricalcium phosphate as a bone growth stimulus 
for enhancing the osteogenic activity of bone in delayed union or pseudarthrosis 
resulted in formation by this material. Further studies on the affect of the use of 
calcium phosphates in medicine led to the increase in the popularity of calcium Chapter I. Introduction                                                                                                 
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phosphates as bioactive materials in 1970s and 1980s (Jarcho, 1981, de Groot, 1984). 
Over recent years calcium phosphate  bone substitutes  have been widely used in 
reconstruction of bone tissue predominantly in coating of prosthetic implant devices 
for promotion of implant-bone bonding and osteointegration (Schnettler et al., 
2004).  
   Calcium phosphate based biomaterials are mixtures of several phases which are 
synthesised through the reaction of ammonium phosphate with calcium nitrate or 
calcium hydroxide suspension with phosphoric acid in the form of powder. Different 
synthesis methods including solid-state, wet chemical (i.e. sol-gel), hydrothermal 
reactions, micro-emulsion synthesis and mechano-chemical synthesis are used for 
preparation of calcium phosphates. Each synthesis method produces calcium 
phosphates of different stoichiometry, density, morphology and crystallinity (Burkes 
et al., 2006). The produced powder is either transformed into slurry that is cast in a 
mould by mixing with a binder containing liquid or is dry pressed. This is followed 
by sintering at high temperatures to densify the powder and to remove the porosity 
between the particles. Porous biomaterials are produced by using polymer beads that 
maintain pore space during material processing (Enderle et al., 2005), impregnation 
of polyurethane foam with calcium phosphate slurry or by incorporation of progens 
such as oxygen peroxide, naphthalene or sugar molecules (Wnek and Bowlin, 2008) 
and generation of CO2 bubbles for production of pores (Miao et al., 2003).  Chapter I. Introduction                                                                                                 
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Table 3. Bone hydroxyapatite and different calcium phosphates and their composition (Wopenka and 
Pasteries, 2005) 
 
Name  Chemical formula  Ca/P ratio 
Stoichiometric hydroxyapatite  Ca5(PO4)3(OH)2  1.67 
Hydroxyapatite (HA)  Ca5(PO4)3(OH)2  1.67 
Carbonated apatite: Calcium 
carbonate + ß-TCP 
CaCO3+ Ca3(PO4)2  1.6–2.0,  
a-Tricalcium phosphate 
ß-Tricalcium phosphate 
a-Ca3(PO4)2 
? -Ca3(PO4)2 
1.50 
1.50 
Calcium pyrophosphate 
dihydrate 
Ca2P2O7·2H2O  1.0 
Octacalcium phosphate  Ca8H2(PO4)6·5H2O  1.33 
Dibasic calcium phosphate  Ca(HPO4)  1.0 
Tetracalcium phosphate  Ca4(PO4)2O   
    
   Calcium phosphate biomaterials contribute to bone formation by the induction of 
biological responses in a manner similar to natural bone remodelling (Heise et al., 
1990). Calcium phosphate based bone graft materials promote early bone formation 
within osseous tissue through osteoconduction (Jarcho, 1981) and formation of 
strong bonds between the biomaterial and host bone and also by osteoinduction 
within non-osseous tissues (Osborne and Newesley, 1982; Yuan et al., 1998). Studies 
on calcium phosphate biomaterials have indicated the  in vivo induction of 
osteogenesis in many mammals, including monkey, baboons, dog, rabbit, goat and 
pig, by these biomaterials (Yamasaki et al., 1990; Ripamonti et al., 1991; Yuan et al., 
1997; Yuan et al., 2002; Duan et al., 2003). Accumulation of growth factors and other 
proteins from the body fluids by calcium phosphates in vitro (De Groot et al., 1998) 
has been shown to induce the differentiation of mesenchymal stem cells into 
osteoblasts (Norman et al, 1994; Okumura et al., 1997).  
   The ionic transfer of calcium and phosphorous from the solid material via surface 
hydration of these elements within the biomaterial to the aqueous liquid and also Chapter I. Introduction                                                                                                 
  35 
from the surrounding fluids to the calcium phosphate substrate in vitro and in vivo 
influences the bioactivity of calcium phosphates. This ionic transfer is dependant on 
the material’s composition, the environmental conditions  in vitro  and also the 
implantation site in vivo. Changes in the ratio of calcium to phosphorous modify the 
phase composition of the biomaterial and this in turn influences the rate of ionic 
exchanges (Barrere et al, 2006). The release of ions could alter the resorption of the 
calcium phosphate biomaterial if, for example, high concentrations of the calcium 
ions are released (Heymann and Passuti, 1999).  
   Further, calcium phosphate biomaterials’ surface roughness, due to its role in 
recruitment and retention of cells and proteins required for bone formation, works in 
combination with surface physio-chemistry to induce the appropriate biological 
response (Christophy et al., 2008). As explained before, the presence of micro and 
macrostructures within bone substitutes enhances the bioactivity (Klein et al., 1993; 
Blockhuis et al., 2000; Habibovic et al., 2006). Calcium phosphate biomaterials with 
micro and macro porous structures have been demonstrated to show ectopic bone 
formation due to the availability of a greater surface area for ionic exchanges, protein 
adsorption and cell adhesion, in addition to superior vascular penetration (Zhang et 
al., 2005). Further, strut porosity has been shown to increase in vivo bone formation 
within calcium phosphate based biomaterials and also promote earlier biomaterial 
osteointegration (Hing et al., 2005). The question here remains as to whether 
incorporation of strut porosity within biomaterials enhances the osteoinductive 
property of the biomaterial. However, increasing the strut porosity does reduce the 
strength of the bone graft material.  
   Dissolution, composition, surface energy and topography influence the bioactivity 
of calcium phosphates (Barrere et al., 2006). The dissolution of calcium and 
phosphate ions and their eventual accumulation and precipitation around the implant 
results in the formation of a biological apatite which is  composed of calcium 
phosphates formed in a crystalline structure. The mechanism of osteoinduction by 
calcium phosphates as indicated by Daculsi et al (1990) involves the influence of the 
apatite precipitation on the surface of biomaterials. The nucleation of this apatite 
both on the implant surface and also on the proteins, subsequently modifies the 
implant surface leading to enhanced protein absorption and change in osteoblast cell Chapter I. Introduction                                                                                                 
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adhesion, proliferation, differentiation, maturation and ultimately production of 
mineralized bone (Porter et al., 2004; Barrere et al., 2006). The dissolution behaviour 
of calcium phosphates is known to be affected by the crystalline or amorphous 
features of the CaP. Amorphous biomaterials show faster dissolution; however if in 
crystalline form, the reduction of the crystal size or incorporation of the elements 
present in the bone mineral such as silicate and carbonate change the crystal lattice 
and  enhance the dissolution rate (LeGeros, 1988; Barrere et al., 2000).  Further, 
incorporation of proteins, such as bovine serum albumin, causes a change in the 
crystalline lattice (Liu et al., 2003).  In addition,  the presence of micro and 
macroporous structures within the calcium phosphates, influence the dissolution rate 
of these biomaterials. Thus, it can be elucidated that changes in the biomaterials’ 
chemical composition, leading to physical changes, contribute to the dissolution 
behaviour of the biomaterials. 
   The rate of calcium phosphate biomaterials’ dissolution influences the resorption 
behaviour of that biomaterial (Klein et al., 1983). Biomaterial restorability and 
osteoclastic resorption is known to be dependent on the biomaterial’s nature and the 
physiochemical properties of the material after implantation, including the 
concentration of the released calcium ions and also the crystallinity and the structure 
of the CaP biomaterials (LeGeros, 1988; de Bruijn, 1994; Jones et al., 1995). 
Resorbablity studies on different calcium phosphates have indicated that octacalcium 
phosphates are more resorbable than ß-tricalcium phosphate and hydroxyapatite, the 
two most popular calcium phosphates (Kamakura et al., 2002).  Natural bone 
resorption is mediated by acid production by osteoclast cells, which dissolve the 
small, finely divided carbonate-rich b one salts, exposing the organic matrix for 
enzymatic degradation. The process of resorption of calcium phosphate biomaterial 
is known to involve engulfing small biomaterial particles generated as a result of 
mechanical stress or dissolution at grain boundaries, by macrophages and 
macrophage polykaryons or osteoclasts in which an acidic environment or enzymatic 
attack dissolves the biomaterial particles (Boyde et al., 1999; Heymann, 1999). 
Physiochemical changes such as disintegration, loss of mechanical strength, changes 
in porosity and dissolution contribute to biodegradation and bioresorbablity of 
calcium phosphate biomaterials (LeGeros et al., 1988; Kurashina et al., 2002). The Chapter I. Introduction                                                                                                 
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resorption or degradation products of calcium phosphates are naturally metabolized 
and no abnormal calcium or phosphate levels can be found in the body fluids or 
organs (Hollander et al., 1991). 
   The mechanical properties of bone substitute materials are important factors for 
their use in hard tissue prosthetics. Porous bone substitute materials exhibit similar 
strength to cancellous bone, with tensile strengths of 5 MPa and compressive 
strength of up to 40 MPa (depending on level of porosity). Dense bone grafts show 
greater mechanical strength, however, the bioactivity of these biomaterials is severely 
compromised due to their smaller surface area (Shi, 2006) (Table 2). 
   Calcium phosphate bone substitutes and dimeneralised bone matrix (Urrotia et al., 
2008) have been the substitutes for auto and allograft bone used in spinal fusions. 
Silicon substituted Hydroxyapatite specifically, has been found to promote excellent 
fusion when used in adult patients (Dickerman et al., 2008) due to the effect of its 
chemical composition, which will be discussed in the following sections. 
 
1.2.3.2.1  Tri-Calcium Phosphates (TCP) 
Tri-Calcium Phosphate (Ca3(PO4)2) or calcium orthophosphate found in alpha (a) or 
beta (ß) forms, is a common calcium phosphate based biomaterial.  ?eta Tri-Calcium 
Phosphate (ß-TCP) is one of the first developed calcium phosphate bone graft 
substitutes with compressive and tensile strengths similar to natural bone (Moore et 
al., 2000). Accelerated repair of bone defects by the use of tricalcium phosphates was 
first reported by Albee and Morrison (1920) (Shakelford, 1999). ß -Tricalcium 
phosphate bone substitute materials are resorbable biocompatible biomaterials with 
osteoconductive properties (Saikia et al., 2008).  In vivo analysis of ß -TCP/bone 
interface has indicated direct biomaterial/ host bone contact and presence of 
osteocyte cells with elongated processes as the factors contributing to bone 
formation by this biomaterial (Fujita et al., 2003). ß -TCP is known to promote 
osteogenic differentiation of marrow stromal cells  in vitro (Kawagoe et al., 2004; 
Kotobuki et al., 2006). The mechanism of osteoconduction by ß-TCP is known to 
involve direct biomaterials/bone contact, osteoclastic resorption and complete Chapter I. Introduction                                                                                                 
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substitution for bone tissue after induction of bone generation (Kamitakahara et al., 
2008).  
1.2.3.2.2  Synthetic hydroxyapatite 
Bone mineral (Ca5 (OH) (PO4)3/HA) is the main inorganic component of bone and 
teeth tissues with Calcium to Phosphate ratio of 1.67 (Biltz and Pellegrino., 1969). 
Stoichiometric Hydroxyapatite (HA), Ca10(PO4)6(OH)2 is the most widely used bone 
graft biomaterial due to its similar structure to the mineral component of the natural 
bone (Figure 4) (Heise et al., 1990; Balas et al., 2002).  
 
 
Figure 4. Crystal Structure of HA (Vallet Regi and Acros, 2005) 
 
 
   Despite the understanding of the osteoconduction mechanism by hydroxyapatite, 
the mechanism of osteoinduction by this biomaterial as a result of chemical 
composition and/or physical structure is not clearly understood. Studies by 
Ripamonty et al (1991, 96 and 99) on the induction of osteogenesis on porous HA 
indicated that bone formation on HA may be through the action of this biomaterial 
as a medium for adsorption of the circulating BMPs or their storage and controlled 
release or their expression at the HA-tissue interface. The  in vivo studies of 
heterotopic bone formation within baboons indicated mesenchymal condensations at 
the HA interface and extensive vascular penetration, followed by bone formation 
within the porous structure, without the presence of any chondrogenic phase 
(Ripamonti et al., 1993). This indicated the involvement of an intramembranous 
mechanism of osteoinduction without the involvement of the bone morphogenic Chapter I. Introduction                                                                                                 
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proteins in induction of bone formation by this biomaterial. Bone morphogenic 
proteins when used often promote bone formation through formation of a cartilage 
intermediate which is then calcified by endochondral ossification. A study by 
Okumura et al (1998) in a rat animal model demonstrated that osteoblasts deposit the 
osteoid matrix, which is not yet calcified, directly on the surface of HA and the 
osteoid then undergoes maturation into fully mineralized bone. Further, Winter and 
Simpson (1969) identified the importance of calcification prior to induction of bone 
formation through an experiment where bone formation was observed within a 
synthetic polyhydroxyethylemethacrylate sponge implanted in the skin of a p ig 
experimental model, by initial calcification of the polymeric sponge followed by bone 
formation. This indicated the role of calcification in mechanism of osteoinduction by 
calcium phosphates (Habibovic et al., 2004). 
    The analysis of the role of biomaterial structure on the mechanism of 
osteoinduction has identified that factors such as shape, porosity, pore size and 
permeability (Ripamonti et al., 1999; Habibovic et al., 2007) of HA biomaterials also 
contribute to the mechanism of osteoinduction. A s tudy by Van Eeden and 
Ripamonti et al (1994) indicated that HA samples in block form exhibited 
heterotopic bone formation in baboons; however, porous HA granules did not 
indicate any bone formation. Jin et al (2002)  demonstrated that the geometry of 
hydroxyapatite implants in the form of porous particles, porous blocks or 
honeycomb shaped HA, influences the vascular capillary invasion and consequently 
the growth, differentiation and phenotypic expression of osteogenic cells. Gray et al 
(1996) showed that bone formation on inert surfaces is favoured in grooves and 
crevices with depths similar to that of resorption loci, Howships lacunae left by 
osteoclasts. Further, the shape and the size of gaps and the discontinuity in 
osteoblast sheets influence the proliferation rate and the differentiation, function 
activity of osteoblast cells.  
   Yuan et al (1999) reported ectopic bone formation due to the effect of the 
variation in the levels of microporosity by two HA samples with similar chemical and 
crystallographic structures implanted in the muscle tissue of dog animal models. Such 
studies indicate that the surface characteristics and geometric parameters are 
important factors in the osteogenic function of bone substitutes.   Chapter I. Introduction                                                                                                 
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   Synthetic Hydroxyapatite is widely used as orthopaedic or dental implant coating to 
promote  osteointegration and implant stabilization. Despite these favourable 
properties of HA, the rate of osteointegration by HA compared to bioactive glasses 
or glass ceramics is known to be slow.  
   HA does not degrade significantly and exhibits slow bioresorbability (Pietak et al, 
2007; Bjerre et al., 2008). For  these reasons,  the  development of novel  HA 
biomaterials with enhanced efficacy are required (Webster et al., 2001). Biomaterials 
that exhibit the bone forming properties of HA have been developed by the 
incorporation of additional phosphorous compounds into the HA structure to form 
materials such as ß -TCPs which show enhanced solubility and resorbable 
characteristics, leading to complete substitution for the bone tissue after induction of 
bone formation (Sato et al., 2005; Kamitakahara et al., 2008). Several scientists have 
also doped HA with ionic substitutions such as K
+, Mg
2+, Na
+, CO3
2-  and F
-  present 
in biological HA crystals to enhance the bioactivity of this biomaterial (Webster et al., 
2003). Studies on the enhancement of HA bioactivity have shown that incorporation 
of silicon into the HA structure  enhances bone formation through e nhanced 
osteoblast cell activity (Gibson et al., 1999; Patel et al., 2002). A study by Patel et al 
(2002) on the  in vivo response of pure HA and carbonate substituted HA 
demonstrated that the substitution of carbonate groups into HA enhanced the 
bioactivity of this biomaterial. Carbonate is the major impurity (2-8wt%) of bone 
mineral. Hydroxyapatite can accommodate carbonate at OH
- and PO
3-
4 sites (Zakaria 
et al., 2005). Studies on carbonate substituted HA have indicated that the presence of 
carbonate enhances the production of multinucleated cells on the ceramic surface in 
vivo and consequently enhances the bioresorbability of HA. This in turn promotes 
new bone formation through the mechanism of osteoclasts activity and remodelling 
processes, which in turn triggers osteoblasts activity and deposition of bone matrix 
via a coupling process, which was described in section I (Spence et al., 2008).  
      In 2001 Ergun et al. tested the effect of doping hydroxyapatite with magnesium, 
zinc, cadmium and yttrium. This study indicated that substitution of trivalent yttrium 
for calcium ions within HA resulted in the formation of an excess positive charge. 
Formation of a calcium ion vacancy for each two yttrium ions substituted for one 
calcium ion and segregation of the yttrium ions to the biomaterial surface was Chapter I. Introduction                                                                                                 
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suggested to contribute to the provision of protein adsorption and consequent cell 
attachment sites (Urgun et al., 2001). A previous study by Owada et al (1989) on 
calcium phosphates substituted with other elements for calcium ions, indicated an 
increase in the amount of surface of hydroxyl groups in relation to the amount of 
yttrium doped on HA, contributing to the high affinity of this biomaterial for water 
molecules. This study also indicated a reduction in electrical resistance of yttrium 
doped. The electric conductivity of this biomaterial, in addition to its water loving 
nature and the role of these factors in bone formation, contributed to further 
investigation of this biomaterial as a bone substitute biomaterial (Sato et al., 2006). 
Further, the in vitro study of Webster et al (2001) on osteoblast adhesion to yttrium 
doped HA showed that yttrium doped hydroxyapatite demonstrates enhanced 
osteoblast adhesion compared to yttrium free HA through superior calcium 
absorption and cell adhesion proteins such as vitronectin and collagen. Massa et al 
(2002) also demonstrated significantly greater osteoblast adhesion on HA doped with 
trivalent yttrium in comparison with pure HA. A study by Sato et al (2006) indicated 
superior amounts of calcium deposition by osteoblasts on yttrium doped HA. As cell 
adhesion to biomaterials contribute directly to their function and differentiation 
capacity, the results of these studies indicate that, yttrium substitution would 
contribute to enhancement of osteoblast cells’ functions and consequently  the 
amount of bone formation (Webster et al., 2002).  
 
   The capability of both calcium phosphate bone substitutes and DBM biomaterials 
in promotion of bone formation raises the question of “Which of these two groups, 
calcium phosphate bone substitutes or DBM, promotes superior osteoconduction in 
vivo?”  
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1.2.4  The effect of silicate ion substitution on bone formation 
Rapid bone repair and bone tissue regeneration is an important issue in orthopaedics 
and maxillofacial surgery. It is desirable for bone formation by bone graft materials 
to occur in the shortest possible time as the stability and the mechanical properties of 
the implanted region are greatly affected by the formation of strong bonds between 
the body cells and the implant (Porter et al., 2004). Bone mineral contains variable 
deficiencies in Ca, P and OH. A number of cations including magnesium, sodium, 
silicon and strontium ions that can substitute for the calcium, in addition to a 
number of anions such as chloride or fluoride that can be substituted for the 
hydroxyl groups of the HA content of the bone mineral, have been identified 
(Robinson, 1952; LeGrose, 2002). The substitution of elements in the hydroxyapatite 
structure contribute to the bioactivity of bone, in particular silicon (8wt%) which is 
found to be an essential element for skeletal bone and cartilage development (Pietak 
et al., 2007) have been identified within this tissue. The biological activity of bone 
mineral and also calcium phosphate biomaterials is known to be enhanced by the 
presence and incorporation of the substitution elements in the apatite structure. 
Incorporation of the elemental substitutions influences the solubility, surface 
chemistry and morphology of the material. Amongst the known substitutions, Silicon 
(Si) is known as an essential element for a variety of life processes, for example, a 
metabolite affecting cellular processes and also a regulator of gene expression 
(Hildebrand et al., 2003). In the 1970s, Carlisle reported silicon as an essential 
element for normal bone and cartilage growth and development. Carlisle (1970) 
reported the unique localisation of silicon in active calcification sites of the bone. A 
further study investigating the effect of silicon deficiency showed the stunted growth 
of growing chicks and defective bone and connective tissue formation. Further, high 
concentrations of silicon have been detected in metabolically active osteoblasts 
(Carlisle, 1976). The role of silicon in bone healing through its effect on 
vascularisation, bone metabolism and bone matrix mineralisation and organisation 
has been shown to have a direct connection with the levels of dietary silicon 
(Schwarz et al., 1977). Hott et al (1993) reported prevention of trabecular bone loss 
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formation through a possible effect of silicon on the formation or stabilization of the 
bone matrix. Calomme and Vanden-Berghe (1996) indicated a positive correlation 
between silicon concentrations in serum and collagen concentration within cartilage, 
as well as showing that silicon increases the serum calcium levels. The results 
suggested the role of silicon in the formation of the extracellular matrix and calcium 
metabolism. Silicon deficiency has been reported to decrease collagen formation in 
bone (Seaborn and Nielson, 2002). The results of a recent study by Jugdaohsingh et 
al (2008) reported the inhibition of growth plate closure and increased longitudinal 
growth of rats due to silicon deficiency. Soluble silicate ions have been demonstrated 
to stimulate the expression of type-I collagen  and osteoblastic differentiation  in 
osteoblast-like cell cultures (Refitt et al., 2003). Pabruwe et al (2004) demonstrated 
enhanced in vivo osteogenesis of silicon doped alumina. Further, development and 
structural integrity of connective tissue is known to be dependent on the 
bioavailability of silicon (Hing et al, 2006).  Moreover, this element has been 
proposed as a factor involved in the formation of the collagen matrix and the 
mineralisation of bone tissue (Zuo et al., 2008). 
   With respect to the accumulating data on the role of silicon on the cellular 
responses and bone formation, substitution of this element has been incorporated 
into the structure of different biomaterials. Of these biomaterials, Bioglasses with 
more than 60% silica (SiO2) content are known to promote bone formation through 
induction of high local turnover of bone formation and resorption (Valimaki and 
Aro, 2006). Further compounds such as Pseudowollastonite (CaSiO3) and calcium 
phosphate based materials with trace levels of Si, such as Silicon substituted HA and 
Si-TCP, can be named (Pietak et al., 2007). Pseudowollastonite is a highly bioactive 
silicate mineral ceramic which forms a hydroxyapatite surface layer on an amorphous 
silica interlayer by releasing calcium and silicate ions into solutions influencing the 
bioactivity of osteoblasts and bone formation (De Aza et al., 1994 and 2000). 
   Identification of the factors involved in the stimulation of osteogenesis through the 
direct effect of cell-implant or through the presence of soluble ions released into the 
adjacent environment, is essential in understanding the mechanism of bone 
formation by these biomaterials. Silicate ions are known to stimulate heterogeneous 
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calcium phosphate solutions (Tanizawa et al., 1995). The improved in vitro bioactivity 
of silicon substituted apatite is known to be affected by the nature of the silicate 
species, since m onomeric silicate ions are known to promote calcium phosphate 
apatite layers with higher activity in comparison with polymeric silicate species (Ballas 
et al., 2002). Enhanced metabolic activity and proliferation of human osteoblast-like 
cells have been reported in culture media supplemented with silicon (Zuo et al., 
2008). Ionic products of Bioglass dissolution are known to have a direct effect on 
gene expression in human osteoblast cells (Xynos et al., 2001). Valerio et al (2003) 
reported higher collagen production by osteoblasts cultured on bioactive glass 
containing 60% silica. Phan et al (2003) indicated enhanced proliferation of human 
osteoblasts on silica containing calcium phosphate particles. Silicon doped-TCP has 
also been shown to enhance the differentiation of mesenchymal stem cells and 
osteoblastic activity through formation of a bone-like apatite on the surface of the 
biomaterial (Camire et al., 2005).  
   The incorporation of silicate ion in the hydroxyapatite structure substituting 
phosphorus ions was first reported by Gibson et al (1998) through  an aqueous 
precipitation chemical reaction between calcium hydroxide and orthophosphoric acid 
solutions. This substitution was then reported to enhance the bioactivity of human 
osteoblast cells and apatite formation in simulated body fluid in vitro (Gibson et al., 
1999). Development of silicon substituted HA and its function in enhancement of 
the rate of bone formation and consequent early bonding of the implant with the 
host tissue, has contributed to increased use of this osteogenic biomaterial.  
   In vitro studies on the bioactivity of silicon substituted hydroxyapatite have reported 
enhanced in vitro metabolic activity of human osteosacrcoma cells on SiHA. A study 
by Botelho et al (2006) indicated increased osteoblastic protein production in human 
osteoblast cells on SiHA discs compared with pure HA. This study also indicated 
higher osteoblastic markers expression on 0.8 wt% silicate ion substitution when 
compared with 1.5wt% silicate substituted HA. A previous study by Porter et al 
(2003) showed an influence on the dissolution of silicon ions in vivo by increasing the 
level of silicon substitution (0< 0.8wt% <1.5wt%). Another study that investigated 
different levels of silicon within SiHA showed that 0.8wt% silicon level was the 
optimal level for the induction of bone formation. This level promoted fast bone Chapter I. Introduction                                                                                                 
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apposition and greater volume of bone ingrowth due to its effects on both bone 
forming and bone resorbing cells (Hing et al., 2006). Further, in vivo studies of the 
SiHA have indicated enhanced bioactivity of this biomaterial in comparison with 
pure HA. Patel et al (2002) reported an increase in bone apposition rate at the surface 
of SiHA implants when compared with pure HA. Further, the presence of organized 
mineralised collagen fibres within the implant pores at the host bone/SiHA interface 
was observed by Porter et al (2006). 
   Despite accumulating evidence indicating the superior SiHA bioactivity compared 
to normal HA, a  detailed  understanding of the mechanisms  of the increased 
bioactivity involved has not yet been achieved. So far, studies investigating SiHA 
bioactivity have proposed a number of different mechanisms. Substitution of silicate 
ions into the HA structure is known to result in enhanced adsorption of anions to 
the surface and consequently a reduction of the surface charge of this material to a 
value more negative than that of HA in solution (Botelho et al., 2002). In addition, 
silicon substitution within HA is known to enhance the electrostatic, Van Der Waals 
and surface adhesion of this biomaterial (Vandiver et al., 2003). Protein adhesion, cell 
morphology and adhesion are affected by a material’s surface charge. The negative 
surface charge of SiHA results in faster SiHA dissolution and the surface 
precipitation/apatite formation process, when compared to HA as negative charge 
attracts the positive calcium ions. This, in turn, contributes to SiHA providing a 
favourable site for the nucleation of an amorphous calcium phosphate apatite layer, 
providing the ideal conditions for superior bioactivity of this material (Botelho et al., 
2002). Further, Porter et al (2003 and 2006) demonstrated the increased rate of HA 
dissolution by silicate ions’ substitution due to smaller SiHA grain size, denser and 
less ordered grain boundaries’ density and triple junctions in SiHA. This increased 
solubility of SiHA, and consequently the increased concentrations of Si, Ca and P 
ions at the HA/ceramic interface, is suggested as the contributing factor in the 
formation of the apatite layer involved in induction of bone apposition. Micro-
texture changes including the reduction of the SiHA grain size, have been proposed 
to enhance osteoblasts attachment by causing conformational changes of cell 
anchorage proteins on the surface of SiHA and consequently the availability of RGD 
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proteins involved in cell attachment (Porter et al., 2005; Petty, 1993). Small quantities 
of silicon and calcium ions have been proposed to stimulate the activity of 
osteoblastic genes, resulting in increased osteoblast proliferation and differentiation 
(Hench et al., 2005).  Further, Hing et al (2006) demonstrated early bone apposition 
followed by superior bone ingrowth by porous SiHA (0.8wt%) implants in 
comparison with HA. Through this study the variation in surface chemistry and 
structure was proposed as the contributing factor to the activity of the bone forming 
osteoblast and bone resorbing osteoclast cells. Recent clinical trials have proved 
silicon substituted calcium phosphate bone substitute to be a preferable alternative to 
autograft bone for use in spinal fusion impaction grafting (Drew, 2009). 
    With respect to the accumulating data on the role of silicon in bone formation, the 
question of the influence of Silicon substitution within calcium phosphates on 
promotion of bone formation as a sole chemical factor or a combination of chemical 
and physical factors remains. In general, complex cellular and molecular mechanisms 
contribute to the process of osteogenesis by calcium phosphate biomaterials. 
Understanding of the basis of bone regeneration
 in terms of the expression mode of 
various growth factor proteins and osteogenic genes contributes to the development 
of successful bone regeneration mechanisms (Einhorn and Lee, 2001). 
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1.3  Aim and Hypothesis 
The aim of this thesis was to investigate the bone formation by different 
commercially available calcium phosphate biomaterials in vivo in an orthotopic and 
ectopic site. Further, the role of silicon substitution on the bioactivity of calcium 
phosphate bone substitutes as osteoinductive biomaterials in vivo and also in vitro was 
investigated. In addition, the chemical composition and physical structure on the 
bioactivity of calcium phosphate biomaterials was analysed.  
 
The hypotheses of this thesis are that: 
 
1.  Generally calcium phosphate based bone substitutes demonstrate superior 
osteoconduction in comparison with DBM based biomaterials. 
 
2.  Osteoconduction is influenced by the biomaterial’s chemical composition 
irrespective of structural porosity. 
3.  Silicon substitution within calcium phosphate bone substitute materials 
enhances the cellular activities of human marrow stromal cells through 
regulation of the osteogenic marker genes’ expression. 
 
4.  Silicon substituted hydroxyapatite biomaterial promotes osteoinduction due 
to the role of silicon irrespective of the biomaterial’s porosity. 
 
5.  Incorporation of strut porosity within the biomaterial particles enhances the 
biomaterial’s osteoinductive property.  
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2  Chapter II. In vivo Osteoconduction by Calcium 
Phosphate Bone Substitutes: A Comparative Study 
2.1  Introduction 
Bone grafts are known to be the second most transplanted materials next to blood 
transfusions (Giannoudis et al., 2005), However, with the invention of a wide range 
of new bone grafting materials, the choice of the best graft material is an important 
issue. The ultimate goal of bone graft material is to promote optimal levels of bone 
formation in the shortest possible time through osteoinductive, osteoconductive or 
osteogenic mechanisms to replace structural or mechanical functions (Logeart-
Aramoglu et al., 2005). 
   As described in the  introductory  chapter, a desirable bone substitute material 
should induce greater bone formation in the shortest  possible  time with optimal 
mechanical strength and ultimate resorbablity or remodeling into new bone. In this 
Chapter, the in vivo rate of bone formation by six commercially available calcium 
phosphate bone substitute materials (ApaPore, Actifuse, BiIonic, CPS, Pro Osteon 
500R and Skelite) in comparison with two DBM base bone substitute materials 
(Grafton  Crunch and Accell Connexus DBM putty)  was  investigated. This was 
carried out to evaluate the potential of calcium phosphate bone substitutes in 
promotion of bone formation  as a function of their chemical composition  in 
comparison with other bone substitute materials. This study is the largest comparison 
of bone graft substitute materials carried out to date.    
 
2.2  Calcium phosphate based bone substitute materials 
2.2.1  ApaPore: Hydroxyapatite (HA) 
ApaPore (HA, Ca10 [PO4]6[OH]2) is a synthetic phase pure hydroxyapatite biomaterial 
with a trabecular structure similar to cancellous bone which has been developed by 
ApaTech Ltd and is used in many clinical applications such as repair of bone defects 
or spinal fusions (Hing et al., 2005). This biomaterial has a unique, consistent and 
controlled interconnected micro and macro porous structure (Hing et al., 2003, Chapter II. In vivo Osteoconduction by Calcium Phosphate Bone Substitutes: A Comparative Study                                                                                           
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Kochhar et al., 2004). ApaPore is designed to absorb blood and bone marrow, 
contributing to the diffusion of growth factors and osteogenic proteins deep within 
the structure of the material.  
   HA was originally thought to be non-resorbable as no chemical dissolution was 
observed from this material nor was any cell mediated resorption detected (Osborne 
and Newsley., 1980). However, recent studies have reported that factors such as HA 
particle surface area influences the resorption and dissolution of this biomaterial 
(Mangano et al., 2008). As a result, the incorporation of strut porosity has been 
introduced into the structure of HA in order to enhance the bioactivity of this 
biomaterial.  
 
2.2.2  Actifuse: Silicon Substituted Hydroxyapatite (SiHA) 
Actifuse (Ca10  (PO4)6-x  (SiO4)x (OH)2-x) is a synthetic, 3 -D biomaterial with  80% 
controlled interconnected strut porosity, silicon-substituted (0.8 wt%) hydroxyapatite 
biomaterial developed by ApaTech Ltd. Gibson et al (1999) first investigated the 
substitution of silicate ions with phosphate groups within the calcium phosphate 
structure of hydroxyapatite to test the influence of this element on the bioactivity of 
HA. Gibson, Best and Bonfield (1998 and 1999) incorporated 0.2, 0.4 and 0.8 wt% 
silicon into HA through an aqueous precipitation method using Ca  (OH)2 and 
H3PO4 followed by sintering of the product at 1200 °C. The Ca/(P+Si) ratio of the 
prepared samples was kept constant at 1.67, identical to stoichiometric HA and a 
final substitution of silicon ion into phosphorous sites was obtained (Gibson et al, 
1998). This produced single phase silicon substituted HA, which presented identical 
X-ray diffraction patterns to that of stoichiometric HA with slight structural 
differences (Gibson et al., 1999).  
 
2.2.3  BiIonic: Yttrium stabilized SiHA 
BiIonic or yttrium stabilised silicon substituted HA (Ca10-x Yx (PO4)6-x (SiO4)x(OH)2, is 
a newly developed calcium phosphate based biomaterial. Yttrium is an earth metal 
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the vicinity of vascular channels (MacDonald et al., 1957). A study by MacDonald et 
al (1957)  on the skeletal deposition of yttrium showed the presence of  greater 
amounts of this element in fractured bone  when  compared with intact bone.  
Yttrium has been used in yttrium-stabilised Zirconia for orthopaedics and dental 
purposes (Piconi and Maccauro, 1999) and also to enhance the mechanical properties 
of ceramics (Gülgün et al., 2002).  As  previously  mentioned,  silicon substituted 
hydroxyapatite (SiHA) is known to exhibit superior bioactivity in comparison with 
pure hydroxyapatite. However, incorporation of increased concentrations of silicon 
higher than 5.57  wt%  within the HA structure are known to result in structural 
instability of this biomaterial.  Stephen et al 2007, synthesised Y
3+/ SiO4
4-co-
substituted HA. The co-substitution of Y
3+ was carried out for Ca
2+ and SiO4
4-  for 
PO4
3- ions within the HA composition in order to further enhance the stability and 
also the bioactivity of SiHA (Massa et al., 2001). This in turn would be expected to 
enhance the bone forming capacity of this biomaterial more than pure HA.   
 
2.2.4  CPS: Calcium Phosphosilicate 
Silicocarnotite (CPS)-(Ca5(PO4)2Si04)- is a calcium phosphosilicate originally found in 
Thomas slag, which is a by-product of steel production (Dickens and Brown, 1970). 
A study by  Kim et al., 2003 showed that silicon substituted hydroxyapatite 
compounds doped with 3.76  wt% silicate and sintered at 1100°C, undergo 
decomposition into Calcium Phosphate Silicate (CPS), a -TCP and CaO.  The 
chemical composition of Silicocarnotite is known to posses similarities with that of 
HA (Ca5(PO4)3OH) found in the inorganic phase of human bone tissue (Dickens and 
Brown, 1970). Within CPS, the PO4
3-– anions are substituted by the tetrahedral SiO4
4 
anions which contribute to removal of hydroxyl anions in the HA, compensating for 
the charge difference. The phosphorous and silicon ions are randomly distributed 
within the crystalline structure of CPS and  isolated  SiO4 and  PO4 tetrahedra are 
found within the carnonite structure of Silicocarnotite (Ballas et al., 2002).  
   CPS is produced by mixing of  colloidal SiO2 with stoichiometric solutions of 
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by 2 hours sintering at 700°C. The dried gel is shaped into pellets and the pellets are 
then flamed for half an hour at 1600° C followed by heat treatment at 1420° C for 9 
hours. The pellets are quenched, re-ground and finally flamed again at 1450° C for 27 
hours  (Fotheringham, 2006). As Silicocarnotite/CPS exhibits similarities to 
stoichiometric HA, the bioactive potential of this material has been investigated. The 
chemical composition of CPS is expected to promote faster dissolution of calcium 
and phosphate ions and consequently enhanced bone formation by this biomaterial.  
 
2.2.5  Pro Osteon 500R 
Pro Osteon 500R is a porous (pores of ~500µm) granular resorbable bone substitute 
material manufactured by Biomet Inc., composing of a thin HA layer covering a 
calcium carbonate core. Pro Osteon 500R is produced by hydrothermal 
transformation of sea coral, which is comprised of calcium carbonate (CaCO3), to 
HA. Pro Osteon biomaterials either consist of fully reacted HA or a thin layer of HA 
covering a calcium carbonate core. Calcium carbonates are known to be more soluble 
than calcium phosphates and the superior solubility of these compounds contributes 
to their increased rate of resorption. Consequently, a biomaterial which contains a 
carbonate composition is expected to show an increased resorption rate and also to 
exhibit earlier replacement of the biomaterial by newly formed bone tissue (Fontaine 
et al., 2005). Pro  Osteon 500R  is known to promote  osteointegration within 6 
months through the generation of woven bone formation followed by remodeling to 
mature lamellar bone (Walesh et al., 2003). 
 
2.2.6  Skelite 
Skelite is a synthetic multiphase silicon stabilised tricalcium phosphate (Si-TCP) 
based biomaterial with an interconnected open pore structure  produced by EBI 
OsteoStim® used for repair of bone defects. The composition of Skelite consists of 
67% Si-TCP and 33% hydroxyapatite (HA)/ß-tricalcium phosphate ( ß-TCP).  ß-
Tricalcium phosphate bone substitute materials are resorbable and biocompatible 
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biocompatibility of HA and the bioresorbable property of ß-TCP, in addition to the 
role of silicate ions  in the promotion of bone formation,  contributed to the 
development of a biomaterial consisting of both HA and Si-TCP elements 
commercially known as “Skelite”. The HA and TCP within this biomaterial 
respectively provide stability and solubility and consequently contribute to the 
resorption rate of Skelite (Combes et al., 2006).  The potential of  Skelite as a 
resorbable biomaterial  and its contribution to the initiation of the  natural bone 
remodelling process and formation of new bone makes it an ideal bone substitute 
biomaterial. Skelite is available in granular or block forms with approximate porosity 
of 70% and an average pore size of 350µm (Leroux et al., 2007). This biomaterial is 
used for reparation of bone gaps or defects and also spinal fusions. 
 
 
2.3  DBM based biomaterials 
2.3.1  Grafton DBM crunch 
Grafton® DBM crunch is a highly water soluble, bioresorbable DBM in a glycerol 
carrier biomaterial developed by Osteotech. Grafton DBM crunch is composed of 
demineralised bone fibers mixed with demineralised bone cubes. This biomaterial is 
used for repairing of segmental defects caused by cancer, tissue damaged by cancer, 
filling bone voids, augmentation of prosthesis, spinal fusion and also to replace 
damaged ligaments and tendons (Kim, Vaccaro, Fessler., 2005).  
   Production of DBM crunch involves the aseptic  harvesting of human  allograft 
tissue. The harvested tissue is then sterilised by a low dose electron beam, washed 
and then sonicated, followed by antibiotic treatment. Demineralisation of the tissue is 
then carried out by acid treatment to obtain less than 0.5% calcium phosphate; the 
demineralised tissue is then combined with glycerol, resulting in a product featuring 
putty like composition. The product  obtained  is then irradiated (? irradiation) to 
inactivate H IV-I, Hepatitis- B and C, Cytomegalovirus and poliomyelitis viruses 
(Peterson et al., 2004).  
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2.3.2  Accell Connexus DBM Putty 
Accell Connexus DBM putty is a poloxamer reverse phase medium carrier form of 
DBM derived from banked human bone tissue developed by IsoTis Orthobiologics 
(Peterson et al., 2004). Poloxamers are non-ionic tri-block copolymers composed of 
central hydrophobic chain flanked by two hydrophilic chains and are used for 
increasing the water solubility of hydrophobic substances (Karmarkar et al., 2008). 
DBM putty is an osteoinductive demineralised bone matrix used in orthopaedics for 
filling gaps and voids within bone tissue that do not require a stable structure. The 
Connexus DBM putty contains a selection of growth factors, including TGF-beta-1 
and a variety of natural human bone morphogenetic proteins  including BMP-2, 
BMP-4 and BMP-7, contributing to  the  promotion of bone formation by this 
material (FDA report, 510 (k)). DBM putty is known to thicken at body temperature, 
adding to the stability within the implanted site. 
   DBM biomaterials are expected to promote greater osteoconduction compared to 
calcium phosphate bone substitutes due to the presence of cytokines within their 
structure. However the rate of bone formation by this group of bone substitutes in 
comparison with calcium phosphates, which take advantage of the calcium and 
phosphate ions within their composition for promotion of bone formation, needs to 
be studied. 
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2.4  Aims and Hypothesis 
The aim of this study is to investigate and compare the rate of osteoconduction by 
calcium phosphate based  bone substitute  biomaterials  in comparison with DBM 
based biomaterials. 
 
 
The hypotheses of this study are that: 
 
1.  Calcium phosphate based bone substitute materials  promote  greater 
osteoconduction in comparison with DBM based biomaterials at early time 
points. 
 
2.  Osteoconduction is  influenced by the biomaterial’s chemical composition 
irrespective of structural porosity. 
 
3.  Silicate ion incorporation into the calcium phosphate based biomaterials 
enhances the bioactivity of these biomaterials.  
 
4.  The  presence of Yttrium  ions  within silicon substituted  hydroxyapatite 
further enhances this bioactivity of the biomaterial. 
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2.5  Materials and Methods 
2.5.1  Study design 
This study was designed to assess the osteoconduction rate of eight bone substitute 
materials based on preliminary data collected from a study carried out by Nuss et al., 
2006. To achieve significance of P< 0.05, the study was designed for comparison of 
six calcium phosphate  based  bone substitute biomaterials  with two DBM based 
biomaterials in 5 repeats (n=5) in a femoral condyle site where the overall standard 
deviation is around 8% (normal distribution with equal variation) with power of 0.8 
using the David Shoenfeld’s power analysis software. The  eight different bone 
substitute materials investigated are listed below in Table 4.  
 
Table 4. Bone substitute materials. P-G: Porous granules, D-G: Dense granules, P-C: Porous cylinder 
 
 
Name 
 
Biomaterial 
 
Company 
 
Catalogue 
 
ApaPore (P-G) 
 
HA 80%  
 
ApaTech Ltd. 
 
B011-2005H 
 
Actifuse (P-G) 
 
SiHA 80% 
 
ApaTech Ltd. 
 
B210-2005B 
 
BiIonic (D-G) 
 
Yttrium-SiHA 
 
Dr Ian Gibson 
 
JS115 
 
CPS (D-G) 
 
Silicocarnotite 
 
ApaTech Ltd. 
 
AF5 
 
Pro Osteon 500R 
(P-G) 
 
Carbonated 
HA 
 
Biomet Inc. 
 
5RGE10 
 
Skelite ™ (P-C) 
 
Si-TCP 
 
EBI OsteoStim 
 
LNK0420C03 
 
Grafton Crunch  
 
DBM 
 
Musculoskeletal 
Transparent 
Foundation 
 
124105 
 
Accell Connexus 
Putty 
 
DBM 
 
 
IsoTis 
Orthobiologics 
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2.5.2  Surgery 
All procedures in this experiment were performed in accordance with the Animals 
Act 1986 (Scientific procedure). Seventeen skeletally mature commercially bred sheep 
aged 4 to 6 years old and weighing between 65 kg to 80 kg w ere used in this 
experiment.  Prior to surgery, the  sheep were premedicated with intramuscular 
administration of Xylazine 0.1 mg/kg, and a naesthesia induced by intravenous 
injection of Ketamine 2mg/kg and Midazolam 2.5mg. Approximately ten minutes 
later anaesthesia was maintained by a Halothane (2%) and Oxygen (25%) mixture. 
Animals were placed in supine position and the area above the medial aspect of both 
the right and left femoral condyles were shaved and washed with an iodine scrub in 
addition to a betadine antiseptic solution. Proximal-distal incisions of ~4 cm were 
made on the medial aspect of each distal femoral condyle, cutting through the skin, 
hypodermis layer and along the muscle tissue fibres, exposing the femoral condyle. 
The periosteum was then scraped from the surface exposing the underlying bone. 
Two cylindrical defects of 8 ± 0.3 mm in diameter and 15 mm length were created in 
each condyle using an air powered surgical drill with a 4.5 mm external diameter drill 
bit. The defects were flushed with sterile saline to remove debris. The selected bone 
substitute materials (1.2 ml) were then randomly packed into the implantation sites 
(Figure 5) in a manner that no one animal was implanted with two of the same 
biomaterial. The incision was then closed using resorbable Vicryl sutures. Animals 
were allowed full mobilisation as tolerated and at 1, 3 and 6 weeks post surgery, 
animals were  euthanized  and t he implanted  biomaterials  retrieved for 
histomorphometric analysis. After sacrifice the femora were removed, all soft tissue 
was separated and the femoral condyles collected.  
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Figure 5. Defects within femoral condyle head filled with test biomaterial 
 
 
2.5.3  Undecalcified Hard Resin Histology 
The fresh femora were fixed by immersion in 10% neutral buffered formalin at room 
temperature for 7 days. Following this, the samples were prepared for undecalcified 
hard resin histology. Samples were dehydrated by immersion in industrial methylated 
spirit (IMS) at increasing dilutions of 30%, 50%, 75%, 85%, 95% and two changes at 
100% for three days at each concentration. The samples were then defatted by 
immersion in chloroform for 3 days to remove lipids and to facilitate the penetration 
of the embedding medium into the sample. Samples were then cleared of chloroform 
followed by immersion in 100% IMS for 3 days. A solution of 50:50 LR White
TM 
hard grade
 resin (London Resin Company Ltd.) and IMS was then prepared and the 
samples were placed in this solution for 3 days, followed by a final immersion in 
100% LR White resin for 6 days during which the samples were kept in a cool, dark 
and dry area to avoid autopolymerisation of the resin. Following the final processing 
stage the samples were immersed in fresh hard grade LR White resin in moulding 
containers. Infiltration of the resin into the samples was aided  by application of 
vacuum pressure for 10 minutes. A catalyst was added to the resin (one drop/10ml) 
to initiate polymerisation and the samples were placed in a 4 °C refrigerator to allow 
slow setting and decipation of heat due to the exothermic reaction.  Chapter II. In vivo Osteoconduction by Calcium Phosphate Bone Substitutes: A Comparative Study                                                                                           
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  The embedded samples were then sectioned longitudinally through the centre of 
each defect using an Exakt saw machine (EXAKT, Germany) followed by grinding 
the prepared sample slide to the desired thickness of ~ 70 µm using the Exakt micro-
grinding system (EXAKT, Germany). The prepared thin sections were then polished 
using the Motopol 2000 machine (Buehler, UK).  
   In order to carry out histomorphometric analysis,  samples were stained w ith 
Toluidine Blue for 20 minutes (stains the nuclei and cellular details), followed by 15 
minutes of staining with Paragon for the identification of bone within the samples.  
 
2.5.4  Histomorphometry 
Comparison of the amount of new bone formation within the different materials was 
made using histomorphometry techniques. The percentage area occupied with new 
bone, the percentage new bone in contact with the biomaterial surface and changes 
in the percentage biomaterial present were quantified using the Axiovision Release 
4.6 image analysis  system (Zeiss, Germany). Eight i mages were  taken at x5 
magnification, four views at the periphery and four views at the centre, of each 
stained thin section. The images were then overlaid with a grid (10x12 units) and the 
line-intercept method ( Figure  6) was used to quantify  percentage area,  bone-
biomaterial contact and implant area  where each line crossed the type of feature 
being measured.  
 
Figure 6. A photo micrograph showing the grid placed over the image and the type of tissue (I: 
Biomaterial, Red stain/NB: Bone or ST: Soft Tissue) present was measured at each intersection 
ST 
I 
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2.5.5  Back scattered electron microscopy  
Back scattered electron microscopy (BSEM) and Energy Dispersive X-Ray analysis 
(EDAX) were carried  out  in order to analyse bone formation and the elements 
present within the bone substitute biomaterials. One thin section sample slide from 
each biomaterial group was mounted on aluminium stubs and then sputter coated 
with gold palladium particles using an EMITECH K550 machine. The coated slides 
were then analysed using a JOEL JSM-5500LV scanning electron microscopy unit 
and back scattered electron microscopy images  of the samples  were obtained. 
Elemental maps of the samples containing new bone were also obtained using 
Energy Dispersive X -ray microanalysis (EDAX, UK) to investigate the elements 
present in the newly formed bone and soft tissue next to the implanted biomaterial. 
 
2.5.6  Statistics 
Statistical analysis was carried out using SPSS statistics software (SPSS v10.1, SPSS 
Inc. Chicago, USA). Non parametric data was analysed using Man Whitney U-test 
and p< 0.05 was considered to represent statistical significance.  
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2.6  Results 
2.6.1  Histomorphometry 
2.6.1.1 New Bone Area 
Histomorphometry results showed bone formation within all biomaterials. The CaP 
based biomaterials ApaPore (AP), Actifuse (AF), CPS, BiIonic (BI) and Pro Osteon 
500R (PO) promoted significantly (P<0.05) greater bone formation by 6 weeks with 
the exception of Skelite (SK) when compared with both DBM putty (CO) and DBM 
Crunch (CR) (Figure 7). 
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Figure 7. New bone area percentage within Actifuse (AF), ApaPore (AP), BiIonic (BI), CPS, DBM 
Crunch (CR), DBM putty (CO), Pro Osteon 500R (PO) and Skelite (SK) samples at weeks 1, 3 and 6. 
(Numbers 1, 3 and 6 next to the letters indicate time point. e.g. AF1: Actifuse at week 1) 
 
 
Results showed that biomaterials of calcium phosphate composition promoted high 
levels of bone formation from week 1 to week 6 (Figure 7). At 6 weeks significant 
levels  (P<0.05)  of new  bone  were observed within  CPS, BiIonic, ApaPore and 
Actifuse compared to bone formation within these biomaterials at weeks 1 and 3. 
CPS samples presented the highest level (30.77%) of bone formation at 6 weeks 
compared to the other groups.  Skelite  biomaterials  exhibited  the lowest  (3.01%) 
amount of bone formation at 6 weeks.  
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   BiIonic (28.94), ApaPore (28.70%) and Actifuse ( 26.83%) samples respectively 
showed significantly greater bone formation (P=<0.001) compared to Pro Osteon 
500R  (11.1%)  and Skelite  (3.01%)  samples at week 6 .  Pro Osteon 500R (PO) 
biomaterials showed no significant  difference  (P=0.06)  in the amount of newly 
formed bone from week 3 to 6 (Figure 7).  
   A significant difference of P< 0.005 was observed between the area of new bone 
measured within Actifuse (AF1), ApaPore (AP1) and CPS (CPS1) in comparison 
with BiIonic (BI1) and Skelite (SK1) at week 1 (AP1:BI/SK1, P=0.000; AF1:BI1, 
P=0.001; AF1: SK1, P=0.000; CPS1:BI1, P=0.009).  However, no significant 
difference was observed between ApaPore and Actifuse samples in comparison with 
CPS at week 1. CPS (CPS3) and ApaPore (AP3) showed greater bone formation at 3 
weeks compared to BiIonic and Actifuse respectively, with a significant difference 
(P=0.000) between CPS3 and AF3 and BI3. The amount of bone formation within 
Pro Osteon 500R (PO3 and 6) samples by 6 weeks was not significantly different 
(PO3:AF3, P=0.82; PO6:BI3, P=0.12; PO6:AP6, P=0.89)  from that of Actifuse 
(AF3), ApaPore and BiIonic (BI3) biomaterials at week 3. The amount of new bone 
formation at 6 weeks was not significantly different (P> 0.05) when CPS (CPS6), 
BiIonic (BI6), ApaPore (AP6) and Actifuse (AF6) samples were compared 
(AF6:AP6, P=0.65; AF6:BI6, P=0.67; CPS6:AF6, P=0.21). Skelite (SK6) samples at 6 
weeks showed similar amounts of new bone within CPS (CPS1) samples at week 1. 
   Both DBM based  biomaterials showed the lowest amount of bone formation 
compared to the calcium phosphate based biomaterials, with the exception of Skelite.    
DBM Crunch (CR) promoted greater bone formation by week 6 compared to DBM 
putty (CO), however this difference was not significant (P>0.05)  (Figure  7).  No 
significant difference was observed in the amount of bone formation within DBM 
crunch and DBM putty biomaterials at 3 weeks (Figure 7). The amount of bone area 
within the DBM putty samples at week 1 did not show any change in comparison 
with week 3, however significantly more bone was formed by week 6 of the study 
(CO1: CO6, P=0.01). 
 Chapter II. In vivo Osteoconduction by Calcium Phosphate Bone Substitutes: A Comparative Study                                                                                           
  62 
2.6.1.2  Bone–Biomaterial Contact 
Results showed variable amounts of new bone in contact with the surface of the 
different biomaterials. Significantly greater bone formation (P<0.05) was observed 
adjacent to the calcium phosphate based biomaterials in comparison to the DBM 
samples (Figure 8).  
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Figure 8. % bone contact for samples at weeks 1, 3 and 6. AF: Actifuse, AP: ApaPore, CO: 
Connexus, BI: BiIonic, CPS, PO: Pro Osteon 500R, SK: Skelite 
 
 
ApaPore showed greater bone formation in contact with the surface (40.1%) and 
Skelite samples indicated the lowest amount of bone contact  (3.3%)  (Figure  8). 
Similar to the results obtained for percentage new bone area within the implanted 
biomaterials, ApaPore (40.1%), CPS (32%), Actifuse (31.7%) and BiIonic (32.2%) 
demonstrated significantly increased amounts of new bone contact (P<0.05) by week 
6 compared to Pro Osteon500R and Skelite. Analysis of CPS samples showed a fast 
and high amount of bone contact by week 3 of the study with a slight decrease in the 
levels of newly f ormed bone  in contact with  the  biomaterial surface at week  6 
compared to week 3. However, close correlation between the increase in the amount 
of newly formed bone and the  biomaterial surface was observed for ApaPore, 
Actifuse and BiIonic samples from week 1 to week 6. Levels of bone formed in 
contact with  Pro Osteon 500R samples were observed to be lower at week 6 
compared to week 3. Skelite biomaterials showed a decrease in the amount of new 
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bone in contact with the biomaterial from week 1 to week 3 followed by an increase 
in bone contact from week 3 to week 6 (Figure 8). 
   DBM Crunch (CR) samples demonstrated greater bone contact compared with 
DBM putty (CO) samples at 3 and 6 weeks. Significantly greater new bone contact 
(P<0.05) was observed in both DBM CR and CO samples at 6 weeks compared to 
samples at week 3 (Figure 8). DMB Crunch showed similar amounts of bone contact 
at week 6 to ProOsteon 500R at week 3. 
 
 
2.6.2  Biomaterial Area  
Histomorphometry analysis of the percentage implanted material’s area within the 
femoral condyle  defects indicated variable  changes  in the amount of  implanted 
material within the 6 week period of the study (Figure 9).  
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Figure 9. Percentage of biomaterial area within calcium phosphate based and DBM based 
biomaterials 
 
 
Results demonstrated resorption of both Skelite and DBM putty samples within 6 
weeks. Analysis of Actifuse, ApaPore, BiIonic, CPS and Pro Osteon 500R samples 
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observed to show a lower biomaterial area at week 3. As the biomaterials area at 
week 6 were observed to be similar to week 1 based on the histomorphometry 
results, the lower biomaterial area at week 3 was deduced to be due to the differences 
in packing of the material into the defects at point of implantation.  
   Skelite (SK) samples  demonstrated a significant reduction (P=<0.001) in 
percentage of biomaterial area from week 1 to week 6. The area of the implanted 
material in Skelite samples was observed to reach half the initial implanted amount 
by week 3, followed by no change in this reduction up to week 6 of the study.  
   Analysis of the DMB group of biomaterials showed a non-significant reduction 
from week 3 to week 6 in the area of implanted DBM Crunch (CR) biomaterial. 
DBM putty (CO) samples, however, demonstrated a significant reduction (P=0.000) 
in the percentage of biomaterial area from week 1 to weeks 3 and 6.  
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2.6.3  Dense vs. Porous biomaterials 
Analysis of the dense ApaPore (dAP6) and Actifuse (dAF6) samples in comparison 
with the porous samples (AP6 and AF6) indicated significantly greater bone 
formation (P=0.000) by week 6 in both porous ApaPore and Actifuse biomaterials. 
Significantly greater bone formation (AF1: dAF6, P=0.004; AP1; dAP6, P=0.04) was 
observed  in porous samples (AP1 and AF1)  at week 1 compared to the dense 
samples (dAP6 and dAF6) at week 6 (Figure 10).  
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Figure 10. % bone area within porous and dense ApaPore and Actifuse calcium phosphates within 6 
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2.6.4  Histological Analysis 
2.6.4.1 New Bone Area 
Light microscopy analysis showed varying amounts of new bone formation within all 
groups analysed at weeks 1, 3 and 6 .  In all groups, w oven bone formation was 
observed to be greater on the periphery of the defects where the biomaterials were in 
contact with host bone. The amount of bone formation within the centre of the 
studied biomaterials was observed to be material dependant.  
 
2.6.4.2 Actifuse 
Histology and BSEM images of Actifuse showed the presence of woven bone within 
the scaffold at the periphery and deep within the centre of the implants by week 6. 
New bone was observed adjacent to the biomaterial surface, within the pores and 
also in between the biomaterial granules (Figure 11). Bone formation was observed 
to be  initiated by mesenchymal condensation by week 1 , followed by bone 
deposition by osteoblasts and formation of lamellar bone by week 6 of the study. No 
sign of any inflammatory response was observed. 
 
   
Figure 11. New bone formed within Actifuse at 6 weeks. A) Histology image: “*”/ Red stain 
indicating new bone. I: Biomaterial, ST: Soft tissue; Bar=100 µm B) BSEM image, Arrows: new bone, 
I: Actifuse, Bar = 100 µm 
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High magnification images of the samples  showed  presence of osteoblasts  and 
centres of ossification and zones of newly deposited bone matrix on the surface of 
the pore (Figure 12, Figure 13 and Figure 14). Presence of multinucleated giant cells 
and  osteoclasts within the scaffold suggests remodeling of the bone (Figure 16). 
Lamellar bone was observed by week 6 of the study (Figure 15). 
 
 
Figure 12. Actifuse sample at week 1. 
 
 
Figure 13. Actifuse at week 3. Red, Bone, Arrows: Osteoblast.  
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Figure 14. Image of new bone formed within Actifuse at week 6. Arrows: osteoblasts, I: Biomaterial, 
NB: New bone, ST: Soft tissue. Circle: mesenchymal condensation. Yellow arrow: osteoclasts. 
 
 
Figure 15. Lamellar bone within Actifuse sample at week 6.  
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Figure 16. Actifuse at week 3. Arrow: Multinucleated giant cell.  
 
 
2.6.4.3 ApaPore 
Analysis of histological and BSEM (Figure 17 and Figure 18) images of ApaPore 
samples indicated the presence of bone both in the periphery and also in the centre 
of the graft. Bone was observed within the biomaterial pores and also in between the 
ApaPore granules.  Zones of mesenchymal condensation were  observed on the 
concave face of the ApaPore pores. Lamellar bone was observed by week 6 of the 
study (Figure 19). 
   High magnification images showed the presence of osteoblasts in the vicinity of 
the newly formed bone adjacent to the biomaterial surface by week 6 (Figure 20). 
The presence of osteocyte cells and  blood vessels (Figure 20) was also observed 
within the samples ( Figure  21).  Further  osteoclast like foreign body giant cells 
(FBGC)  were identified in the vicinity of ApaPore particles ( Figure  20) (Tatrat 
resistant acid phosphatase (TRAP) would confirm the nature of these cells as 
osteoaclasts or FBGCs). 
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Figure 17. New bone formation within ApaPore at week 3. Red stain/arrows: New bone, I: Implant; 
ST: Soft tissue. HB: Host bone 
 
Figure 18. BSEM image indicating new bone within and between ApaPore pores. Arrows: new bone 
 
 
Figure 19. Lamellar bone within ApaPore at 6 weeks. Red stain: Bone; Green Arrow: Mesenchymal 
condensation.  
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Figure 20. New bone within ApaPore at week 6. Black Arrows: osteoblast. Yellow arrow: Blood 
vessel, Red stain: NB: New bone, ST: Soft tissue 
 
 
Figure 21. New bone within ApaPore at 6 weeks. Black arrows: osteoblasts, white arrows: osteocytes, 
Green arrow: osteoclasts and implant resorption zone.  
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2.6.4.4 BiIonic 
Woven bone was observed within BiIonic samples by week 3 of the study (Figure 22, 
Figure 23). High magnification images indicated the presence of attached osteoblasts 
on  the  1-2 mm dense  BiIonic granules  surface (Figure 25). Bone formation was 
observed initially at the periphery of the defects at week 1 and at this time no bone 
formation was seen within the  centre of the defect. By week 6 new bone was 
observed within the centre of the defects deep within the BiIonic samples (Figure 
25).  
 
Figure 22. New bone within BiIonic sample at 6 weeks. Red stain/ *: New bone, ST: Soft Tissue 
 
 
Figure 23. BSEM image indicating new bone within BiIonic. Arrows: New Bone 
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Figure 24. Osteoblast cells surrounding BiIonic particles at 3 weeks. Arrows: Osteoblasts, ST: Soft 
Tissue.  
 
 
Figure 25. New bone formation within a BiIonic sample at 6 weeks. Arrows: Osteoblasts, NB: New 
Bone.  
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2.6.4.5 CPS 
Bone formation was observed within all CPS samples at weeks 1, 3 and 6 (Figure 26). 
BSEM images indicated the presence of new bone in contact with the dense 1-2 mm 
CPS particles  possessing sharp edged structure)  and in between the biomaterial 
particles by week 6. CPS particles were observed to have been resorbed on the edges 
and the surface deforming into grooved particles (Figure 27, Figure 28). Osteoblasts 
and blood vessels were observed adjacent to the surface and within the samples 
(Figure 28, Figure 29). 
 
Figure 26. New bone formation within a CPS samples at week 6. Red stain indicating new bone. 
 
 
Figure 27. BSEM image indicating new bone within CPS. NB: New bone. Magnified image indicates 
new bone attachment to CPS. Green arrow indicates material dissolution 
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Figure 28. Presence of osteoblasts adjacent to CPS at 6 weeks. NB: New bone.  
 
 
Figure 29. CPS sample at 3 weeks. Yellow arrows: Osteoclasts, Green arrows: blood vessel.  
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2.6.4.6 Pro Osteon 500R 
Woven bone was observed on the surface of Pro Osteon 500R samples by week 6 
(Figure 30). Osteoblasts were identified on the surface of the newly formed bone 
(Figure 31). Analysis of the high magnification images showed bone formation on 
the surface of the converted HA layer around the calcium carbonate core of the Pro 
Osteon 500R samples (Figure 31). 
 
   
Figure 30. Pro Osteon 500R. Red stain indicating bone. NB: New Bone, ST: Soft Tissue, PO: Pro 
Osteon 500R 
 
 
BSEM and histology images of Pro Osteon 500R (PO) samples showed woven bone 
within the biomaterial particles. New bone was seen to bridge Pro Osteon 500R 
particles together (Figure 32). Zones of biomaterial resorption were observed starting 
from the edges of the PO particles deep into the biomaterial particles (Figure 33). 
Bone formation was formed on the HA layer of the PO particles (Figure 33 and 
Figure 34). High magnification BSEM and EDAX analysis images showed presence 
of calcium phosphate precipitation nodules within the samples (Figure 34). Blood 
vessel formation was also visible within the samples (Figure 31). 
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Figure 31. New bone within Pro Osteon 500R. White arrows: HA layer surrounding the PO particle, 
Star: blood vessels, Black arrows: Osteoblasts, Yellow arrows: Osteocytes and NB: New Bone.  
 
 
Figure 32. BSEM image indicating bone formation in between Pro Osteon 500R particles. Arrows: 
HA layer  
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Figure 33. BSEM image indicating bone formation on Pro Osteon 500R and zones of biomaterial 
resorption. Yellow arrows: HA, Red arrows: resorption zone, NB: New Bone 
 
 
 
Figure 34. High magnification BSEM image. Zones of Pro Osteon 500R (PO) resorption and 
presence of CaP nodules. Yellow Arrows: HA, stars *: zones of resorption 
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EDAX analysis of the layer surrounding the Pro Osteon 500R indicated the calcium 
carbonate composition of the coral surrounded by the calcium phosphate rich layer 
of the converted HA. Analysis of elements present within the  nodules  also 
demonstrated a calcium phosphate rich composition (Figure 35). 
 
 
   
 
   
 
   
 
 
 
Figure 35. EDAX spectrums of elemental composition of PO samples and the surrounding HA 
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2.6.4.7 Skelite 
Skelite  samples demonstrated  minimal amounts of new bone formation  on the 
surface of the particles within 6 weeks (Figure 36 and Figure 37) and (Figure 38). 
Analysis  showed  red stained zones within the  samples; however analysis  at  high 
magnification did not confirm the red stain as newly formed bone (Figure 38). BSEM 
images indicated new bone on the surface of the Skelite particles (Figure 37). 
 
 
Figure 36. New bone formation on a Skelite at 6 weeks. Red stain/Arrow indicates new bone. ST: 
Soft tissue 
 
 
Figure 37. BSEM image indicating new bone within Skelite at 6 weeks 
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Figure 38. Skelite sample at 3 weeks. SK: Skelite; ST: Soft Tissue.  
 
 
High magnification analysis  of the Skelite samples  showed the  presence of 
osteoclasts and multinucleated giant cells indicating presence of active mechanisms 
of biomaterial resorption (Figure 39, Figure 40 and Figure 41). 
 
 
Figure 39. Skelite at 6 weeks. Arrows indicating osteoclasts and nucleated giant cells 
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Figure 40. BSEM image. Arrows indicate implant resorption sites within Skelite 
 
 
Figure 41. Skelite at 6 weeks. Arrow indicating multinucleated giant cells 
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2.6.4.8 Grafton DBM Crunch 
Minimal bone formation was observed within Grafton crunch samples (Figure 42 
and  Figure 43).  Osteoblasts and o steocytes were also  present  (Figure 45) on t he 
biomaterial surface indicating new bone formation on the DBM particles (Figure 42 
and Figure 45). Remineralisation of DBM particles and presence of multinucleated 
giant cells was observed adjacent to the Grafton Crunch particles (Figure 44 and 
Figure 45). 
 
 
Figure 42. New bone within Grafton crunch at 6 weeks. Arrow indicating remineralised DBM 
ST: soft tissue 
 
 
Figure 43. BSEM Image indicating Grafton Crunch DBM. 
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Figure 44. B). Remineralised Grafton Crunch DBM particle. Arrow: bone. NB: New bone 
 
 
 
Figure 45. Grafton crunch sample. Blue arrow: multi nucleated giant cell. Yellow arrows: osteoid and 
osteoblasts.  
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2.6.4.9 Accell Connexus DBM putty 
Histology analysis of the DBM samples showed the presence of minimal amounts of 
new bone by 6 weeks (Figure 46 and Figure 47). The presence of osteoclasts and 
multinucleated giant cells was observed in the vicinity of the DBM particles (Figure 
48).  
 
Figure 46. Accell Connexus DBM putty sample at week 6. CO: DBM putty, ST: Soft tissue 
 
 
Figure 47. BSEM image of Accell Connexus DBM particles (CO). 
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Figure 48. DBM putty particles. CO: Connexus DBM. Red arrows: osteoblasts. Green arrow: 
Osteocytes, Yellow arrows: osteoclast cells.  
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2.7  Discussion  
The results of this study indicate that all the calcium phosphate bone graft materials 
(p=<0.05) investigated in this study exhibited significantly greater bone formation 
compared to the DBM based biomaterials. Calcium phosphate based biomaterials 
have been widely used as osteoconductive materials and the results of this study 
further confirmed the influence of these biomaterials on bone formation. CPS, 
BiIonic, Actifuse and ApaPore exhibited the highest amount of bone formation and 
Pro Osteon 500R and Skelite demonstrated the lowest amount of new bone within 6 
weeks. Different mechanisms of bone formation, endochondral ossification in DBM 
samples and intramembranous ossification in CaP samples, were involved  in the 
process of bone formation within the implanted biomaterials. In this study different 
mechanisms of bone formation through the effects of chemistry and also 
microporosity must have contributed to the level of bone formation by the 
implanted Calcium Phosphates.  CPS, ApaPore, Actifuse,  Pro Osteon 500R and 
Skelite particles were of a porous structure and bone formation was observed deep 
within the pores and in between the biomaterials’ particles, whereas BiIonic particles 
comprised of a dense structure and new bone were observed in contact with the 
particles surface. It is known that a biomaterial’s microstructure influences the rate of 
bone formation (Karageorgiou and Kaplan, 2005). High porosity and interconnected 
porous structures are important factors in promotion of biomaterial vascularisation 
and consequent bone formation through facilitation of cell migration and proteins, 
growth factors and body fluids’ access into the biomaterial structure (Mastrogiocomo 
et al., 2006). As the results of this study indicated significantly greater bone formation 
(P<0.05) was obtained on CaP biomaterials (Actifuse and ApaPore) with porous 
structures in comparison with dense particles. However, it should also be noted that 
the superior bone formation within the porous materials could also have been due to 
the effect of the extra space in the pores, allowing the growth of more new bone. 
   Calcium phosphate biomaterials implanted in osseous tissue are known to dissolve 
and release calcium phosphate ions into their surrounding. The released Ca and P 
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apatite composed of endogenous proteins on the surface of the material (Daculsi et 
al., 1990; Villarreal et al., 1998). This is followed by attachment of osteogenic cells to 
this apatite layer and production of extracellular matrix which undergoes 
mineralisation by osteoblast cells and formation of woven bone within the 
biomaterials’ pores and along the surface. This process is followed by remodelling of 
the woven bone by the activity of osteoclast cells (D. Le Nihouannen et al., 2005). 
The results of this experiment indicated that some of the materials resorbed quickly, 
however the release of Ca and P ions  alone  did not promote enhanced bone 
formation by these biomaterials in comparison with Actifuse. This indicated that the 
role of calcium and phosphorous ions is not sufficient for promotion of faster 
osteoconduction by calcium phosphate biomaterials and the presence of other ions 
or structural variations also contribute to superior rates of bone formation. 
   The results of this study indicated 29% bone area and 30% contact of the new 
bone with ApaPore  biomaterial by week 6. The area of new bone within this 
biomaterial was significantly enhanced from week 3 to week 6. The level of bone 
contact with ApaPore was observed to increase proportionally from week 1 to week 
3 and then week 6. Results of the histomorphometry analysis of this biomaterial 
indicated n o significant change in the area of the ApaPore implants by week  6. 
However analysis of the histology images exhibited the presence of osteoclast cells 
within the samples. This indicated  resorption of ApaPore particles,  although  this 
resorption was not observed to be significant within the period of this study. The 
results of t his study confirm the findings of other studies (Klein et al., 1983; 
Frayssinet 1993)  in terms of the slow resorption rates of this biomaterial.  The 
presence of new bone matrix deposited by osteoblasts and vascular tissue within the 
macro and micropores of this biomaterial indicated osteoconduction through 
transfer of cells, body fluids, growth factors and nutrition into this biomaterial. 
   Analysis of the Actifuse, silicon substituted HA, samples indicated 27% bone area 
deposited by osteoblasts within the biomaterial’s macro and micropores by week 6. 
Bone formation within this biomaterial was enhanced significantly from week 3 to 
week 6  (P<0.05). New bone formation in contact with Actifuse samples was 
observed to increase proportionally during the time points of this study with 31% Chapter II. In vivo Osteoconduction by Calcium Phosphate Bone Substitutes: A Comparative Study                                                                                           
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bone contact by week 6.  Presence of osteoblasts on the surface of bone matrix 
deposited on the surface of the biomaterial and blood vessels within the samples 
indicated  bone formation  by  Actifuse  through the mechanism of chemical 
composition and structure of this biomaterial.  The area of the Actifuse particles 
within the implanted defects were observed to have reduced by week 6 (45% to 
41%), however this reduction was not significant. Silicate ions within SiHA are 
known to be released from the crystalline lattice of this biomaterial  in vitro with 
possible re-precipitation on the surface of the material (Guth et al., 2006). Silicon is 
known to affect the bioactivity of HA through transformation of the HA surface 
energy to a more electronegative surface, ideal for apatite formation and also 
increased solubility of the material by  the  formation  of  an apatite similar to the 
natural bone (Pietak et al., 2007). The surface chemistry of Actifuse is also known to 
promote greater absorption of growth factors, cell adhesion proteins and osteogenic 
protein to the surface of this material, enhancing the volume of newly formed bone 
and formation of mature lamellar bone in a shorter period of time (Hing et al., 2003). 
The trabecular network formed on Actifuse in known to undergo extensive 
remodelling, contributing to the formation of an organised and strong bonding 
between the host bone and the graft material (Porter et al., 2005).   
   Analysis of the BiIonic samples indicated ~ 29% new bone area  within these 
particles within 6 weeks. Bone formation was observed in between the BiIonic 
particles. The presence of osteoblast cells depositing bone matrix on the surface of 
BiIonic particles was detected. Incorporation of Yttrium into the structure of SiHA is 
known to enhance osteoblast adhesion and consequently osteoconduction by this 
biomaterial (Massa et al., 2001). Although in studies by Webster et al (2002 and 
2004), Sato et al (2006) and Massa et al (2005) Yttrium doped HA is shown to 
enhance calcium and protein adsorption and consequently adhesion and 
differentiation of osteoblasts in vitro, the results of this study did not indicate that in 
comparison with HA and SiHA, Yttrium-SiHA promotes any earlier bone formation 
in vivo. Although as the implant area was not significantly changed during the 6 week 
period of this study and no material disintegration was observed the role of Yttrium 
on stabilization of SiHA was evident. It should be noted that the implanted BiIonic Chapter II. In vivo Osteoconduction by Calcium Phosphate Bone Substitutes: A Comparative Study                                                                                           
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particles were in dense form whereas the SiHA and HA particles were porous and 
the effect of porosity on bone formation should not be neglected. In addition, the 
mentioned studies were carried out on primary human osteoblast cells and in this 
study ovine animal models were used and the variation in the effect of biomaterials 
on different cells should also not be ignored. The level of new bone contact showed 
a significant increase from week 1 (1.3%) to ~ 32% by week 6 as observed in 
ApaPore and Actifuse samples. This could be due to the effect of Yttrium promoting 
protein adsorption and cell attachment to the BiIonic particles (Urgun et al., 2001). 
The percentage of implanted particles’ area did not indicate a significant change from 
week 1 to week 6. 
   CPS or the Silicocarnotite samples exhibited ~ 31% bone formation by week 6. As 
demonstrated in a study by Ballas et al (2002), the substitution of PO4
3- by SiO4
4- 
within the structure of CPS results in the loss of biomaterial crystallinity, increased 
surface area and a slight reduction in the pH. This in turn may play a role in the 
bioactivity of this biomaterial and the formation of the bone-like apatite on the CPS 
surface and consequently bone formation on the biomaterial particles. The newly 
formed bone within these samples was observed to show ~ 32% contact with the 
biomaterial particles. Bone contact with CPS particles  was observed to be 
significantly high (P<0.05) by week 6   compared to week 1,  However, unlike 
ApaPore, Actifuse and BiIonic samples, the levels of bone contact with CPS particles 
was observed to be slightly (~35%), but not significantly, higher at week 3.  No 
significant difference was observed in the area of the implanted CPS particles within 
the defects on weeks 1 (62.1%) and 6 (62.9%), However as detected for Actifuse, 
ApaPore and BiIonic samples, the area of CPS particles was reduced on week 3 to 
~51%, which was elucidated to be due to human error during packing of the 
particles at the time of implantation. Further analysis of these samples is required to 
understand whether the change in implant area on the third week of implantation 
was due to different packing densities implied by human error during the impaction 
process or to a biological response. However, as the amount of implanted particles 
were kept constant for all samples (1.2ml) at the time of implantation, the effect of 
packing density on this reduction should be minimal.  Chapter II. In vivo Osteoconduction by Calcium Phosphate Bone Substitutes: A Comparative Study                                                                                           
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   Further, t he results of this study indicated  11% bone area within the defect 
containing Pro Osteon 500R. There was no difference in the level of bone formation 
at week 3 compared with week 6. However, the level of bone contact was observed 
to have reduced from week 3 to week 6 , suggesting increased bone  formation 
between  the biomaterial particles.  The histomorphometry results of this study 
indicated no significant reduction in the area of the Pro Osteon 500R biomaterials 
implanted  within the femoral condyle defects. However, the histology images 
obtained for this biomaterial indicated zones of biomaterial resorption as previously 
shown in studies by Walsh et al., 2003 and Stubb et al., 2004, surrounded by a layer 
of precipitates identified as calcium phosphate.  The  study by Doi et al. (1993) 
indicated that the presence of carbonate in the apatite lattice is known to contribute 
to the process of  resorption in bone tissue.  As  Pro Osteon 500R is primarily 
composed of calcium carbonate, the resorption zones observed within  this 
biomaterial may be associated with the removal of calcium carbonate. Presence of 
osteoclasts surrounding the  Pro Osteon 500R confirmed the resorbablity of this 
biomaterial, as claimed by the manufacturers. A study by Spence at al., 2008 on 
osteoconductivity of carbonated HA  indicated that osteoclast cells influence the 
bioactivity of the biomaterials through modification of the biomaterial surface in 
favour of osteoblast cells response to the biomaterial surface and indirect 
enhancement of osteoconduction through enhanced bio-resorption.  The HA 
converted  from  calcium carbonate of the coral contributed to the slow 
biodegradation of the biomaterial due to its low solubility. Further, the HA on the 
surface of the biomaterial undergoes gradual resorption, whereas fast resorption of 
the calcium carbonate core of the biomaterial was observed in this study and in the 
study by Walsh et al., 2003. 
   Following the 6 week period, the amount of newly formed bone on Skelite samples 
was observed to be lowest (~3%). The amount of bone formation in contact with 
the implant particles was not significantly different at weeks 1 and 6 of the study. 
Histological a nalysis of Skelite samples indicated the presence of osteoclast and 
multinucleated giant cells surrounding the biomaterial particles indicating resorption 
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mechanism  by  increased binding of osteopontin and osteoclastic proteins  to its 
surface and by recruiting both osteoblasts and osteoclasts to the vicinity (Pietak et al., 
2004; Leroux et al., 2007). A study by Mastrogiacomo et al., 2006 investigating the 
repair of large bone defects by implantation of Skelite, demonstrated that it 
promoted significant bone formation and integration within the host tissue within 
two years of implantation. Skelite also exhibited progressive osteoclastic resorption 
and complete resorption within the two year period of this study. The results of this 
work do not support the work by Mastrogiacomo et al., 2006 who suggested that 
resorption or dissolution of this biomaterial was observed with the presence of active 
new bone deposition. In this study, a cylindrical form of Skelite was used. At the time 
of implantation and impaction of the biomaterial into the defects, the porous 
cylinders were fragmented and lost their structural integrity. The histomorphometry 
results of this study indicated that Skelite particles exhibited a significant reduction 
(P<0.05) in the biomaterial area from week 1 to week 6. The results of this study 
further confirmed the results of the study by Leroux et al.,  2007 indicating the 
presence of a foreign body reaction for Skelite samples in vivo as a result of premature 
rapid fragmentation of Skelite within the implanted site.   
   The ideal bone substitute material is expected to promote osteoblastic activity for 
formation of new bone, in addition to promotion of natural bone remodelling 
through its resorption by osteoclasts (Langstaff et al., 1999). The resorption rate of a 
biomaterial is known to depend on the biomaterial’s composition, geometry and 
implantation location (Bohner and Baumgart, 2003). During the 6 week period of 
this study, Pro Osteon 500R and Skelite demonstrated greater resorption, however 
the amounts of new bone formed on these biomaterials (Pro Osteon 500R: ~11% 
and Skelite: ~3%) was significantly lower (P<0.05) than the amount of bone formed 
on ApaPore, Actifuse, BiIonic and CPS samples. As bone formation by these 
biomaterials is proposed to be the function of a couple processing between 
resorption and bone deposition, the results of this study suggest that this is not the 
case with more stable non-resorbable calcium phosphate materials, inducing much 
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   DBM biomaterials are known to induce bone formation through osteoinduction 
and osteoconduction mechanisms (Iian and Ladd, 2003). However, the results of this 
study showed that the rate of osteoconduction by the tested DBM (Grafton Crunch 
and Accell Connexus putty) biomaterials was not as high as calcium phosphates by 6 
weeks. DBM promotes osteoconduction through apposition of new bone matrix on 
the DBM particles, followed by  mineralisation of this matrix and also 
remineralisation of the DBM particles, inducing new bone apposition (Hagen et al., 
1992). The presence of osteoclast cells within DBM samples indicated resorption of 
this biomaterial within the implanted site. Studies on resorption of this biomaterial 
have indicated  inconsistent results as some report complete resorption of DBM 
particles, whereas others have not observed any sign of osteoclastic activity 
(Groenveld et al., 1998). The histomorphometry and histological results of this study 
demonstrated  a  significant reduction (P<0.05) in Accell Connexus DBM putty 
implant area from week 1 to week 6, however DBM Grafton Crunch samples did not 
resorb significantly during the period of this study. In addition to the low rate of 
bone formation by DBM biomaterials in comparison with Calcium phosphates, the 
resorption of the graft and the limited amount of bone for production of these 
biomaterials are restricting factors in their use (Hagen et al., 1992).  
   As indicated in various in vivo and in vitro studies, silicon substitution within the HA 
structure improves the bioactivity of this biomaterial (Gibson et al., 1999; Patel et al., 
2002; Ballas et al., 2002). The histomorphometry results of this study indicated that 
the incorporation of silicate ion within Actifuse, CPS and BiIonic  increased  the 
formation of new bone within t heses samples, irrespective of  the structural 
properties of these biomaterials. BiIonic is a dense biomaterial and Actifuse and CPS 
are porous structures.   
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2.8  Conclusions 
The results of this study indicated that calcium phosphate bone substitute materials 
promote greater bone formation in comparison with DBM based biomaterials. CPS 
exhibited the highest amounts of bone formation within the 6 week period of this 
study. ApaPore, BiIonic, Actifuse, and Pro Osteon 500R respectively demonstrated 
superior bone formation. Skelite exhibited the lowest amount of bone formation by 
week 6. Both DBM samples, Grafton Crunch and Accell Connexus putty samples 
indicated minimal amounts of bone formation by week 6. However Grafton Crunch 
exhibited greater bone formation in comparison with Accell Connexus putty. 
ApaPore showed the highest amount of new bone in contact with the biomaterial, 
followed by Actifuse. Bionic and CPS showed similar amounts of bone contact by 
week 6, but at lower percentages than bone contact with Actifuse. Percentage of 
bone contact with Pro Osteon 500R was reduced from week 3 to week 6 of the 
study. Skelite samples showed the lowest amount of bone contact in comparison 
with other analysed calcium phosphate based biomaterials. The percentage of bone 
contact with this biomaterial was similar on week 1 and week 6 . The area of 
implanted ApaPore, Actifuse, BiIonic, CPS and Pro Osteon 500R calcium phosphate 
based biomaterials particles did not indicate any significant change during the 6 week 
period of this study.  However, Skelite samples exhibited a significant (P<0.05) 
reduction in the area of Skelite particles from week 1 to 6. Grafton Crunch DBM 
particles did not indicate a significant area reduction, however the area of Accell 
Connexus putty particles exhibited a significant reduction (P<0.05) from week 1 to 6. 
     Presence of porosity within the biomaterial structure can contribute to increased 
bone formation. However, it is not essential as, for example, the amount of newly 
formed bone on dense BiIonic particles was similar to the amount of bone formed 
on porous ApaPore. This suggests that the chemical composition of a biomaterial 
has an effect on bone formation irrespective of the structural porosity due to the role 
of the elements present within its structure.  
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3  Chapter III. Cellular and Molecular Mechanism of 
Osteoinductivity by Silicon Substituted Hydroxyapatite  
3.1  Introduction 
The results of chapter II suggested that the presence of silicate ions (Si) within 
calcium phosphate based bone substitute materials play a role in the rate of bone 
formation.  Trace amounts of silicon are known to enhance bone formation by 
increasing o steoblast activity (Keeting et al., 1992). In 1999 Gibson et al 
demonstrated that the bioactivities of osteoblasts in vitro are enhanced on silicon 
substituted-hydroxyapatite (SiHA). It is known that one common mechanism 
involved in bone formation by calcium phosphate based biomaterials is the 
dissolution of calcium and phosphate ions from the biomaterial (Weng et al., 1995) 
and the deposition of a biological apatite back onto the surface. A study by Xynos et 
al (2001) also indicated that release of silicate and calcium ions from bioactive glasses 
lead to an enhanced rate of new bone proliferation due to a process of gene 
activation and control of the cell cycle. A study that investigated the effect of a 
physiological concentration of soluble Si on human osteoblast-like cells indicated an 
increase in osteoblasts’ differentiation, proliferation and also collagen production 
(Reffitt et al., 2003). Botelho et al (2006) demonstrated that 0.8wt% silicon within 
hydroxyapatite enhanced protein production of human osteoblast cells in addition to 
enhanced expression of some osteogenic marker genes. Further, human osteoblast-
like cells grown on SiHA exhibit enhanced cell adhesion, spreading, extracellular 
matrix production and mineralisation when compared with HA (Thian et al., 2006). 
Therefore it is possible that Si HA may induce different gene expression when 
compared to pure HA. 
 
3.2  Osteoblast Proliferation and Differentiation 
Genes encoding transcription factors and osteogenic proteins are known to be 
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differentiation of the three specific cell types of bone tissue (Karsenty, 1998). This 
study analysed the proliferation, mineralisation and mRNA expression pattern of 
angiogenic factor,  the VEGF gene, early/late markers of osteogenesis such as 
Osteopontin, Osteonectin, Osteocalcin, Bone Sialoprotein and transcription factors 
Cbfa1/RUNX2 and Osterix in hMSCs cultured on this biomaterial in comparison 
with hMSCs cultured on HA and Therminox discs.   
 
3.2.1  Transcription factors 
3.2.1.1  Cbfa1/Runx2 
Core binding factor A1 which is a runt (DNA binding transcription factor) related 
transcription factor from the RUNX family of transcription factors (Cbfa1/Runx2) is 
involved in transcriptional control of osteoblast differentiation and osteogenesis as 
its core element (Karsenty and Wagner, 2002). Cbfa1/RUNX2 is expressed in the 
common ancestor between the stromal cells and osteoblasts known as the 
osteoprogenitor cells, during the earliest phases of ossification (Otto et al., 1997). 
Cbfa1 is necessary for differentiation of mesenchymal progenitor cells to osteoblasts, 
and Cbfa1/RUNX2 is known as an essential factor for the control of bone 
formation by differentiated osteoblasts (Masato, 2001). Cbfa1 is known to induce 
expression of osteonectin, osteocalcin and bone sialoprotein osteogenic markers and 
these genes are known to exhibit Cbfa1 binding sites in their promoters (Ducy et al., 
1997; Komori and Kishimoto, 1998). This transcription factor is known to control 
the expression of other genes encoding osteoblast specific transcription factors such 
as Osterix (Karsenty and Wagner, 2002). Early stage osteoblast differentiation is 
known to be positively regulated by Cbfa1 with negative regulation at later stages of 
osteoblast development (Igarashi et al., 2004). 
 
3.2.1.2  Osterix 
Osterix (Osx)/SP7 is an osteoblast specific transcription factor essential for positive 
regulation of osteoblast differentiation and bone formation (Nakashima et al., 2002; 
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endochondral bone formation. Inactivation of the gene encoding for Osx in growing 
bones is known to delay osteoblast maturation and result in an accumulation of 
immature osteoblasts and the reduction of osteoblast function in bone formation 
(Cao et al., 2005; Baek et al., 2008). Osterix is proposed to be involved in the control 
of osteoblast
 differentiation by regulating gene expression which is not controlled by 
Runx2 (Matsubara et al., 2008). Recent studies investigating the function of this 
transcription factor have demonstrated that Osx induces the expression of 
osteogenic genes; however, it is not enough for terminal osteogenic differentiation 
(Yeon-Ju et al., 2006; Kurata et al., 2007).  
 
3.2.2  Osteoblastic marker proteins 
 As well as gene expression, particularly the expression of transcription factors, 
protein production by cells is a key function of terminal differentiation and is used to 
investigate the effect of biomaterials on the differentiation of cells.  Osteoblastic 
differentiation is marked by the production of specific proteins associated with 
mineralisation and bone formation. The following proteins will be used in this study 
to investigate the effects of SiHA on osteoblast differentiation.  
 
3.2.2.1 Osteopontin 
Osteopontin (OPN), also known as secreted phosphoprotein-1 (SPP1), is an 
extracellular matrix cell adhesion multifunctional phosphorylated acidic glycoprotein 
identified by Oldberg et al in 1986. It is expressed in many mineralized and soft 
tissues including bone, dentin, elastin, muscle, tumours and also in body fluids such 
as milk, the inner ear and urine (Brown et al., 1992; Gericke et al., 2005). 
Osteopontin is produced during the early developmental stage by pre-osteoblasts, 
osteoblasts and also osteoclastic cells and is secreted into osteoid and then integrated 
within bone (Butler, 1989). This protein is known to be localized in the mineralized 
phase of bone matrix in endochondral and intramembranous bone (Young et al., 
1992). Osteopontin is abundant in the bone matrix and forms strong bonds with 
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that osteopontin stops the growth of hydroxyapatite surfaces at the end of active 
bone formation. This protein is known to inhibit mineral formation and growth of 
mineral crystals and proliferation (Hunter et al., 1994; Boskey et al., 2001). 
Osteopontin is known to be important in the differentiation and recruitment of 
osteoclast cells (Gericke et al., 2005). It has been s uggested that osteopontin 
contributes to bone resorption by facilitating the attachment of osteoclasts to the 
extracellular matrix (Fisher et al., 1990; Asou et al., 2001). Remodelling of mature 
bone depends critically on the presence of osteopontin (Denhardt et al, 2001). An in 
vivo study by Asou et al (2001) demonstrated that the absence of osteopontin 
impaired angiogenesis, osteoclast accumulation and consequent bone resorption.  
 
3.2.2.2  Osteonectin 
Osteonectin/SPARC (secreted protein acidic and rich in cysteine) is a major non-
collagenous glycoprotein of the bone matrix with calcium ion binding sites. This 
protein is involved in tissue remodelling, cellular response to injury and tumour 
formation (Termine et al., 1981; Turk et al., 2005). Osteonectin is found t o be 
abundant in bone tissue and non-skeletal tissues such as the kidneys’ renal tube and 
the salivary epithelium. Osteonectin is found in osteoblast precursor cells, 
osteoblasts, newly formed osteocytes and the mineralizing chondroid of the 
developing bone (Young et al., 1992). This protein is known to be involved in the 
control of osteoblast and osteoclast cells’ proliferation, cell spreading, cell 
interactions with the extracellular matrix (Tremble et al., 1993; Delany et al., 2000) 
and also detachment of the cells from the extracellular matrix (Sage et al., 1989), in 
addition to the modulation of angiogenesis (Turk et al., 2005). Osteonectin is also 
known to exhibit an affinity with collagen I and hydroxyapatite for the control of 
mineralization nucleation in bone tissue (Price et al., 1976; Termine et al., 1981; 
Young et al., 1992).  
 Chapter III. Cellular and Molecular Mechanism of Osteoinductivity by Silicon Substituted Hydroxyapatite                                                                                                
  99 
3.2.2.3  Bone Sialoprotein 
Bone sialoprotein (BSP) is a bone extracellular matrix glycoprotein with cell 
attachment and bio-mineralization functions (Hunter and Goldberg, 1994, Harris et 
al., 2000). This protein is known to make up 8-12% of the non-collagenous proteins 
of the bone. Malaval et al (2008) demonstrated that BSP deficiency impairs bone 
growth and mineralization. Bone sialoprotein is localized in the extrafibrillar mineral 
of woven bone, dentin, cementum and hypertrophic cartilage (Ganss, 1999). This 
protein is expressed by mature osteoblast cells localized in active osteogenic cells and 
sites of de novo bone formation and mineral deposition (Harris et al., 2000). This 
protein exhibits affinity sites for type I collagen and calcium ions and is also known 
to initiate hydroxyapatite crystal formation in the bone matrix (Young et al., 1992; 
Ganss, 1999). Hydroxyapatite nucleation, binding and mediation of cell attachment 
to mineralised tissues, combined with a direct role in mineralisation, are the known 
functions of bone sialoprotein. Further, this protein is a valuable marker of 
osteogenic differentiation and specifically terminally differentiated osteoblasts (Ganss 
et al., 1999; Benson et al., 2000). 
 
3.2.2.4  Osteocalcin 
Osteocalcin/ BGP (bone gla/gamma-carboxyglutamate protein) is the most 
abundant non-collagenous protein expressed specifically in growing bone tissue and 
is involved in the modulation of bone mineralization and bone turnover (Young et 
al., 1992). Osteocalcin is expressed late in the process of osteoblast maturation and at 
the onset of extracellular matrix mineralisation (Bronner and Farach-Carson, 2003). 
This protein exhibits binding affinity for hydroxyapatite and calcium ions involved in 
the initiation of tissue mineralization (Hauschka et al., 1975). In addition to its 
binding properties, osteocalcin is involved in cell signalling and in the recruitment of 
osteoblasts and osteoclast cells (Hoang et al., 2003). Osteocalcin has been identified 
as the negative regulator of bone formation through limitation of bone matrix 
formation and inhibition of calcification and studies have demonstrated that 
osteocalcin deficient mutant mice exhibited excessive bone matrix deposition by 
osteoblasts (Wolf, 1996; Ducy et al., 1996 and Luo et al., 1997). Chapter III. Cellular and Molecular Mechanism of Osteoinductivity by Silicon Substituted Hydroxyapatite                                                                                                
  100 
3.2.2.5  Alkaline phosphatase  
Alkaline phosphatase is a de-phosphorylation enzyme found in all body tissues, with 
a tissue specific structure responsible for splitting inorganic phosphates from organic 
phosphate esters. This enzyme is known to be localised on the surface of osteoblast 
cells and secreted by these cells into the calcifying matrix, creating an alkaline 
environment for new bone formation. The presence of this enzyme was first 
reported in 1923 by Robinson through his study of the biochemical mechanism of 
bone calcification (Siffert, 1951). Alkaline phosphatase activity is observed at an early 
stage of osteoblast differentiation with an increase during osteoblast maturation up 
to the mineralisation phase (Stein et al., 1990). ALP isoenzyme has been proposed to 
play a role in bone mineralization and deactivation of this gene results in poor 
mineralisation of cartilage and bone (Hessle et al., 2002). 
 
   Bone formation by calcium phosphate biomaterials involves a complex set of 
cellular and molecular activities, including expression of osteogenic genes and protein 
synthesis influenced by the chemical composition of the biomaterial. Given the 
significant role of silicate ion in bone formation and the evident effect of the 
substitution of this ion into the structure of calcium phosphate biomaterials on the 
rate of bone formation, study of the influence of this ion on cellular and molecular 
mechanisms of cell differentiation and proliferation would be an important step in 
understanding the mechanism of bone formation by silicon substitution.  
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3.3  Aims and Hypothesis 
The aim of this part of this study was to investigate the effect of silicon substituted 
hydroxyapatite (SiHA) on the osteogenic differentiation of human marrow stromal 
cells and the osteoinductivity of this biomaterial in vitro in comparison with pure 
hydroxyapatite. The focus of this study was the analysis and comparison of mRNA 
expression of the VEGF gene, early/late markers of osteogenesis, the osteopontin, 
osteonectin, osteocalcin, bone sialoprotein genes, in addition to the transcription 
factors Cbfa1/RUNX2 and Osterix in hMSC grown on SiHA with plain HA. 
 
 
Hypothesis: 
The hypotheses for this part of this study are that: 
 
1.  Silicon substituted HA (SiHA) demonstrates in vitro osteoinduction through 
osteoblastic differentiation of hMSCs 
 
2.   Compared with HA, SiHA enhances osteogenic differentiation through 
stimulation of the expression of specific osteogenic marker genes  
 
3.  SiHA promotes osteogenesis via enhancement of the bioactivity of hMSCs 
through its chemical composition irrespective of the influence of osteogenic 
supplements or surface morphology 
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3.4  Materials and Methods 
In this study human marrow stromal cells were grown on dense SiHA, HA and 
Therminox cover slip discs for periods of up to 24 days. Cell morphology analysis 
was carried out using SEM analysis on days 1, 7, 14 and 24. DNA and protein assays 
on days 3, 12 and 24 were performed to study the bioactivity of these cells on these 
materials. Further, RNA extraction and RT-PCR analysis was performed to analyse 
the expression levels of RUNX2, Osterix, Osteopontin, Osteonectin, Osteocalcin, 
Bone sialoprotein and VEGF genes on days 1, 3, 6, 12 and 24 of the study within 
hMSCs grown on the discs in normal and osteogenic growth conditions. 
 
3.4.1  Disc production 
Hydroxyapatite (Batch no. A00P0B06500) and Silicon-substituted hydroxyapatite 
(Batch no. B276-2005) powder was provided by ApaTech Ltd. 1 gram of the powder 
was pressed at 155 Nm
-2 force using a mechanically operated press machine and 
metallic dyes specially designed for making dense discs of 11 x 3 mm (Figure 49). 
The SiHA and HA discs were then sintered in a furnace at 1300°C and 1250°C 
respectively. The temperature of the sintering furnace was set to increase at a rate of 
5°C/min up to the set plateau temperature followed by 2 hours of standstill. The 
temperature was then reduced down to 26°C at the rate of 10°C/min. the sintered 
discs were then heat sterilised at 160°C for 1 hour in a dry oven. 
 
   
Figure 49. a) Discs of SiHA/HA. b) SEM image of SiHA surface 
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3.4.2  Human Marrow Stromal Cells (hMSCs) culture  
Frozen Human marrow stromal cells of passage 0 suspensions (kindly provided by 
Dr Michelle Korda, IOMS, UCL) were expanded in culture to obtain the required 
number of cells. The cryo-preserved cells were initially thawed in a 37°C water bath. 
The cells were gradually reactivated by the addition of 1:1 increasing concentrations 
of standard culture medium [Dulbecco’s modified eagles medium (DMEM, D6249 
Sigma ®), supplemented with 10% fetal calf serum (FCS, First Link, UK) and 100 
units/ml penicillin/streptomycin (P/S, 0082, Invitrogen, Paisley, UK)] and 
centrifugation at 2000 rpm for 5 minutes up to three times. The cell suspension was 
then centrifuged for 5 minutes at 2000 rpm to obtain the cell pellet. The cell pellet 
was then separated from the supernatant and re-suspended in 1 ml DMEM using a 
19 gauge needle and 1 ml syringe. Following this, the cell suspension was transferred 
to T25 polystyrene cell culture flasks (Corning® cell culture flask, Sigma Aldrich) 
containing 4 ml of standard DMEM media, followed by incubation in a humidified 
incubator with 5% CO2 supplied at 37°C. Following 7-14 days of incubation and 
once the cells had covered 70% of the cell culture flask surface, the cells were 
expanded/passaged to obtain the required number of cells for this study. 
   In order to expand the number of cells grown in the initial culture flask, the 
DMEM media was first removed and discarded. The cells were then washed with 
cold phosphate buffered saline (PBS, P5493, Sigma-Aldrich). The washed cells were 
then detached from the culture flask by using a 1% Trypsin solution diluted with 
PBS (0.5% trypsin with EDTA 4Na, Invitrogen. 15400054, UK) solution stock at 
37°C for 5 minutes. Following this time and the detachment of the cells, the trypsin 
solution was neutralised by the addition of a 1:1 concentration of DMEM media. 
The suspended cells were then centrifuged for 5 min at 2000 rpm and the 
supernatant was removed. The cell pellet was then re-suspended in 1 ml DMEM 
media, and a cell viability test was then carried out by using a 1:1 ratio of the 
suspended cells to 0.4% Trypan Blue solution (T8154, Sigma-Aldrich, UK). The 
concentration of the cells was then quantified using a Haematocytometer viewed 
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dead and the unstained cells were counted as live cells. The cell suspension was then 
centrifuged for 5 minutes at 2000 rpm and the obtained cell pellet was re-suspended 
in 1 ml fresh DMEM using a 19 gauge needle and syringe. Cell suspension was then 
divided into two or three according to the number of counted cells and 4-5,000 
cells/cm
2 were seeded in new culture flasks containing DMEM media. Cells were 
washed and the media was changed every 2-3 days and further passaging (up to 
passage 3-4) of the cultured cells was carried out upon reaching 70-80% confluency.  
 
3.4.2.1  Characterisation of the Marrow Stromal Cells (MSCs) 
The morphology of the human marrow stromal Cells (hMSCs) used in the 
experiment was monitored under light microscopy at regular intervals during the 24 
day course of the study. In order to test the pluripotent characteristic of the MSCs, 
cells were differentiated along the adipogenic and osteogenic lineages. 
 
3.4.2.1.1  Osteogenic Differentiation 
Osteogenic differentiation of the MSCs was carried out in osteogenic supplemented 
medium. This medium was prepared by the addition of the following osteogenic 
supplements to DMEM (500 mg/L glucose; 110mg sodium pyruvate/L: L -
glutamine; sterile filtered and endotoxin tested, D6249, Sigma®) media. 
 
§  10% Fetal Calf Serum (FCS; First Link, UK) 
§  1.0% Penicillin/Streptomycin (P/S, 15070063, Gibes ®; Invitrogen 
TM ) 
§  x 10
-7 M Dexamethasone, water soluble (D2915, Sigma®) 
§  5.0 x 10
-4 M Ascorbic Acid 
§  0.02 M ß-glycerophosphate, disodium salt, pentahydrate (B69629, 
Calbiochem) 
 
To make the osteogenic medium, the FCS and P/S were added to the DMEM 
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by sterilisation using a 0.2 µm filter and sterile 10 ml syringe and then added to the 
prepared DMEM medium. The prepared medium was then added to 50,000 cells 
seeded in duplicate in 6 well cell culture plates (M8562, Sigma®). A second group of 
cells were also seeded in culture plates as the experiment control; however for these 
cells, non-osteogenic supplemented medium/standard DMEM medium was used. 
The cultured cells were then incubated in 5% CO2 at 37°C for 24 days. Following 
this time period, the cells were washed with PBS and fixed using 80% ethanol for 10 
minutes before Von Kossa staining for the detection of calcification and 
mineralisation. Von Kossa staining was carried out by the addition of 2% silver 
nitrite solution (S2252, Sigma®) to the cells. This was followed by exposure to a 
bright light for one hour, two washes with distilled water and 5 minutes treatment 
with 2.5% Sodium Thiosulphate (S7026, Sigma®). The cells were then washed with 
distilled water and counter stained with 1% Neutral Red (N4638, Sigma®). Stained 
cell nuclei were then observed under an Olympus BH2 photographic light 
microscope and the presence of calcium deposition confirmed the osteogenic 
differentiation of the cells. 
 
3.4.2.1.2  Adipogenic differentiation 
Adipogenic differentiation of the MSCs was carried out by culturing 50, 000 cells in 
adipogenic  medium. Preparation of the adipogenic  medium was carried out by 
supplementation of DMEM  medium (D6249,  Sigma®) with the supplementary 
factors listed below: 
 
§  20 ml 200 mM L-Glutamin 
§  3500 md-glucose 
§  10% FCS (First Link, UK) 
§  1.0% Penicillin/Streptomycin (P/S, 15070063, Gibes ®; Invitrogen 
TM ) 
§  1.0 x 10
-6 Dexamethasone, water soluble (D2915, Sigma®) 
§  200 µM Indomethacin 99% TLC (I7378-5G, Sigma®) 
§  500 µM 1-Methyl-3-Isobutylxanthine 99% (IBMX) (I5879, Sigma®) 
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The prepared adipogenic medium was added to the cells seeded in 6 well cell culture 
plates. A control group of cells was also cultured in normal/non-adipogenic 
supplemented DMEM medium. Samples were incubated at 37°C for a period of 21 
days, following which the medium was aspirated from the wells, the cells were 
washed with PBS and then fixed with 10% formal saline (formaldehyde (11-0705, 
Sigma) and NaCl solution) for 5 minutes for identification of intracellular lipid within 
the adipogenic differentiated cells by Oil-Red-O staining. Staining was carried out by 
rinsing the fixed cells with distilled water, followed by soaking in oil red O stain 
(O0625, Sigma) for 20 minutes. The cells were then rinsed with distilled water and 
counterstained with hematoxylin (H3136, Sigma) for 3 minutes. Cells were rinsed 
with distilled water and then air dried. The red stained lipid molecules and the blue 
nuclei within the cells were observed under light microscopy. 
 
3.4.3  Cell seeding on discs 
To assess the effect of SiHA on the proliferation and differentiation of human 
marrow stromal cells (hMSCs), three repeats (n=3) of dense SiHA and HA discs 
were seeded with passage 3 (P3) hMSCs and compared with hMSCs seeded on 
Therminox discs (Agar scientific, L4350). Osteoblastic differentiation was 
investigated by observing the morphological changes, osteoblastic marker proteins 
and osteogenic marker gene expression on SiHA, HA and Therminox coverslips. 
The prepared sterile SiHA and HA discs were placed in the wells of a 12 well cell 
culture plate.  50,000 hMSCs suspended in DMEM  medium were then dispensed 
onto the surface of HA, SiHA and Therminox discs and were left for one hour in the 
incubator to attach. Following this time, 2 ml of standard DMEM culture medium 
was added to the sample wells and the plates were incubated in 5% CO2 at 37°C for a 
period of 24 days, during which timed the samples were tested at days 1, 3, 6, 12 and 
24 for their cellular activities. A second group of discs were also seeded with hMSCs 
in the same manner, however these cells were grown in osteogenic medium in order 
to evaluate the effect of the osteogenic environment on the cellular activities of the 
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3.4.4  Osteogenic Differentiation- Morphology  
3.4.4.1  Scanning Electron Microscopy 
In order to study the morphological changes of cells seeded on SiHA and HA dense 
discs in comparison with cells seeded on Therminox discs, the discs loaded with cells 
(n=2) were processed for SEM analysis on days 1, 7, 14 and 24 of the study. 
   The cell loaded discs were first fixed with the addition of 1.5% glutaraldehyde 
(R1011, Agar Scientific) in 0.2 M Sodium Cacodylate buffer (BDH Chemicals 30118) 
for 24 hours at 4°C. Following this time, the glutaraldehyde was removed and the 
samples were washed with 0.1 M sodium cacodylate buffer for 10 minutes to remove 
the remaining glutaraldehyde residues.  1% osmium tetroxide in 0.1 M sodium 
cacodylate was then prepared for staining of the cells and added to the samples for 
60 minutes. Following this the samples were washed twice, each time for 5 minutes, 
with 0.1 M sodium cacodylate buffer. The samples were then dehydrated through 
increasing concentrations of ethanol (20-100%), twice at each concentration and each 
for 5 minutes. Following dehydration, hexamethyldisilazane, HMDS, (H4875, 
Sigma), a transition solvent was added to the samples for the purpose of drying the 
biological specimens. The samples were then left for 24 hours to air dry following 
which they were mounted on aluminium discs, sputter coated with a gold-palladium 
mixture using an Emitech K550 sputter coater (Emitech, UK). Samples were then 
visualized under a Joel JSM-5500LV Scanning Electron Microscope using the relative 
Joel User Interface version 4.04 at 15 kV.  
 
3.4.5  Cellular Proliferation 
3.4.5.1  Total DNA  
To measure the DNA content of the samples, on days 3, 12 and 24 the medium was 
removed from the culture wells. The cells were washed with PBS solution and then 
lysed with 1 ml of de-ionized water by repeated freeze-thawing of the cells three 
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Quant-iT
TM dsDNA Broad Range Assay kit (Q33, 130, Invitrogen). The assay was 
performed by transferring 10µl of the lysate into the provided microwell plate in 
duplicate and adding dsDNA BR reagent and dsDNA BR buffer. This was followed 
by measuring the fluorescence observed from the samples at 510/590 nm 
excitation/emission levels. The obtained readings were plotted against a standard 
curve and the quantity of the DNA content of the cells seeded on SiHA, HA and 
Therminox cover slip samples was measured. 
 
3.4.5.2  Alamar Blue activity assay 
The metabolic activity of the cells seeded on SiHA, HA and Therminox cover slip 
was measured using the Alamar Blue
TM assays on days 1, 3, 6, 12 and 24. To perform 
this assay the medium was removed from the wells. Alamar blue (10%) was prepared 
in phenol red free medium and then added to the wells of the test samples and also 
to an empty well as a control. The samples were incubated for 3 hours following 
which, 100 µl of the Alamar Blue
TM from each sample well was transferred to a 
micro-well plate and the absorbance levels of the samples were read (Fluoroskan 
Ascent machine at 510/590 nm). The obtained readings were then compared against 
standard absorbance values and the results were interpreted. 
 
3.4.6  Osteogenic Protein Expression 
The differentiation of the hMSCs on SiHA, HA and Therminox discs was quantified 
and compared by measuring the level of osteopontin and osteocalcin proteins’ 
secretion by these cells. As the amount of protein produced by cells is relative to the 
number of cells present, the amount of protein produced by each sample was 
standardized for a variation in the number of cells grown in each sample over the 
period of the study. This was done by calculation of the measured protein content of 
the cells divided by the DNA content of the cells grown on the SiHA, HA and 
Therminox discs. 
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3.4.6.1  Total protein assay 
The total protein content of the cells seeded on SiHA, HA and Therminox coverslips 
was measured on days 3, 12 and 24 using Bradford reagent (B6916, Sigma), which 
has a binding capacity for protein molecules. To run this assay, the culture medium 
which contained the proteins in solution released from the samples and a set of 
known concentration BSA (Bovine Serum Albumin) protein standards were 
transferred to micro-well plates. This was followed by the addition of Bradford 
reagent and measurement of the absorbance at 595 nm. The obtained readings were 
then plotted against a standard curve of absorbance versus protein and the 
concentration of the total protein within the cells was calculated using the obtained 
measurements.  
 
3.4.6.2  Osteocalcin Assay 
To measure osteocalcin protein activity within the cells seeded on SiHA, HA and 
Therminox discs an osteocalcin assay was performed. To run the assay, the culture 
medium was removed on days 3, 12 and 24 and levels of osteocalcin protein within 
the medium was measured using the Metra
TM Osteocalcin EIA Kit (8002, Quidel, 
USA) according to the protocol provided by the manufacturer. The levels of 
osteocalcin protein within the collected  medium were calculated using optical 
densities measurement of the samples at 405 nm wave length using a Dynatech 
MR700 plate reader (Dynatech Laboratories, UK). 
 
3.4.6.3  Osteopontin Assay 
Levels of osteopontin protein produced by the cells were measured by using the 
Quantikine ® Human Osteopontin Immunoassay Kit (R&D Systems). To run this 
assay culture  medium from the samples on days 3, 12 and 24 were used as 
osteopontin is an extracellular protein and the assay was run according to the 
instructions of the manufacturer. Levels of osteocalcin present within the test 
samples were calculated by reading the absorbance measurements at 450nm and 540 Chapter III. Cellular and Molecular Mechanism of Osteoinductivity by Silicon Substituted Hydroxyapatite                                                                                                
  110 
nm. The obtained readings were then plotted against a standard curve containing a 
set of known standard concentrations and the osteocalcin content of the test samples 
was calculated.  
 
3.4.7  Osteogenic Gene Expression 
3.4.7.1  Real Time PCR 
In order to quantify the expression of osteopontin, osteocalcin, osteonectin, bone 
sialoprotein, VEGF, RUNX2 and Osterix genes by real time polymerase chain 
reaction (Q-PCR), mRNA extraction from cells seeded on SiHA, HA and 
Thermanox cover slips (n=3) was required. mRNA extraction was carried out on 
days 1, 3, 6, 12 and 24 from 50, 000 cells seeded on SiHA, HA and Thermanox cover 
slips using QIAGEN RNeasy mini kit (74104, QIAGEN, UK). To carry out the 
mRNA extraction medium was removed from cell seeded discs within the wells. 
Cells were washed with PBS and then lysed following the manufacturer’s protocol 
provided by QIAGEN. The amount of RNA extracted was then measures using 
ND-1000 Nanodrop® spectrophotometer (Labtech Ltd., UK) and the yield of 
mRNA was calculated in 50 µl volume.  
   Following mRNA extraction, reverse transcription reaction was carried out to 
convert the mRNA to complementary DNA (cDNA) for use in later Q -PCR 
analysis. CDNA was synthesised by using the TaqMan High Capacity cDNA Reverse 
Transcription Kit (4368813, Applied Biosystems, UK). The mRNA was converted to 
cDNA by the action of the reverse transcriptase enzyme in combination with 
dNTPs, Oligo dT, RNAse inhibitor and buffer solutions. The reverse transcription 
reaction was carried out in a Gene Amp thermal cycler with 10 minutes at 25°C, 2 
hours at 37 °C and 5 seconds at 80°C. The synthesized cDNA was then used for 
amplification in the Q-PCR process. 
   The generated cDNA was amplified in a real time polymerase chain reaction 
(QPCR) for quantification of the amount of osteogenic marker genes. QPCR was 
carried out for specific primers for human Osteopontin, Osteocalcin, Osteonectin, 
Bone Sialoprotein proteins and VEGF, RUNX2 and Osterix transcription factors. Chapter III. Cellular and Molecular Mechanism of Osteoinductivity by Silicon Substituted Hydroxyapatite                                                                                                
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The QPCR reaction involved the amplification of the cDNA templates by a set of 
fluorescent oligonucleotide probes, followed by real time quantification of the DNA 
following each amplification cycle. Quantification of the expression levels of the 
specified genes was performed at the Genome Centre, Queen Mary University of 
London by Dr Charles Mein and the calculated quantities were normalised to a 
housekeeper index for the ATPs and UBC genes. 
 
3.4.8  Statistical analysis 
Results obtained in this chapter were compared statistically using the nonparametric 
tests, Kolmogorov Smirnov Z test and Mann-Whitney U  test, which define 
significant differences between two samples. Any P value less than 0.05 was 
considered significant. 
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3.5  Results 
3.5.1  Characterisation of MSCs 
Light microscopy showed the long spindle like nature of the cultured marrow 
stromal cells (Figure 50) grown on Therminox. Trypan blue staining showed live and 
dead cells within the culture flask. 
 
 
Figure 50. Confluent Passage 3 hMSCs after 14 days. Arrows: Spindle like cells Thermanox cover 
slips 
 
3.5.1.1  Osteogenic differentiation  
Von Kossa staining showed black stained calcium and red stained cells within the 
cultured cells indicating the presence of calcification and mineralisation of the 
extracellular matrix of cells grown in osteogenic medium on thermanox cover slips 
(Figure 51). 
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Figure 51. Von Kossa stain indicating mineralisation and calcium deposits within osteogenic 
differentiated hMSCs on Thermanox discs. Black Arrows: Calcium; Red Arrows: Cells. 2.5 X 
magnification 
 
 
3.5.1.2  Adipogenic differentiation 
Red stain within the Oil Red O stained cultured cells represented the presence of 
lipid molecules within the cells confirming the differentiation of the hMSCs into 
adipocytes (Figure 52). 
 
 
Figure 52. Oil red O stained hMSCs. Arrows: Lipids within the cultured cells on Thermanox discs. 
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3.5.2  Osteoblastic Differentiation- Morphology  
3.5.2.1  Scanning Electron Microscopy 
Scanning Electron Microscopy (SEM) analysis of the cells on day 1 showed cell 
attachment at points of contact to all three surfaces. Cells seeded on control samples 
represented spindle-like morphology (characteristic of fibroblasts). Centrifugal 
growth o f filopodia was observed within the samples (Figure 53). Both HA and 
SiHA cultures hMSCs indicated a spread out, flat structure at the centre with visible 
cell processes representing attachment to the surface and also cell-cell contacts. 
MSCs seeded on SiHA exhibited a more flat morphology covering the surface of the 
discs; however, cells of spindle-like structure were also observed (Figure 53) as was 
seen previously under light microscopy (Figure 50). 
 
   
   
Figure 53. Day 1 hMSC on Control and HA discs. White arrows: adherent hMSCS cells. Yellow 
arrow: Presence of cell filopodia in contact with SiHA. 
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MSCs seeded on SiHA discs on day 7 demonstrated a spread out morphology 
forming a layer over the surfaces of the discs.  MSCs seeded on HA discs also 
demonstrated a spread out cuboidal structure, following the trend reported in other 
studies (Arcos et al., 2006; Annaz et al., 2004; Thian et al., 2006); however, spindle 
like cells were also observed on the surface of the biomaterial (Figure 54). 
 
 
   
 
   
 
Figure 54 . Day 7 hMSCs on SiHA and HA discs. Arrow: spindle like cell. Stars: Cuboidal cells.  
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On day 14, hMSCs seeded on Therminox cover slip discs (control) exhibited a well 
organised cell arrangement formed over the surface of the discs. HA seeded discs 
exhibited similar morphological structures observed on day 7, however, an increased 
number of cells with a spread out and flat morphology was observed over the HA 
surface. SiHA seeded cells exhibited densely packed osteoblastic cuboidal structures 
coating the surface of the discs (Figure 55).  
 
 
   
         
      
 
Figure 55. Control, HA and SiHA d14. Stars: cuboidal osteoblasts. 
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The hMSCs seeded on control discs on day 24 exhibited a spread out structure 
covering the surface of the Therminox discs; however, spindle like cells making 
attachment with the disc surface were also observed. Cells seeded on both HA and 
SiHA discs exhibited flat cuboidal shapes arranged in line forming a layer over the 
surface of the discs, representing osteoblasts. SiHA discs, however, exhibited the 
presence of globular calcium phosphate nodules (Kalia et al., 2007, Thian et al., 2006) 
on the formed cell layer (Figure 56). 
 
 
 
   
 
   
 
Figure 56. Day 24 hMSCs on Control, HA and SiHA discs. White arrow: Spindle like cells, Star: 
Osteoblast cells, Yellow arrow: Globular nodules. 
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3.5.3  Cellular Proliferation 
3.5.3.1  Total DNA 
Results demonstrated an increase in the amount of DNA from days 3 to 12 in all 
samples. Cells grown in osteogenic medium (SiHA
+ = 1.04±0.13, HA
+ = 1.69±0.39
 
and Cntrl
+= 3.2±1.01) did not indicate any significant difference in levels of DNA 
content in comparison with cells grown in normal medium (SiHA
- = 1.07±0.34, HA
-
= 1.64±0.41 and Cntrl
- = 2.51±0.32) by day 24 of the study. HA (HA
+= 0.83±0.22; 
HA
- = 0.52±0.09) samples indicated higher DNA content on day 12 in comparison 
with SiHA (SiHA
+= 0±0.01; SiHA
-= 0.29±0.24) samples. DNA content of cells 
seeded on HA (HA
+= 1.69±0.39; HA
- = 1.64±0.41) samples indicated higher levels 
of DNA in comparison with SiHA (SiHA
+ = 1.04±0.13; SiHA
- = 1.07±0.34) seeded 
cells by day 24. Cells seeded on Therminox cover slip discs (Cntrl 
-/
+) exhibited the 
highest amounts of DNA (Cntrl
+ = 3.2±1.01 and Cntrl
- = 2.51±0.32) in comparison 
with SiHA and HA samples by day 24 of the study (Figure ). 
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Figure 57. Total DNA content within hMSCs seeded on SiHA, HA and Control discs grown in 
Normal (-) and Osteogenic (+) medium. 
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3.5.3.2  Alamar Blue activity assay 
Alamar Blue assay results demonstrated that cells seeded on SiHA discs and 
Therminox discs grown in normal  medium (SiHA
-= 96.35±12.17 and Cntrl
-
=99.44±32.44) exhibited the highest level of cellular activity and cell growth in 
comparison with other groups by day 24 (SiHA
+ =29.98±0.92; HA
+= 55.6±5.30; 
HA
-= 76.72±7.64; Cntrl
+=82.70±16.92. The cellular activity of cells seeded on SiHA
- 
samples was observed to be higher than other HA and Control groups on days 12 
and 6 ( Table  5). Cells seeded on HA
- discs indicated higher cellular activity 
(=38.65±2.6) on day 3 in comparison with the SiHA
-  (29.96±14.07), SiHA
+ 
(=7.39±5.55) and cells seeded on HA discs in osteogenic  medium (HA
+  = 
2.02±0.15). Cellular activity of SiHA (SiHA
+/
-) seeded cells were observed to be 
higher than cells seeded on HA (HA
+/
-) discs on day 1 (Figure 58).  
 
Table 5. Mean values (±standard error values) of the cellular activity (RFU/1000s) of hMSCs grown 
on SiHA, HA and Control discs in osteogenic (+) and normal (-) medium on days1, 3, 6, 12 and 24. 
SiHA+ SiHA- HA+ HA- Cntrl+ Cntrl-
 d1 22.64±2.74 30.18±4.33 18.16±1.35 17.70±7.64 33.82±5.63 31.46±0.34
 d3 7.39±5.55 29.96±14.07 2.02±0.15 38.65±2.6 2.47±0.25 24.45±4.17
 d6 20.21±8.30 67.92±6.36 69.03±7.32 38.27±11.71 42.91±40.09 27.09±23.58
 d12 25.23±9.92 79.16±3.51 53.19±0.44 45.94±2.93 60.63±17.37 70.44±9.00
 d24 29.98±0.92 96.35±12.17 55.60±5.30 76.71±16.91 82.70±16.91 99.44±32.44  
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Figure 58. Alamar Blue absorbency of hMSCs seeded on SiHA, HA and Control Therminox disc in 
Normal (-) and Osteogenic (+) medium within 24 days 
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3.5.4  Osteoblastic Protein Expression 
3.5.4.1  Total protein  
Results of the amount of total protein produced by hMSCs seeded on SiHA, HA and 
Therminox discs indicated higher levels of total protein production by cells seeded 
on the control (Cntrl
+/
-) samples on days 3 and 24 of the study in comparison with 
the SiHA and HA seeded cells. Both SiHA (
+/
-) and HA (
+/
-) seeded cells indicated 
higher levels of protein production on day 12 compared to the control group. No 
significant difference was observed in the level of protein production in cells grown 
in normal medium in comparison with osteogenic medium. HA seeded cells (HA
+/
-) 
indicated slightly higher levels of protein production on day 3 in comparison with 
SiHA (
+/
-) samples (Figure 59). No significant difference was observed in any of the 
groups (P>0.05). 
   Normalization of the total protein produced by the cells to the DNA content of 
the cells indicated that cells seeded on SiHA, HA and control discs grown in both 
osteogenic and normal medium exhibited highest levels of protein production on day 
12. A reduction in the level of total protein/DNA was observed from days 12 to 25, 
however, cells seeded on SiHA discs in normal medium (SiHA
-) demonstrated more 
protein production than other groups ( Table  6). None of the groups showed 
statistically significant results when compared (P>0.05). 
 
Table 6. Mean total protein/DNA (ng/ml)/(µg/ml) content of hMSCs seeded on SiHA, HA and 
Control discs in normal (+) and osteogenic (-) medium on days 3, 12 and 24 
 
 
Total protein SiHA+ SiHA- HA+ HA- Cntrl+ Cntrl-
d3 0±0 0±0 0±0 0±0 0±0 16591.61±16591.6
d12 10492.80±10492.8 3415.81±1204.5 2485.62±695.0 3507.11±612.3 2313.18±310.0 2270.11±102.1
d24 1590.02±260.7 1920.95±515.48 1174.17±377.4 1211.23±344.5 778.38±244.06 908.23±126.0  
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Figure 59. Total protein production within hMSCs seeded on SiHA, HA and Control discs in 
Osteogenic (+) or Normal medium (-) 
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Figure 60. Total protein production normalized to DNA levels 
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3.5.4.2  Osteocalcin protein production 
Normalised results showed higher amounts of osteocalcin protein production by 
cells grown on SiHA discs by day 24 of the study (Table 7). Levels of osteocalcin 
protein was highest on day 12 compared with other time points. SiHA seeded cells 
demonstrated higher amounts of osteocalcin protein compared with HA and control 
groups on day 12 of the study. SiHA seeded cells showed higher osteocalcin 
expression on day 24 compared to the control group. Next to SiHA seeded cells, HA 
samples indicated greater amounts of osteocalcin protein by day 24 compared with 
the control group. Osteocalcin protein produced by SiHA and HA samples were 
observed to be higher in cells grown in normal medium (SiHA
- and HA
-) (Figure 61). 
No statistically significant (P>0.05) difference was observed when groups were 
compared. 
 
Table 7. Mean osteocalcin protein expression values (±standard error values) 
Osteocalcin SiHA+ SiHA- HA+ HA- Cntrl+ Cntrl-
d3 0±0 0±0 0±0 0±0 0±0 0±0
d12 0±0 43.48±14.72 14.20±9.40 36.47±5.45 20.78±1.94 19.83±0.82
d24 21±4.96 18.64±6.76 12.87±4.85 12.16±4.91 4.14±1.09 5.94±0.57  
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Figure 61. Normalised data for Osteocalcin/DNA production by hMSC seeded on SiHA (SiHA+/-), 
HA (HA+/-) and control discs (Cntrl+/-) grown in Normal (-) or Osteogenic medium (+) Chapter III. Cellular and Molecular Mechanism of Osteoinductivity by Silicon Substituted Hydroxyapatite                                                                                                
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3.5.4.3  Osteopontin protein production 
Protein expression to DNA content data showed significantly (P<0.05) greater 
osteopontin production by the hMSCs seeded on SiHA, HA and control discs on day 
12 of the study compared to other time points. The hMSCs seeded on SiHA
- discs 
demonstrated higher levels of osteopontin production in comparison with HA
- 
samples on days 12 and 24 (Table 8). Cells seeded on SiHA (
+/
-) discs indicated 
increased osteopontin production by day 24 of the study compared with the HA and 
control groups, however the levels were not significantly (P>0.05) different. 
 
Table 8. Mean osteopontin protein expression values (± standard error values) 
 
Osteopontin SiHA+ SiHA- HA+ HA- Cntrl+ Cntrl-
d3 0±0 0±0 0±0 0±0 0±0 0±0
d12 0.21±0.31 0.16±0.0001 0±0.04 0.32±0.07 0.07±0.01 0.29±0.06
d24 0.64±0.64 0.12±0.01 0.021±0.009 0.085±0.01 0.009±0.001 0.02±0.02  
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Figure 62. Normalized Osteopontin/DNA production by hMSC seeded on SiHA, HA and Control 
discs grown in Normal (-) and Osteogenic (+) medium. 
. 
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3.5.5  Osteoblastic gene expression 
Analysis of the mRNA expression of osteogenic marker genes and transcription 
factors of hMSCs grown on SiHA, HA and Therminox discs indicated a set of 
varying expression levels for the tested genes. The housekeeping genes UBC and 
ATPs were expressed in all groups. The relative expression of RUNX2 transcription 
factor indicated significantly higher levels of expression on day 24 of the study in 
SiHA and HA seeded cells grown in osteogenic medium (SiHA
+ and HA
+) compared 
with other groups. Cells seeded on SiHA
+ discs indicated higher RUNX2 expression 
levels. No significant difference was observed in level of RUNX2 expression on cells 
seeded on SiHA, HA or control discs on days 1, 3, 6 and 12. At day 1, there was no 
difference in expression of Osterix transcription factor on all samples. HA and SiHA 
seeded hMSCs grown in normal medium indicated higher Osterix expression on days 
6 and 8, with higher expression of this gene on HA discs (Figure 63). 
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Figure 63. The relative expression of transcription factors RUNX2 and Osterix Chapter III. Cellular and Molecular Mechanism of Osteoinductivity by Silicon Substituted Hydroxyapatite                                                                                                
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The mRNA expression of osteoblast differentiation marker gene, osteopontin, was 
observed to be higher in SiHA seeded cells grown in osteogenic medium on day 24. 
HA (HA
+/
-) samples indicated higher osteopontin expression on day 24 compared to 
other groups. No significant difference (P>0.05) was observed for osteopontin 
expression on days 6, 8 and 12 on all samples. SiHA and HA seeded cells in normal 
medium (SiHA
- and HA
-) expressed higher amounts of osteopontin on day 3 (Figure 
64). 
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Figure 64. Relative expression levels of osteopontin gene. 
 
 
The mRNA expression of genes expressed in differentiated osteoblasts forming new 
bone matrix, the bone sialoprotein and osteonectin genes indicated increase in the 
levels of bone sialoprotein expression on SiHA (SiHA
+ and SiHA
-) seeded discs by 
day 24. Cells seeded on HA discs cultured in osteogenic medium expressed higher 
levels of bone sialoprotein compared with the control groups (Figure 65) however, 
these r esults were not significantly different (P<0.05). The mRNA expression of 
osteonectin gene responsible for mineralisation initiation was observed to be 
significantly higher on Therminox seeded cells in comparison with cells seeded on 
SiHA discs on day 24. Expression of this gene was observed to be statistically higher 
(P=0.05) on SiHA discs on days 6 and 8 of the study when compared to other 
groups ( Figure  65). No significant difference (P>0.05) in expression of the 
mineralisation marker, Osteocalcin on any of the samples was observed. However, 
HA seeded cells cultured in normal medium indicated higher levels of osteocalcin 
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The mRNA expression of the VEGF gene, the marker for vascularisation 
mechanism of cells indicated significantly higher levels of expression on SiHA and 
HA discs grown in normal medium on days 3 and 6 of the study. VEGF expression 
levels were also observed to be higher on HA and SiHA seeded on day 12 of the 
study compared with the control group. No significant difference (P>0.05) was 
observed for VEGF expression on SiHA samples compared with HA samples at this 
time point (Figure 66). 
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Figure 66. Relative expression of VEGF gene  
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3.6  Discussion 
The aim of this study was to investigate the influence of silicate ion on stimulation of 
in vitro osteoblastic differentiation of hMSCs seeded on dense SiHA discs and the 
osteoinductivity potential of SiHA bone substitute biomaterial. In this study the 
morphological changes and the cellular activities involved in osteogenic 
differentiation of hMSCs by SiHA were analysed. The results of this study indicated 
that SiHA promoted osteoblastic differentiation of hMSCs in vitro in 21 days. The 
rate of the expression of osteoblastic genes, specifically the vasculogenic gene 
VEGF, was observed to be different on cells grown on SiHA samples compared to 
HA. As hydroxyapatite bone substitute materials are calcium phosphate based 
biomaterials with substantial dissolution properties in vitro, gradual dissolution of 
HA and release of calcium and phosphate ions and precipitation of the local ions is 
known as the mechanism of osteogenesis for this biomaterial (Chang et al., 2000; 
Leewenburgh et al., 2006). Bone marrow cells are reported to undergo osteoblastic 
differentiation and exhibit upregulated expression levels of Osteopontin, Bone 
Sialoprotein and ALP messages on HA surfaces (Ozawa and Kasugai, 1996). Wang et 
al (2003) reported differential expression of osteocalcin, Bone Sialoprotein and 
osteonectin genes in osteoblasts grown on HA discs. It is known that local release of 
soluble silicon induces osteogenic differentiation and bone formation by osteoblasts 
(Reffitt et al., 2003). Silicon substitution within the structure of HA is also known to 
enhance the bioactivity of human osteoblasts in vitro through combination of the 
bioactivity of HA with the bioactive properties of silicate ion (Gibson et al., 1999; 
Brandoff et al., 2006). Further, up regulation of a number of genes expressed by 
osteoblasts by exposure to ionic products of silica based bioactive glasses have been 
reported by Gao et al (2001) and Xynos et al (2001). Marrow stromal cells derived 
from bone marrow stroma because of their regenerative properties and the potential 
for  differentiation into osteoblast, chondrocytes and adipocytes provide the 
possibility of study of the osteogenic potential of bone graft substitutes. 
Observational study of the cellular differentiation on SiHA indicated that pluripotent 
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and cultured in normal and osteogenic  medium, underwent osteogenic 
differentiation. Marrow stromal cells are known to undergo differentiation into 
osteoprogenitor and then maturation into osteoblast cells when cultured under 
appropriate chemical and physiological conditions (Zue and Chen, 2007). As 
indicated in a study by Zuo et al (2008), silicon supplementation increases the 
proliferation and cellular activity of human osteoblast-like cells (Zuo et al 2008). The 
differentiation of the seeded spindle like hMSCs into flat cuboidal osteoblasts on the 
surface of SiHA discs, as observed by scanning electron microscopy, was due to the 
chemical composition of SiHA and the increase in the metabolic activity and cellular 
proliferation of the seeded hMSCs. The significance of this osteogenic morphology 
could be further analysed by measurement of the cells’ aspect ratios, fluorescent 
staining of the cells on the test discs or FACS analysis. As dense SiHA discs were 
used for this study, the influence of porosity on the differentiation of these cells was 
eliminated in favour of the role of the chemical composition on in vitro osteogenic 
differentiation of the hMS cells. Induction of the osteogenic potential of the seeded 
hMSC and their differentiation towards the osteogenic phenotype was achieved 
through culturing in the presence of osteogenic medium. As indicated in a previous 
study by Castano-Izquierdo et al (2006), secretion of bone-like, possibly extracellular 
matrix by these cells may have promoted the osteoindution behaviour of these cells 
seeded on the test materials.  
   Cell differentiation is controlled by a complex set of cellular and molecular 
activities and an inverse relationship exists between o steoblast proliferation and 
differentiation (Malaval et al., 1999). Analysis of the DNA content as a direct 
measurement of cell number, indicated a higher number on control discs in 
comparison with HA and SiHA samples. The lowest amount of DNA content was 
observed on SiHA samples. The proliferation and differentiation of cells are inverse 
functions, the lower DNA content of hMSCs seeded on SiHA discs concomitant 
with the flat cuboidal osteoblastic phenotype observed under SEM as early as day 7 
indicates earlier differentiation of the SiHA seeded cells in comparison with the HA 
and control group. It should be noted that in order to evaluate the direct influence of 
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performance of the required assays (e.g. DNA/ Alamar Blue/ OP and OC assays), 
the cultured discs were moved to new well plates. This was carried out to avoid 
detection of signals from cells which had not attached to the disc surface and had 
fallen to the bottom of the well and consequently were not in direct contact with the 
test material. For this reason, the higher cell number obtained from the control 
samples could be due to the difference in the growth of the number of cells attached 
to the SiHA and HA disc surfaces in comparison with the control Therminox discs. 
   Alamar Blue absorbency obtained from cells seeded on SiHA, HA and control 
Therminox discs indicated superior metabolic activity for hMSCs seeded on SiHA 
discs cultured in normal medium from day 6 to day 24 of the study compared with 
the HA group. The hMSCs seeded on control discs also indicated similar levels of 
cellular activity to cells seeded on SiHA discs on day 24 of the study. Analysis of the 
total protein levels of hMSCs seeded on SiHA, HA and the control discs did not 
indicate any significant difference between these groups within the period of the 
study.  
   The results of this study and the production of osteoblastic marker proteins, in 
addition to the morphological changes of the hMSCs seeded on SiHA and HA discs, 
indicated the differentiation of these cells into osteoblasts. Expression of specific 
transcription factors and proteins are known to contribute to the mechanism of cell 
differentiation. The initial commitment of mesenchymal stem cells to a particular cell 
lineage  followed by induction of  tissue s pecific patterns of gene expression is 
required for the process of differentiation (Franceschi, 1999).  Osteogenic 
differentiation involves the expression of transcription factors such as 
Cbfa1/RUNX2, the osteoblast specific factor, Osterix and osteoblastic proteins 
including osteopontin, osteonectin, bone sialoprotein and osteocalcin. Neo-
vascularisation is known to be an important factor for cell differentiation and the 
metabolic functions of developing cells (Jarrahay et al., 2005). Vascular Endothelial 
Growth Factor (VEGF) is known as an important gene involved in angiogenesis and 
the process of vasculogenesis (Patan, 2000). Vasculogenesis is an essential factor in 
bone formation by bone substitute materials and the process of bone remodelling 
and osteoblast differentiation (Sibilla et al., 2006). Formation of an appropriate blood Chapter III. Cellular and Molecular Mechanism of Osteoinductivity by Silicon Substituted Hydroxyapatite                                                                                                
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vessel network is known as one of the factors contributing to the rate of bone 
formation. Several studies have shown that proliferation, migration and 
differentiation of osteoblasts is stimulated by VEGF (Furumatsu et al., 2003).  
   In this study gene expression analysis of RUNX2 transcription factor indicated up 
regulation of this gene in hMSCs seeded on SiHA and HA discs grown in osteogenic 
medium by day 24 of the study. However, no significant difference was observed on 
the level of RUNX2 expression in cells grown in normal medium on SiHA and HA 
discs in comparison with the control group. Karsenty (1998) has shown that 
Cbfa1/RUNX2 is a necessary factor for differentiation of mesenchymal progenitor 
cells to osteoblasts. This transcription factor is known to control the expression of 
other osteoblast specific transcription factors such as Osterix. (Karsenty and Wagner, 
2002). Osterix (Osx) is expressed in osteoblast progenitors downstream of the 
Cbfa1/RUNX2 gene as Cbfa1 is known to be expressed in Osx deficient mice, while 
no expression of this gens in observed in Cbfa1 deficient mice (Nakashima et al., 
2002). This gene is known as a positive regulator of osteoblast differentiation and 
bone formation (Baek et al., 2008). Osterix over-expression is known to up regulate 
the expression of osteocalcin and Cbfa1 genes and to increase the formation of 
mineralised bone nodules in embryonic stem cells (Guangping et al., 2004). Further, 
this gene is suggested to exert indirect feedback to Cbfa1 and activation of signalling 
molecules that lead to osteoblastic differentiation (Tai et al., 2004). Analysis of 
Osterix expression in this study indicated clear activity of this gene on day 1 of the 
study, with down regulation in expression levels of this gene on SiHA in comparison 
with HA and control samples. Down regulation of RUNX2 expression on days 6 and 
8 of the study was observed to be concurrent with up regulation of Osterix 
expression at these time points in cells seeded on all three surfaces. As no clear 
pattern of expression was observed for expression of this gene on hMSCs seeded on 
SiHA discs in comparison with HA and control groups, further analysis of the 
expression of this gene using larger population of cells is required.  
   Osteopontin is known to be expressed during the early stages of osteoblast 
proliferation and differentiation and the later mineralisation of the extracellular 
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affinity for binding with HA and regulation of crystal formation and growth for 
marrow cells differentiation to osteoblasts (Kasugai et al., 1992). The results of this 
study did not indicate any significant change implied by SiHA on expression of the 
osteopontin gene; however, this gene was observed to be expressed significantly 
higher (P<0.05) on HA discs compared with hMSCs seeded on control discs by day 
24 of this study. However, the results of the osteopontin assay indicated production 
of higher amounts of osteopontin protein by hMSCs seeded on SiHA discs when 
compared with the cells seeded on control Therminox discs. 
   Bone sialoprotein (BSP)  is a marker of bone m etabolism  associated with the 
osteoid matrix and is expressed in osteoblasts (Sodek et al., 1992; Stork et al, 2000). 
Analysis of the expression of this gene within hMSCs indicated increased levels of 
BSP expression by day 24 of the study. This suggested a  role of SiHA on 
osteoinduction of the cells through an effect on mineralisation of the bone matrix. 
Supplementation of the medium with osteogenic factors was observed to enhance 
the expression of BSP in both SiHA and HA (SiHA+/HA+) samples.  
   Osteonectin is a bone-specific protein localized in mineralised bone matrix known 
for its binding affinity to hydroxyapatite and collagen which nucleate mineral phase 
deposition (Termine et al, 1981, Bolander et al., 1987). Increased expression of the 
osteonectin gene on days 6 and 8 of this study indicated an early promotion of the 
mineralisation by SiHA.  
   Osteocalcin is a marker of differentiated osteoblasts as it is expressed and secreted 
by these cells (Garcia-Carasco et al., 1988). The expression of this gene is known to 
be regulated by the RUNX-2 transcription factor and associated with growth arrest 
(Stein et al., 1990) and formation of a mineralising matrix (Ducy et al., 1997; Aronow 
et al., 1990). The results of this study did not indicate any significant influence of 
SiHA on expression of the osteocalcin gene by hMSCs; however, the results of the 
osteocalcin protein assay indicated higher levels of osteocalcin secretion by hMSCs 
seeded on SiHA discs by day 24 of the study compared to the HA and the control 
group.  
   Both Osteocalcin and VEGF are critical for bone formation. Expression of the 
VEGF mRNA was observed to be higher on cells seeded on SiHA and HA discs in Chapter III. Cellular and Molecular Mechanism of Osteoinductivity by Silicon Substituted Hydroxyapatite                                                                                                
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comparison with the control group on days 3 and 6 of the study. This indicates the 
contribution of SiHA and HA biomaterials to the promotion of early expression of 
VEGF and consequently the process of vasculogenesis. Increased vascularisation is 
known to enhance mineralised tissue generation (Murphy et al., 2004). Hing et al. 
(2006) reported increased vascular ingrowth into micro and macroporous SiHA. The 
increased expression of VEGF in the hMSCs cells may therefore be a contributing 
factor in the increased vascular ingrowth within SiHA reported by Hing et al.  
  It is known that factors such as apoptosis and osteoblast heterogeneity which are 
regulated by maturational age, environmental and micro-environmental conditions at 
both transcriptional and post-transcriptional levels, contribute to implications for 
osteoblasts function in vitro (Malaval et al., 2006). Therefore it should be noted that 
the results obtained in this study need further analysis in terms of the use of a larger 
number of hMSCs samples. 
   The differences between the levels of DNA and mRNA expression and the relative 
protein expression for the tested genes at the given time points might have been due 
to incomplete translation of mRNA to protein at the time of the quantification 
process or the degradation of the mRNA/DNA, but the presence of the secreted 
protein due to the long life of the protein compared to the respective mRNA or 
DNA (Knab et al., 2004).  
   Further increasing the “n” number in terms of the SiHA and HA disc repeats to 
higher than 3 and also the use of hMSCs from a number of patients rather than just 
one, would also contribute to obtaining statistically significant results for the studied 
genes and protein expression data. 
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3.7  Conclusions 
The ideal bone substitute material should allow for cell migration, attachment, 
proliferation, differentiation and deposition of mineralised osteoid matrix (Jarrahy et 
al., 2005). The results of this study indicate that overall Silicon substituted 
hydroxyapatite promotes the attachment, proliferation and differentiation of hMSCs 
to osteoblasts in vitro, irrespective of the presence of osteogenic supplements. The 
mechanism of osteoinduction by this biomaterial involves the influence of the 
chemical composition of SiHA on expression of osteogenic marker genes and 
secretion of the osteogenic proteins. Early osteogenic differentiation of hMSCs as a 
result of the earlier ending of cell proliferation and initiation of early bone matrix 
mineralisation through expression of the osteonectin gene can be the suggested 
factor involved in osteoinduction by this biomaterial. The current study investigated 
the in vitro mechanism of osteoinduction by silicon substituted hydroxyapatite. For 
further evaluation of this biomaterial as an osteoinductive biomaterial, an in vivo study 
of bone formation by SiHA needs to be carried out. It should be noted that bone 
formation  in vivo  involves a combination of immensely complex and different 
mechanisms from the in vitro test environment as different biological factors, 
including circulating body fluids, biological compounds such as proteins and growth 
factors, influence the mechanism of bone formation by bone substitute materials 
(Leewenburgh et al., 2006).  
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4  Chapter IV. Osteoinduction by Silicon substituted HA 
4.1  Introduction 
The bioactivity of bone graft materials can be enhanced to promote early/greater 
bone formation by the incorporation of elements present in natural bone into their 
chemical composition and structure. Gibson et al demonstrated that the 
incorporation of silicate ions into the structure of stoichiometric hydroxyapatite 
(HA) increases the bioactivity of this biomaterial. This substitution was shown to 
enhance the activity of osteoblast cells in vitro (Gibson et al., 1999). Further, the 
presence of silicate ions within the HA structure was demonstrated to accelerate 
osteoconduction and enhance the rate and amount of bone apposition (Patel et al., 
2002). A study by Porter et al (2004) demonstrated earlier bone formation by SiHA 
implants through enhanced bone remodelling processes compared to pure HA. 
Silicate ion substitution is also known to enhance osteointegration of HA and the 
formation of a stronger contact between bone and this biomaterial (Vallet-Regi and 
Arcos, 2005). The level of silicate ion substitution significantly affects the amount of 
bone formation through osteoconduction. In a study by Hing et al (2006) 0.8wt% 
substitution was identified as the optimal level for promotion of bone formation. 
   Osteoconductive and osteoinductive calcium phosphate biomaterials,  in 
combination with supplementary growth factors, bone morphogenic proteins 
(BMPs) and cell seeding onto the implant surface, are commonly used experimentally 
to enhance bone tissue regeneration and to make the implant more osteoconductive; 
however, an ideal bone graft substitute would promote bone formation without the 
use of supplementary factors. Osteoinduction by cytokines, such as BMPs, promotes 
bone formation through endochondral ossification (Mizutani and Urist, 1982; 
Kuboki et al., 2001) whilst osteoinduction by CaP biomaterials usually occurs by 
direct intramembranous ossification (Le Nihouannen et al., 2005). It has been shown 
that non calcium phosphate materials, such as natural sponges and titanium, can 
induce bone formation in non osseous sites (Urist et al., 1965). The process of 
osteoconduction by Si-HA through direct attachment, proliferation and 
differentiation of bone forming cells, enhanced bone remodelling, increased Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
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dissolution and enhanced bone apposition rate has been studied by various 
researchers (Hing et al., 2006, Porter et al., 2006, Patel et al., 2002). Ectopic 
osteogenesis and osteoinduction by SiHA through stimulation of the differentiation 
of non osteogenic cells down osteoblastic lineage has not yet been investigated.  
   This chapter investigates the osteoinductive properties of Si-HA in comparison 
with pure HA and the effect of this biomaterial's chemical composition and structure 
on bone formation in non-osseous tissue through implantation in the paraspinalis 
muscle of sheep. The large size of the animal body allows for the insertion of larger 
implants and also more implants can be compared in one animal.  
   New bone formation by bone graft substitutes requires successful initial attraction 
of cells to the surface of the biomaterial; besides chemical composition as mentioned 
above,  this cellular response is also affected by the surface structure of the 
biomaterial (Boyan et al., 1996). The presence of interconnected macro (>10µm) and 
micropores (<5 µm) and the physiochemical properties of the biomaterial determine 
which and how molecules and cells can absorb, attach and move into the 
biomaterial’s structure (Bronzino, 2006; Boyan et al., 1996; Ripamonti et al., 1999; 
Christophy et al., 2008). Daculsi et al (1989) demonstrated that the bioactivity of HA 
and the rate and level of bone formation is enhanced through the incorporation of 
microporosity. Based on this information, this chapter also investigates the effect of 
strut porosity on the level of bone formation within SiHA and HA implants.   
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4.2  Aims and Hypothesis 
The aim of this study is to investigate the osteoinductive potential of Silicon 
substituted hydroxyapatite and the effect of chemistry and strut porosity on bone 
formation. 
 
The hypotheses for this experiment are that:  
 
1.  The presence of silicate ion within  hydroxyapatite  induces superior bone 
formation compared to pure HA through osteoinduction when implanted in 
an ectopic site.  
  
2.  Microporosity of ~30% within the biomaterial struts results in greater new 
bone area compared to 10% or 20% strut porosity. 
 
3.  Granular and block implants induce different amounts of bone formation.  
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4.3  Materials and methods 
4.3.1  Study design 
To assess the osteoinductive properties of SiHA in comparison with HA, preliminary 
data was obtained from a study carried out by Patel et al (2002). To achieve 
significance of P< 0.05, the study was designed for comparison of two types of 
calcium phosphate bone substitute biomaterials in (n=4) an ectopic site where the 
overall standard deviation is around 8% (normal distribution with equal variation), 
with power of 0.8 using the Shoenfeld’s power analysis software. Using this data 
eight skeletally mature commercially bred female sheep aged between 4-6 years old 
and weighing of 65-80kg were used in this experiment to study the osseoinductivity 
of 0.8wt% SiHA compared to HA. Further, the effect of strut porosity and implant 
morphology on osseoinduction of Silicon substituted hydroxyapatite (SiHA) and 
pure stoichiometric hydroxyapatite (HA) biomaterials was investigated. Fifty, HA 
[ApaPore, ApaTech Ltd. B021-2005] and SiHA [Actifuse, ApaTech Ltd. B008-
2005G, B040-2005 and B096-2005A] granules (2-6 mm) and blocks (15x15mm) were 
randomly and intramuscularly implanted in the paraspinalis muscle of eight sheep for 
12 weeks (Figure 68).   
   To assess the effect of microporosity on bone formation, four SiHA granules and 
block samples with 10% (SiHA10), 20% (SiHA20) and 30% (SiHA30) strut porosity 
and HA granules and blocks of 20% (HA20) and 30% (HA20) strut porosity were 
used. Both HA and SiHA biomaterials manufactured by ApaTech Ltd. contained 
80% total porosity ( 
Table 9).  
 
Table 9. SiHA and HA implants porosity levels 
Composition  SiHA10  SiHA20     SiHA30  HA20  HA30 
Strut Microporosity  10%  20%  30%  20%  30% 
Total Porosity  80%  80%  80%  80%  80% 
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4.3.2  XRD and XRF Chemical Analysis 
X-ray diffraction analysis patterns of HA and SiHA samples did not indicate the 
presence of any Ca3 (PO4)2 (TCP) or CaO secondary phases (Figure 67). The Ca/P 
ratio of HA and Ca/(P+Si) ratio of SiHA found by XRF spectrometry analysis were 
detected to be 1.67, equivalent to the value of phase pure HA. Further XRF 
elemental analysis confirmed the levels of silicate ion within SiHA as 0.8wt%. 
 
 
 
 
     
  
Figure 67. XRD patterns for HA and SiHA samples. 
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4.3.3  Surgery 
All procedures in this experiment were performed in accordance with the Animals 
Act 1986 (Scientific Procedures) at the Royal Veterinary College, South Mimms. All 
members of the surgical group held the required Home Office licenses. Sheep used 
in the operations were starved 12 hours prior to surgery.  Each animal was 
premedicated by intramuscular administration of Xylazine [Rompun 2%] (0.05 
ml/kg) 10 minutes before the induction of anaesthesia. The animal was then 
anaesthetised by intravenous administration of Ketamin [Ketaset] (0.2 ml/kg) and 
Midazolam [Hypnovel] 2.5 mg. Anaesthesia was then maintained by administration 
of Halothane (2%) and Oxygen mixture.  
   The sheep were placed in dorsal recumbency and the fleece on the centre of the 
animals back above the paraspinous muscle was shaved to expose the skin. The 
exposed skin was then washed with a solution of Pevidine surgical scrub and water. 
Surgical scrub was then made into lather to further clean the skin; this process was 
repeated three times. Sterilization of the surgical site was carried out by washing the 
site from the centre to the outer areas by using a sterile swab and Pevidine antiseptic 
solution. The surgical site was further disinfected by wiping the area with Hydrex 
[Chlorohexadine Gluconate] solution.  
   The paraspinal muscles along the right and left of the spine adjacent to the lumbar 
vertebrae were identified and four longitudinal incisions of a few centimetres were 
then created through the skin, superficial and deep fascia to expose the paraspinal 
muscles. Blunt longitudinal dissections were then made along the muscle fibre to 
create a gap within the muscle tissue. The blunt incisions were in line with the fibres 
of the muscle tissue and not perpendicular to the direction of the fibres. Cylindrical 
plastic containers of 30mm x 15mm in diameter were lined with stainless steel mesh 
in order to constrain the HA and SiHA granules in place. Granules of HA/SiHA 
sterilised with hydrogen peroxide vapour were tipped into the tubes and impacted 
together by hand using tapping force. Autologous jugular venous blood obtained 
from the sheep was added to the granules and left to coagulate. The construct was 
then removed from the container and inserted into the muscle gap. Sterilized 
HA/SiHA blocks of 15mm x 15mm were then inserted into the muscle gap (Figure Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
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68). The incisions were closed by bringing the layers together using absorbable Vicryl 
sutures. The animals were recovered from anaesthesia and an intramuscular daily 
dose of Ceforex (Cefalexin) antibiotic was administered for 5 days post operation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68. a) Image illustrating the location of the implants. b) Radiograph of granular and block 
implants. 
 
4.3.4  Undecalcified Hard Resin Histology 
Following retrieval of the implants and the surrounding tissue at week 12, the 
samples were fixed by immersion in 10% neutral buffered formalin at room 
temperature for 7 days.  Histology processing of the samples was carried out as 
described in chapter II. Dehydration and defatting of the samples were carried out by 
using increasing concentrations of ethanol and chloroform respectively, followed by 
infiltration and embedding in 100% LR white resin (London Resin Co Ltd). 
   Thin sections (100 µm thick) were then made by sectioning the resin embedded 
samples longitudinally through the centre of the biomaterial using an Exakt saw 
(Exakt, Germany). The obtained sections, were then ground to the desired thickness 
by using an Exakt micro-grinding system and then polished to eliminate the scratches 
on the surface of the sections using the Motopol 2000 machine. The prepared thin 
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sections were stained for histomorphometric analysis by staining the section with 
10% Toluidine Blue for 20 minutes to stain the fibrous tissue, followed by 15 
minutes of staining with Paragon, which was prepared by mixing of toludin blue and 
basic fuchsin in ethanol, to stain the new bone.  
 
4.3.5  Histomorphometry Analysis 
The area occupied by the new bone formed within the implanted biomaterial and the 
new bone contact with the biomaterial was quantified using the Axiovision 4.5 image 
analysis system. Eight images of each thin section slide were obtained at 5x 
magnification and the quantification was carried out as percentage of new bone area, 
new bone contact, percentage of biomaterial and percentage of soft tissue by the use 
of a grid system as described in chapter II.  
 
4.3.6  BSEM and EDAX Analysis 
Back scattered electron microscopy (BSEM) and Energy Dispersive X-Ray analysis 
(EDAX) were carried in order to analyse bone formation and the elements present 
within the HA and SiHA samples. One thin section sample slide from each of the 
porous SiHA and HA groups were mounted on aluminium stubs and then sputter 
coated with gold palladium particles using an EMITECH K550 machine (Emitech, 
UK). The coated slides were then analysed using a JOEL JSM-5500LV scanning 
electron microscopy unit (Joel Techniques, UK) and back scattered electron 
microscopy images of the samples were obtained. Elemental maps of the samples 
containing new bone were also obtained using Energy Dispersive X -ray 
microanalysis (EDAX, UK) to investigate the elements present in the newly formed 
bone and soft tissue next to the implanted biomaterial. 
 
4.3.7  Statistical analysis 
Statistical analysis of the data collected from this experiment was carried out using 
the statistical software SPSS v10.1. Mann-Witney U statistical test was used to analyse 
non parametric data and P < 0.05 was considered to be significant.   Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
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4.4  Results 
4.4.1  Histomorphometry 
4.4.1.1   Chemistry 
4.4.1.1.1  Bone Area 
The results of histomorphometric analysis of the Silicon substituted hydroxyapatite 
(SiHA) samples in comparison with pure HA samples (n=4) indicated significantly 
(P=0.014) greater bone area within SiHA samples compared to HA samples at 12 
weeks (Figure 69).  
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Figure 69. Bone area within SiHA implants compared to HA implants. 
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4.4.1.1.2  Bone contact  
Analysis of new bone contact with the implanted SiHA and HA biomaterials 
indicated significantly (P=0.005) greater bone contact with SiHA samples compared 
to HA samples (n=4) (Figure 70).  
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Figure 70. Graph showing % bone contact within SiHA and HA samples. 
 Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
  146 
4.4.1.2  Strut porosity 
4.4.1.2.1  Bone Area  
Significantly greater (P=0.007) bone formation was observed in SiHA30% samples 
compared with SiHA20%. More than 4% of the area of SiHA30% samples was filled 
with new bone (Figure 71). 
   HA30% samples indicated greater bone formation compared to HA20% samples, 
however this difference was not significant (P=0.591). Significantly greater (P<0.05) 
bone formation was promoted by SiHA30% compared to HA30% samples. No bone 
formation was observed within SiHA10% samples (Figure 71). 
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Figure 71. Bone area within SiHA and HA samples with different levels of strut porosity. 
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4.4.1.2.2  Bone Contact 
The results of bone contact between the implant and new bone indicated greater 
bone contact in samples with the highest (30%) microporosity. Comparison of 
SiHA30% with SiHA20% and SiHA10% implants showed significantly greater bone 
contact in SiHA30% samples. HA30% implants also indicate greater bone formation 
compared to HA20%, however the difference in levels of bone contact between 
these samples was not significant (Figure 72).  
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Figure 72. Bone contact measurements for SiHA and HA implants with different strut porosity. Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
  148 
4.4.1.3  Granules vs. Blocks 
4.4.1.3.1  Bone Area 
Comparison of bone formation within SiHA and HA samples in granular and block 
forms did not indicate any differences in the amount of bone formation. SiHA20% 
samples showed greater bone formation in block form compared to granular 
samples, whereas SiHA30% samples showed greater bone formation within the 
granular samples compared to the block samples (Figure 73). Greater bone formation 
was observed within the granular implants of HA20% samples compared to the 
block implants. Block implants of HA30% implants showed greater bone formation 
compared to the granules of this material (Figure 73).  
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Figure 73. Bone area within granular and blocks of SiHA and HA implants. 
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4.4.1.3.2  Bone Contact 
Comparison of bone contact in granular implants compared to block implants did 
not  indicate any specific differences. Both HA20% and HA30% samples show 
greater bone contact in block implants. SiHA 30 samples show greater bone 
attachment for granular implants, whereas SiHA20% samples show greater bone 
attachment to block implants (Figure 74). 
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Figure 74. Bone contact in granular and blocks of SiHA and HA samples. 
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4.4.2  Histology (Light microscopy and SEM analysis)  
4.4.2.1  Chemistry 
Histological analysis of SiHA and HA samples demonstrated bone formation in both 
SiHA and HA samples. Light microscopy images indicated extensive osteoinduction 
through intramembranous ossification within SiHA samples (Figure 75) as no sign of 
cartilage formation was observed. Bone formation in all samples indicated close 
association with the implant particles. No sign of inflammatory response was 
observed within the samples. Presence of osteoblast cells and osteocytes in the 
vicinity of the implant surfaces indicated active sites of new bone formation (Figure 
78). 
 
Figure 75. Images illustrating bone formation on HA 20 and 30% and SiHA 10, 20 and 30% samples. 
FT: Fibrous Tissue. NB: New Bone. No bone formation was observed in SiHA10 samples.  Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
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Detailed analysis of light microscopy images indicated the presence of blood cells 
and fibrous tissue at the implant interface within all groups (Figure 76). Fibrous 
tissue infiltration within the pores and between the pores of t he SiHA and HA 
samples was observed ( Figure  77 and  Figure  81). The presence of osteoblasts 
responsible for bone remodelling was also observed (Figure 77). 
 
 
Figure 76. Blood cells at the implant interface within a pore.  
 
 
Figure 77. Soft tissue infiltration within implant pores. FT: Fibrous tissue, BC: Blood cells. 
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Zones of osteoid formation by osteoblast cells on the surface of the implant pores 
were detected as illustrated in Figure 78 (a). New bone deposited by osteoblast cells 
was observed to be localized circumferentially on the surface of the pores (Figure 
78(b)). The centre of the pores represented a zone of undifferentiated mesenchymal 
tissue (Figure 79). High magnification images of the thin sections indicated zones of 
osteoid formation within the centre of the biomaterials pores (Figure 79).  
 
 
 
Figure 78. New bone formation within SiHA and HA. Black arrows indicate osteoblasts, white arrow 
indicates osteocyte. Star indicates bone matrix. FT: Fibrous Tissue. 
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Figure 79. High magnification image of osteoid formation within SiHA and HA implants. 
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4.4.2.2 Strut Porosity  
Comparison of bone formation within HA and SiHA samples with different strut 
porosity levels indicated greater bone formation in samples with higher porosity 
(Figure 80 and Figure 81). SiHA samples indicated greater bone formation compared 
with HA samples with the same level of strut porosity (Figure 80 and Figure 81). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80. Histology images illustrating new bone within HA20 and SiHA20 implants. NB: New 
bone, FT: Fibrous tissue. 
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Figure 81. Light microscopy images of newly formed bone within HA30 and SiHA30 samples. NB: 
New Bone; FT: Fibrous tissue. 
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Analysis of the back scattered electron microscopy (BSEM) images indicated that all 
implants presented highly cellular, disorganised woven bone. SiHA30% samples 
indicated greater bone formation compared to other samples (Figure 82). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 82. BSEM images illustrating new bone within SiHA30 and HA30% samples. White star 
indicates woven bone. Black star indicates biomaterial. 
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Bone formation was observed within macro and micropores of both HA and SiHA 
samples. High magnification images of thin sections of the implant samples indicated 
preferential bone formation on the concave surface of the implant pores, within the 
macropores of the implant and also deep within the micropores. Stained samples and 
SEM images indicated visible bone formation within pores of less than 20 µm. Zones 
of newly deposited bone were observed on all samples (Figure 83). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 83. Histology and BSEM images 
indicating bone formation within 
SiHA and HA macro and micropores. 
Arrows: bone within pores of ~20 µm. 
NB: New Bone FT: Fibrous Tissue. 
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4.4.2.3 Granules vs. Blocks 
Analysis of stained thin section samples of granular and block SiHA and HA samples 
did not indicate any clear effect due to these morphologic differences on bone 
formation (Figure 84). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 84. Histology images of block (SiHA30-B) and granular (SiHA30-G) implants illustrating new 
bone formed within the implant NB: new bone, FT: fibrous tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SiHA30-B 
SiHA20-G  SiHA20-B 
SiHA30-G 
NB
NB
NB
NB
FT
FT
FT
I 
I 
I 
I Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
  159 
4.4.2.4 New bone characterisation 
EDAX analysis of SiHA samples indicated the presence of Calcium, Phosphorous, 
Silicon, Oxygen and Carbon elements within the samples. The elemental maps 
obtained from a section of SiHA sample containing a pore filled with new bone 
indicated the presence of silicon within the newly formed bone. Silicon was also 
present in the soft tissue adjacent to the biomaterial, however in lesser levels than 
within the new bone. Strong signals of carbon were detected within the soft tissue. 
Peaks of calcium (Ca) and Phosphorous (P) confirmed the new bone composition 
within both macro and micropores of the samples, as illustrated in Figure 85. 
 
 
 
 
 
 
Figure 85. EDAX map of SiHA. Yellow star: Soft tissue, Red star: Implant. 
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4.5  Discussion  
4.5.1  The effect of Silicate ion substitution on osteoinduction 
This study demonstrated the chemical influence of Silicon substituted HA on the 
promotion of bone formation within non-osseous tissue. The paraspinalis muscle 
was chosen for this study to eliminate the osteoconductive influence of host bone on 
bone formation. The ovine animal model was selected for this study as the bone 
metabolism of sheep is more similar to that of humans and sheep represent more 
similarities in terms of weight, bone, joint structure and bone regeneration (Patel et 
al., 2005, Nus et al., 2006). In addition, studies carried out on osteoinduction 
mechanisms have shown that osteoinduction is induced variably depending on the 
nature of the species. Also, it is known that bone formation is not induced in rat or 
mice animal models and rabbits present minimal bone formation. Therefore the best 
models identified so far are known to be those of the large mammals group, sheep 
(Gossain, et al., 2002) dogs (Yuan et al., 2000) and non-human primates, such as 
baboons, as demonstrated in many studies by Ripamonti et al (Habibovic et al, 2006). 
The study by de Bruijn in 1998 also demonstrated bone formation by HA in goat 
animal models.  
   The results of this study indicated that at 12 weeks new bone formation was visible 
within the implanted SiHA and HA granules, and blocks with SiHA samples 
presented superior bone formation. This study illustrated the role of biomaterial 
chemistry in promotion of bone formation, irrespective of structural porosity, as 
comparison of the samples with different porosities indicated that SiHA30% and 
20% implants showed the greatest bone formation and attachment compared to 
HA30% and 20% samples. The  in vivo interactions between the implant and 
surrounding tissue engages highly complex mechanisms including many cellular and 
tissue specific factors, material properties, structural characteristics and numerous 
other undefined factors (Barrera et al., 2006). Promotion of bone formation on a 
biomaterial is dependent on the cellular mechanisms that are triggered during the 
point of implantation and the provoked inflammatory responses leading to tissue 
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formation of a blood clot which ignites a series of cellular mechanisms (Lanza et al., 
1997). In this study, immersion of the SiHA and HA samples into autologous blood 
was suggested to result in exposure of the biomaterial to host specific substances. 
Upon insertion of the SiHA and HA granules and blocks coated with blood into the 
muscle bed, the surface of the biomaterials were covered with a layer of plasma 
proteins from the host blood, followed by adhesion and activation of platelets. 
Platelet activation triggers the release of growth factors and cytokines essential for 
wound healing. This mechanism triggers the attraction of undifferentiated cells 
towards the surface of the biomaterial and the formation of a blood clot facilitates 
the movement of the cells through a biological matrix of fibrin and proteins 
(Gemmel and Park, 2000). This in turn enhances the bonding and the cell-implant 
interactions, resulting in consequent cell differentiation and implant bioactivity.  
  As histological analysis showed the presence of blood within the samples, it was 
concluded that following implantation in the animal body, the ideal living bioreactor, 
the pores and spaces within the samples were filled with circulating blood. The 
presence of proteins and growth factors in blood and body fluids, in addition to the 
recruitment of mesenchymal stem cells present within the muscle tissue into the 
implant area, were elucidated to have contributed to the initiation of the process of 
osteoblast differentiation and bone generation (Kilpadi et al., 2001).   
   Surface roughness and chemistry of the biomaterials influence the initial blood to 
implant interactions through platelet adhesion and activation, protein adsorption and 
also cell attachment to the surface of biomaterials (Schwarts and Boyan, 1994; Park 
and Davis, 2001). Cells’ focal attachments with the biomaterial surface determine the 
shape of cells; this in turn is transduced to the nucleus via the cell cytoskeleton 
resulting in expression of specific phenotypes. The biomaterial’s surface chemistry 
influences the function of osteoblast cells, which in turn affects the rate of bone 
formation on the biomaterial (Boyan et al., 1996). Substitution of Silicate ions within 
HA is known to lower the surface charge of HA and also increase the pH levels in 
solution to a more alkaline pH (Rashid et al., 2008). It is known that positive and 
negative surface charges influence osteoblast adhesion to the biomaterial (Teller et 
al., 2006). Further substitution of 0.8wt% silicate ion is known to increase the Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
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hydrophilicity of HA and contribute to superior protein exchanges. The surface 
composition is known to influence the protein conformation and consequently 
adsorption to the surface (Rashid et al., 2008). Protein adhesion to the biomaterial 
surface is mediated through the activity of the present negative and positive charged 
groups and their affinity for specific ions available on the biomaterials surface. Cell 
attachment, on the other hand, is dependant on cell-protein interactions through the 
RGD sequences. Thus, the negative surface charge of SiHA is suggested to affect the 
binding efficiency of proteins to the biomaterial surface and consequently influence 
the cell attachment and bioactivity of this biomaterial. Zuo et al (2008) have shown 
that Silicon substitution into hydroxyapatite influences the adhesion of human 
osteoblast-like cells in vitro. The influence of the net negative surface charge of SiHA 
in line with the role of material surface charge on cell adhesion suggests a role for 
superior osteoinduction in SiHA samples compared to HA samples (Balas et al., 
2002).   
   Enhanced bone formation by SiHA samples compared to HA samples is suggested 
to be due to the effect of the dissolution of silicate ions into the surrounding area 
provoking enhanced reactivity of the material and promotion of an osteoinductive 
biological response (Porter et al., 2004). A study by Guth et al (2006) showed low 
levels of silicon release from SiHA samples in vitro. In my study EDAX analysis of 
the samples indicated the presence of silicon within the newly formed bone. The 
observed silicon peaks suggest the incorporation of silicate ions into the new bone 
from the biomaterial. Silicon substituted HA is known to show localized grain 
boundary dissolution (Botelho et al., 2002; Porter et al., 2003). In vitro studies have 
shown that soluble silicate ions stimulate the expression of collagen-I in osteoblast-
like cell cultures (Zuo et al., 2008). Reprecipitation of the released silicate ions after 
the initial dissolution from SiHA (Guth  et al., 2006) promotes the formation of 
apatite layers similar to the mineral component of the bone. This apatite layer on the 
surface of the biomaterial triggers a series of physiological reactions within the 
surrounding cells and acts as the ideal site for cell attachment, differentiation, growth 
and maturation (Weng et al., 1997; Porter et al., 2003) and consequently may account 
for the peripheral organisation of bone formation within the samples. The release of Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
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silicate ions could have resulted in bonding of oxygen to these ions, forming a silicate 
network that contributes to the organisation of protein elements in a fashion that 
provides the ideal surface for protein absorption and cell attachment via integrins for 
connective tissue generation (Thian et al., 2006). This in turn may have stimulated 
the cells within the surrounding tissue, in this study the muscle tissue, to initiate 
osteogenesis. Immunohistochemical analysis and protein localisation at the SiHA-
bone interface would provide a better understanding of the proteins involved in the 
mechanism of osteoinduction by this biomaterial.  
   Further, it can be assumed that the presence of silicate ions within SiHA samples 
or the surrounding tissue (as was indicated by EDAX analysis) may have influenced 
the expression of genes involved in osteogenesis, promoting the differentiation of 
the cells present in the muscle bed into osteoprogenitor and/or osteoblastic cells. In 
vivo gene expression analysis of the genes involved in osteogenesis through the use of 
gene expression arrays may contribute to a better understanding of the effect of 
silicate ion substitution on the mechanism of osteoinduction. 
    As demonstrated in a study by Nihouannen et al (2005), BMPs are present at the 
bone HA interface. This suggests a role for HA as the substratum for the adsorption 
and storage of endogenous circulating BMPs. The local accumulation of BMPs may 
stimulate the differentiation of stem cells present within the surrounding tissue into 
osteoblasts.   
   It should be noted that the levels of bone area and contact within both SiHA 
(2.12% ± 1.2 and 9.04% ± 5.4 respectively) and HA (0.7% ± 0.1 and 2.6% ± 0.6 
respectively) samples within the 12 week period of this study were relatively low. A 
previous study by Patel et al (2002) reported 37.5% ± 5.9 of bone ingrowth within 
SiHA granules implanted in femoral condyle defects of rabbit animal models within 
23 days. Although species dependant mode of bone formation and differences in the 
implantation sites should not be ignored, i t can be suggested that in this study, 
however low, the levels of bone formation within the non osseous tissue by 12 weeks 
demonstrate the osteoinductive potential of SiHA.  
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4.5.2  The effect of strut porosity and physical structure  
Quantitative assessment of bone formation within the strut porosity of the samples 
indicated significantly greater bone formation within HA and SiHA samples with 
higher microporosity. Osseous response and bone formation by the implants was 
clearly affected by the levels of microporosity within the implant structure. The 
presence of macro and micropores within biomaterials is known to facilitate the 
penetration of fluids and cells into the core of the biomaterial (Bronzino, 2006).  
Kuboaki et al (1998) demonstrated the role of porosity in an ectopic rat model of 
bone formation. Habibovic et al (2005) reported that changes in microporosity 
contribute to levels of ectopic bone formation. The results of this experiment 
confirmed that SiHA and HA implants with highest strut porosity (30%) presented 
greater bone formation (4.41±1.4 and 0.86±0.4 respectively) through osteoinduction 
compared to the same materials with the lower strut porosity levels (SiHA20%: 
1.9±0.7 and SiHA10%: 0). SiHA30% samples demonstrated superior bone formation 
deep within the biomaterial pores which confirmed the results previously indicated in 
a study by Gauthier et al (1998) on bone formation within microporous structures. 
The porous SiHA and HA samples did not show the presence of any chondrogenic 
phase within the pores and followed the same trend previously described in a study 
by Ripamonti et al (1996) on ectopic bone formation in porous HA in baboons 
through intramembranous ossification. Karageorgio and Kaplan (2005) showed that 
small pores within a biomaterial induce endochondral ossification due to the lower 
amounts of oxygen tension within the pores, whereas large well vascularised pores 
induce intramembranous ossification through a superior supply of oxygen and 
nutrients.  Increased concentrations of oxygen through blood supply within the 
interconnected pores of the SiHA and HA may have contributed to the 
intramembranous bone formed within these samples.  
   The enhanced osteoinduction within the samples with higher porosity could be due 
to the influence of the s trut porosity on osteoblasts’ guidance, attachment and 
movement, increased dissolution rate of ions into the surrounding tissue, enhanced 
ionic exchange rate and vascularisation (Hing et al., 2005; ). Deligianni et al (2001) 
demonstrated increased cell adhesion to HA samples with increased surface Chapter IV. Osteoinduction by Silicon substituted HA                                                                                                       
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roughness  in vitro. As stated by Park and Davis (2001), microstructures within a 
surface influence the initial blood to implant interactions through enhancement of 
platelet adhesion and activation and also fibrinogen adsorption. This in turn 
influences the rate of cell attachment and consequent new bone formation.  
   Detailed analysis of bone formation within SiHA samples in comparison with HA 
samples indicated that bone formation initiated from the centre of the pores within 
HA samples, whereas this bone formation seemed to predominately initiate at the 
concave surface of the pores within SiHA samples. Increased levels of microporosity 
might have resulted in greater surface area availability for faster dissolution and 
precipitation of the material and consequent enhanced bio-reactivity of the material. 
This bone-like apatite layer may have induced the stems cells to undergo osteogenic 
differentiation or the osteoprogenitor cells to initiate bone mineralisation (Ducheyne 
and Qui, 1999). The chemical composition of SiHA and the mentioned 
characteristics of this biomaterial, in addition to the role of porosity and surface area, 
might have been the contributing factors to attraction and attachment of osteogenic 
cells and bone formation on the concave of the SiHA pores. Also, the porous 
structure of the implant might have contributed to formation of a vascular network 
and increased angiogenesis within both HA and SiHA implants. Vascularisation and 
vascular derived factors are known to contribute to the coordination of the bone 
cells' activities (Barou et al., 2002). The enhanced bone formation in the highly 
porous implants could also have been due to the increased rates of fluid and blood 
circulation within the implant area and superior provision of proteins important for 
cell migration and adhesion, such as integrins, growth factors and nutritional factors 
essential in bone formation (Hing, 2005).  
   Despite the increase in bone contact and bone area by high porosity implants, it 
should be noted that increasing the porosity of the biomaterials results in brittleness 
and reduces the mechanical strength (Gauthier et al., 1998) of the biomaterial, thus 
engineering a porous bone graft biomaterial with the appropriate mechanical strength 
and ultimate osteogenic properties is desirable. Nevertheless it should be mentioned 
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bone ingrowth could contribute to the mechanical strength of the biomaterial via the 
presence and the amount of the newly formed bone. 
   Further, the results of this study showed bone formation within both granules and 
blocks of SiHA and HA samples. However no specific difference in the role of these 
structural differences on bone formation in either form was observed. A study by 
Ripamonti et al (1996) showed bone formation within heterotopic implanted blocks 
of HA in baboons and no bone formation in HA granules. I my study bone 
formation was observed within both granular particles and blocks of SiHA and HA 
samples. In comparison with the other groups,  superior bone formation was 
observed within both SiHA blocks and granules with 30% strut porosity.  
   In consideration of the above, the effect of host specific responses to the implants 
and osteoinduction should not be ignored as the concentration of circulating growth 
factors, proteins and cells have been suggested to influence the rate of bone 
formation. In addition, increasing the time point of the study from 12 weeks to a 
longer period of sample incubation within the host animals may also contribute to 
the identification of the time point by which SiHA biomaterials promote the highest 
level of bone formation. This in turn would contribute to a better understanding of 
bone formation in the longer term within Silicon substituted hydroxyapatite 
biomaterial. 
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4.6  Conclusions 
This study demonstrated that SiHA bone substitute materials induce osteoinduction 
without the supplementation of BMPs, growth factors or mesenchymal or 
osteoprogenitor cells as there are disadvantages to the use of supplementary factors, 
such as their high cost of production and their efficacy in bone formation (Lane, 
2001; Maniscalco et al., 2002). Greater bone formation is obtained by SiHA implants 
compared to HA implants in an ectopic site at 12 weeks. Further incorporation of 
interconnected micro and macropores within the structure of the HA and SiHA 
biomaterials contributed to increased bone ingrowth within the implanted 
biomaterials. Comparison of SiHA and HA samples with 10% : 20% : 30% strut 
porosity within the implants indicated that greater bone formation was obtained 
within samples containing the highest level of strut porosity, SiHA30% and HA30%. 
Further SiHA implants with the highest strut porosity (30%) demonstrated greater 
bone formation when compared to all other HA and SiHA samples. These results 
suggest that there is an independent effect of chemistry by the incorporation of 
Silicate ions into the HA structure on osteoinduction by this biomaterial. However, 
inclusion of interconnected macro and micro structures within the biomaterial 
structure results in enhanced ectopic bone formation. 
   In conclusion, the hypothesis of this study proposing that Silicon substituted HA 
promotes osteoinduction was proved. Strut porosity was found to enhance the rate 
of bone formation within biomaterials; however, the effect of granularity nor the 
effect of block structures of the implanted biomaterials were found to imply any 
significant contribution to bone formation.  
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5  Chapter V. Discussion and Conclusions 
5.1  Discussion 
In  this thesis the osteoconductive and the osteoinductive behaviour of calcium 
phosphate bone substitute materials were investigated at both cellular and molecular 
levels.  In the first experimental chapter, the osteoconductive behaviour of eight 
commercially available bone substitute materials was compared. A study by Hing et 
al. (2007) compared the performance of dense calcium sulphate,  ultra-porous ß -
tricalcium phosphate, and porous silicated calcium phosphate in a rabbit model. 
However, my study has covered a larger range of bone grafts which were implanted 
in an ovine model. This experimental model was selected since sheep exhibit closer 
physical, mechanical and biological similarities to human and the results obtained 
from this study can be used as guidelines for future use in human clinical 
applications. In this study the amount of bone formation at 6 weeks, on ApaPore, 
Actifuse, BiIonic, CPS, ProOsteon 500 R and Skelite calcium phosphate based 
biomaterials was compared with osteoconduction on two DBM based biomaterials; 
Grafton Crunch and Accell Connexus putty. The results of this study indicated that 
calcium phosphate bone graft materials exhibited significantly greater bone (P<0.05) 
formation compared to DBM based biomaterials.  However, even with calcium 
phosphate based bone substitute materials there was a very wide osteoconductive 
response. CPS, BiIonic, Actifuse and ApaPore biomaterials exhibited the highest 
amount of bone formation respectively and Pro Osteon 500R and Skelite 
demonstrated the lowest amount of new bone within the period of the study. In this 
study, both osseoinductive and osseoconductive mechanisms of bone formation 
were proposed to have contributed to the rate of bone formation by the implanted 
Calcium Phosphates; however, as all the samples were implanted in contact with host 
bone, distinguishing these two mechanisms of bone formation was not possible, as 
host bone provides both sources of osteoconductive factors and cells and proteins 
promoting osteoinduction.  
   Analysis of the mechanism of bone formation within the implanted samples in this 
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(CPS, Actifuse and BiIonic) indicated the potential role of silicon substitution within 
calcium phosphates on bone formation. As indicated in various in vivo and in vitro 
studies, silicon substitution within the HA structure improves the bioactivity of this 
biomaterial (Gibson et al., 1999; Patel et al., 2002; Ballas et al., 2002). The 
incorporation of silicate ion within Actifuse, CPS and BiIonic contributed to the 
formation of new bone within theses samples, irrespective of the effect of strut 
porosity. It should be noted that levels of new bone formation within Actifuse was 
not significantly different from that of HA by week 6 of implantation within the 
femoral defects. However, results of the osteoinduction study indicated formation of 
significantly higher amount of new bone within SiHA samples by 12 weeks. This 
suggests that, although presence of silicon may not contribute to greater bone 
formation compared to pure HA at early stages of implantation, silicon does enhance 
bone formation at longer time points. 
    A recent paper by Bohner (2009) has mentioned the lack of experimental evidence 
supporting the notion that resorbablity of SiHA, which has been assumed by various 
researchers,  is the contributing factor to the release of Si ions and consequent 
differentiation of osteoblasts. With respect to this, the results of my study provide 
quantitative evidence that silicate containing calcium phosphates such as Actifuse, 
CPS or BiIonic which show significant amounts of new bone, do not show any 
significant material resorption within 6 weeks, with the exception of Skelite (a Si-
TCP based material) which exhibited significant material resorption. As a result, it 
could be concluded that bone formation by Silicated materials is induced by factors 
other than the role of biomaterial resorption such as t he effect of Si ions on 
expression of osteogenic genes and osteogenic proteins production. 
   In order to investigate the influence of silicate on stimulation of in vitro osteoblastic 
differentiation of marrow stromal cells, hMSCs were seeded on dense SiHA discs 
and the osteoinductive potential of SiHA bone substitute biomaterial was monitored. 
Various studies by Gibson et al. (1999), Guth et al. (2006) and Zou et al. (2009) 
demonstrated enhanced metabolic activity and cell proliferation through the effect of 
silicate ions on adhesion, proliferation and differentiation of cells. However most of 
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this study has employed the use of pluripotent human marrow stromal cells. A study 
by Xynos et al. (2000) demonstrated the gene expression profile of human 
osteoblasts on Bioglass 45S5. However, in his study it was not clear whether bone 
formation was the result of direct cell-biomaterial contact or the effect of the 
released ions. However, a study by Guth et al. (2006) did demonstrate the release of 
silicate ions from SiHA into solution.  In this study, the osteogenic differentiation of 
the hMSCs could be speculated to have been due to both cell-biomaterial contact 
and ionic dissolution of SiHA. The presence of silicon ions within new bone (in vivo) 
and osteoblastic cell differentiation on the surface of the tested discs (in vitro) were 
indicative of the involvement of such mechanisms. Production of osteoblastic 
marker proteins, in addition to the morphological changes of the hMSCs seeded on 
SiHA and HA discs, indicated the differentiation of these cells into osteoblasts. Gene 
expression analysis indicated up regulation of RUNX2, Bone Sialoprotein and VEGF 
genes in hMSCs seeded on SiHA and HA discs by day 24 of the study. Expression of 
the VEGF mRNA was observed to be higher on cells seeded on SiHA and HA discs 
in comparison with the control group on days 3 and 6 of the study. This indicated 
the contribution of SiHA and HA biomaterials to the promotion of early expression 
of VEGF and consequently the possible early initiation of vasculogenesis.  
   In future, work on in vivo mRNA gene expression analysis could be carried out to 
analyse the effect of calcium phosphate bone substitute materials on the expression 
levels of osteogenic marker genes and the vasculogenic gene, VEGF, involved in the 
mechanism of osteoconduction. For this purpose, the same femoral condyle model 
could be employed for RNA extraction and mRNA expression quantification a t 
different time points in implanted calcium phosphate biomaterials.  
  Further, immunohistochemical analysis of the osteogenic proteins and their cellular 
localization on in vivo implanted calcium phosphate bone substitutes would be the 
direction for more detailed analysis of the influence of these biomaterials on cellular 
mechanisms of osteoblastic differentiation and mineralization. It should be noted 
that immunohistochemical staining is performed on decalcified low temperature resin 
embedded samples; as the decalcification process may take a long time, resulting in 
possible protein degeneration and also removal of the CaP component of the Chapter V. Discussion and Conclusions                                                                                                        
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implanted biomaterial samples, in order to obtain accurate results improved 
techniques of immunohistochemistry need to be developed.  
   Following the analysis of the role of silicate ion substitution on the osteoblastic 
differentiation of hMSCs and induction of osteoinduction in vitro, the osteoinductive 
property of SiHA in vivo and the effect of silicate ion substitution within HA was 
analysed as the next step into the study of this biomaterial. Woven bone apposition 
into the periphery and in the centre of SiHA and HA granules and blocks implanted 
in paraspinalis muscle of sheep was observed. SiHA promoted osseoinduction in an 
ectopic site with significantly higher (P < 0.05) levels of bone formation in 
comparison with HA. The osteoinductivity of HA and SiHA was enhanced by the 
incorporation of strut porosity; however, as shown in chapter four, SiHA promotes 
superior amounts of bone formation irrespective of its physical structure. It should 
be mentioned that the 80% porous structure of SiHA can only support bone 
formation within non-load bearing tissues, therefore, this material is not a suitable 
candidate for use in load bearing environments. However in spinal fusion procedures 
where osseoinduction and new bone formation is more important, strut porosity and 
chemical composition of SiHA contribute to the promotion of rapid bone formation. 
The study of the effect of strut porosity on osteoinduction confirmed the results 
previously indicated in a study by Gauthier et al (1998) on bone formation within 
microporous structures and indicated that increased strut porosity enhances the rate 
of new bone formation. This can be speculated to be due to communication of 
osteoblasts with one another through diffusion of chemicals, blood vessels’ ingrowth 
and connective tissue cells with osteogenic potential penetrating across the 
biomaterial micropores, as indicated in previous studies by Winter in 1970, which 
showed intramembranous ossification within the pores of an ectopically implanted 
synthetic sponge.  
   Future work  could utilize cDNA microarrays in order to determine gene 
expression of cells growing on silicon substituted hydroxyapatite. As long as plain 
hydroxyapatite is used as control, this would be beneficial because key genes 
associated with enhanced osteoinduction and osteoconduction on SiHA could be 
identified. Immunohistochemical analysis could be carried out to obtain a b etter Chapter V. Discussion and Conclusions                                                                                                        
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understanding of the influence of silicate ions on the expression and localization of 
osteogenic genes. Chapter V. Discussion and Conclusions                                                                                                        
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5.2  Conclusions 
In conclusion, the hypothesis  that  generally  calcium phosphate bone substitute 
materials promote greater bone formation in comparison with DBM based 
biomaterials within 6 weeks was  proved. The poor performance of DBM in 
comparison to calcium phosphates is considered to be due to the absence of the 
calcium phosphate component which plays an essential role in promotion of bone 
formation.  Calcium phosphate based biomaterials are widely used in various 
orthopaedics and maxillofacial applications, specifically for spinal fusions. The fast 
rate of bone formation by these biomaterials in comparison to DBMs makes them 
the ideal group of bone substitute materials where bone regeneration in a short 
period of time with the appropriate resorption and mechanical properties is required. 
The p resence of  strut  porosity within the biomaterial structure  was shown to 
enhance new bone formation; however, chemical composition of a biomaterial was 
observed to contribute to the rate of bone formation irrespective of the structural 
porosity. Silicon substituted hydroxyapatite  was also shown to  promote the 
attachment, proliferation and differentiation of hMSCs to osteoblasts, irrespective of 
the presence of osteogenic supplements or porosity. The chemical composition of 
SiHA was shown to contribute to the mechanism of osteoinduction  through 
influencing the  expression of osteogenic marker genes and secretion of the 
osteogenic proteins. Early osteogenic differentiation of hMSCs as a result of the 
earlier initiation of bone matrix mineralisation through expression of the osteonectin 
gene,  was  suggested as on of the factors involved in osteoinduction by this 
biomaterial.  Further, SiHA was proved to induce osteoinduction without the 
supplementation of BMPs, growth factors or mesenchymal or osteoprogenitor cells. 
In addition, incorporation of 30% strut porosity within the structure of the HA and 
SiHA biomaterials contributed to increased bone ingrowth within the implanted 
biomaterials in vivo. These results clarified the independent effect of chemistry on 
osteoinduction.  Chapter V. Discussion and Conclusions                                                                                                        
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   In general it was concluded that not only the chemistry of a biomaterial is 
important for promotion of bone formation, the implant morphology also plays a 
significant role.    
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